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 Despite large investment in biomedical research by government, foundations and private 
organizations around the world, we are not experiencing an increase in the new medicine 
reaching the market. Many studies point out that this productivity decline in biomedicine is 
mainly due to the difficulty in translating basic science into clinical setting. Translational 
research emerged as a key research policy tool to address this problem over the last decade. 
Translational research aims to bridge the gap between basic science and clinical science to 
accelerate the process of moving research innovation into clinical use. In the United States, the 
National Institutes of Health (NIH) took the lead in supporting translational research by 
developing the Clinical and Translational Science Award (CTSA) in 2006. In this dissertation, 
the author examined the impact of NIH’s effort on supporting translational research focusing on 
two topics, which are collaboration network structure and production of translational 
publications. Regarding the collaboration landscape, the change of social network analysis 
measures showed that the CTSA award had an impact in changing the biomedical research 
landscape into denser and less centralized form. The result of the network regression models 
showed that receiving CTSA award led individual institutions to collaborate more with other 
institutions. For the test on the production of translational publications, which is the second topic 
of interest, a unique measure using the composition of forward citation of publications is 
introduced. The results from difference-in-difference regression and mediation tests showed that 
the CTSA award leads to the increase of publications and this relationship is mediated by inter-
collaboration feature of institutions after the CTSA program is well stabilized. The author 
expects that the study will provide insight into the effects of translational research initiatives and 
have implications on the government policy regarding biomedical research more broadly. 
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CHAPTER 1. INTRODUCTION 
 
1.1. Research Motivation 
  
 Translational research emerged as a key research policy issue over the last decade. This 
was a response to a series of studies concluding that remarkable advances in basic biomedical 
research were not leading to a significant increase in the development of new medicines (Butler, 
2008; Moran, 2007; Zerhouni, 2005; Woolf, 2008). Translational research aims to fill the gap 
between basic science and clinical science to accelerate the process of moving research 
innovation into clinical use (Fishburn, 2013; The President’s Council of Advisors on Science and 
Technology, 2012). Translational research initiatives use several strategies to reach these goals, 
including providing tools that promote collaboration among institutions and researchers, building 
research infrastructure with multiple purposes, supporting pilot programs, training students and 
faculty members, and providing regulatory support (CTSA Principal Investigators, 2012; Lander 
& Atkinson-Grosjean, 2011).  
 Within the United States, the National Institutes of Health (NIH) took the lead in 
supporting translational research by announcing its Roadmap Interdisciplinary Research 
Initiative in 2005, developing the Clinical and Translational Science Award (CTSA) in 2006 and 
establishing the National Center for Advancing Translational Sciences (NCATS) in 2011 
(Blümel, 2017; Gittelman, 2016; Obeid, Johnson, Stallings, & Eichmann, 2014). NIH awarded 
its first twelve CTSA awards in 2006 and now supports around sixty institutions nationwide 
providing money for the instrumentation, infrastructure, training, pilot projects and regulatory 
support (Clinical and Translational Science Awards Consortium, n.d.-a). Individual CTSA 
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receiving institutions are funded usually through 5-year agreements and their annual budget 
ranges from $4 million to $23 million1 (Leshner, Terry, Schultz, & Liverman, 2013). NCATS, 
which had a budget of over $500 million in 2017, houses the CTSA program and many other 
programs that facilitate translational research (Liu, Chen, Sinoway, & Berg, 2013).  
 Given the scale of NIH’s support for translational research and interest in and support for 
translational research efforts around the world, it is important to understand if these research 
policies are meeting their goals. By systematically assessing the effects of NIH’s CTSA program, 
I aim to increase understanding of the impact of translational research policies and identify 
strategies to improve the design and implementation of biomedical research funding programs. 
Also, I aim to improve the evaluation of programs designed to foster translational research by 
proposing and completing preliminary assessments of the reliability and validity of a novel 
measure to assess the translational nature of research articles based on their forward citation 
profiles. 
 
1.2. Research goals and objectives 
 
 In this dissertation, I aim to examine the impact of NIH’s primary effort to support 
translational research, the development and implementation of the CTSA Award. My aim is to 
test several hypotheses on how NIH’s support for translational research changed the 
collaborative network structure in biomedical research and how, if at all, production of 
biomedical research articles – a key output of the research enterprise – changed due to this 
transformation. Here, my goal is to find out, in particular, whether NIH’s support for 
                                                 
1 For instance, Emory University received $104.7 million of sponsored research funding in Fiscal Year 2016 and 6% 
($6.2 million) of them were related to the CTSA program. 
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translational research was associated with the production of research articles that were used in a 
translational manner. My specific research questions are as follows: 
 
• Motivating questions 
1) Has the government’s support for translational research through the CTSA program 
changed the overall biomedical research collaborative landscape among research 
universities in the U.S.? 
2) Has the NIH’s increasing support for translational research led to more production of 
research outcomes that translate basic science findings into clinical setting? If so, what are 
the mediating factors in the relationship? 
 
 Thus far, several studies have looked at the impact of support on translational research, 
mainly with basic descriptive analysis focusing on individual institutions (e.g., Liu et al., 2013; 
Knapke, Haynes, Kuhnell, & Tsevat, 2015). However, there has been less focus on conducting 
comparative assessment among different organizations using archival data. In that regard, the 
objectives of my study are as follows: 
 
• Specific objectives 
1) Quantitatively analyze if NIH’s support for translational research changed the features of 
biomedical research collaboration landscape using social network (SNA) analysis measures 
and models. 
2) Analyze the archival data related to publications and use appropriate multivariate regression 
techniques to assess the impact of NIH’s policy on the characteristics of research outcomes 
and institutions’ research performance. 
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3) Contribute to the literature on the effectiveness of government intervention in biomedical 
research collaboration and performance. 
 
1.3. Overview of the chapters 
 
 The remaining parts of the dissertation will be structured as follows. In chapter 2, I will 
provide an overview of the policy background relevant to this dissertation. First, I will explain 
general aspects of biomedical research then explain how these features lead to the need for 
collaboration in biomedical research. In particular, the presence of the “valley of death” in 
biomedical research will be explained with the reasonings why it is present. Then, I’ll discuss a 
new approach to biomedical collaboration, which is translational research. First, I will explain 
the concept and briefly explain the background that led to the emergence of this type of research. 
Then, I will provide information on the efforts of the U.S government regarding the support of 
translational research. Although the focus of this dissertation is translational research policy in 
the United States, for comparative purposes, I will briefly introduce similar policies in other 
countries in Europe and Asia.  
 In chapter 3, I will investigate how the collaborative landscape among research intensive 
universities changed due to NIH’s support for translational research. Following a discussion of 
key literature on research collaboration, focusing on studies that examine the factors influencing 
the level of collaboration and how external forces induce research network changes, and relevant 
theoretical background, I provide an explanation of my empirical setting. The multi-step process 
of developing the dataset for this analysis is detailed and explanation of the variables and models 
used for the assessment of the CTSA program is provided. Then, the descriptive analysis of 
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network measures, and the results of network regression models will be provided. The chapter 
concludes with a discussion of the results of my analysis, along with interpretation of these 
results. 
 The focus of chapter 4 is the development and preliminary assessment of a novel measure 
on the translational feature of publications. First, background on why a new measure on 
translational feature of publications is necessary will be presented. Then, a detailed explanation 
of the new measure – the TS score – that measures the translational feature of individual articles 
or institutions will be provided. Finally, results on the tests on the reliability and the validity of 
the new measure will be described.  
 The goal of chapter 5 is to extend the analysis from chapter 3 and to assess the 
relationship between research performance and support for translational research. Drawing on 
the review of related theories and previous studies, I hypothesize that the NIH’s support for 
translational research changed scientist’s behavior to produce research outcomes that can be 
considered translational publications. Using the TS score to determine translational publications 
(described in chapter 4), I test this hypothesis by econometrics methodologies like difference-in-
difference methodology in various settings. Furthermore, tests on the mediation effects of two 
major factors that NIH emphasizes for the successful operation of the CTSA program, inter-
organizational collaboration and multidisciplinary research, are tested. Then, the result with 
descriptive analysis of key variables and model estimation results are presented. In closing of 
this chapter, the discussion on the results will be provided. 
 Finally, chapter 6 will provide a summary of the findings, implication of the study, and 
limitation with suggestion on further studies.  
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CHAPTER 2. POLICY BACKGROUND 
 
2.1. Overview of the biomedical research pipeline 
 
2.1.1. Complex and multi-stage process  
 
 In biomedical research, there are multiple stages to go through to translate a discovery 
from the laboratory to a product with commercial value. The first step, in the typical 
development of new drug2, is the discovery and development process, which usually occurs in 
the laboratory (U.S. Food and Drug Administration, 2018). In this stage, researchers conduct 
tests to find promising compounds that may stop or reverse the effect of a particular disease. If a 
promising compound is identified, researchers conduct experiments to characterize the 
compound and determine, for example, an effective delivery mechanism, an appropriate dosage, 
and its interaction with other drugs. The second stage is preclinical research (U.S. Food and Drug 
Administration, 2018). In this stage, researchers seek information on dosing and toxicity levels 
of potential drugs by conducting in vitro and in vivo tests including animal tests. When the tests 
suggest that the potential drug has a reasonable chance of successful development and passed 
basic tests on drug’s safety, an Investigational New Drug (IND) application, which includes 
information such as preclinical study data, manufacturing information, clinical protocol, is 
submitted to the FDA (Niosi, 2011; Fishburn, 2013). FDA staff review the submitted information 
and make a go - hold decision, which can take as long as six months (Niosi, 2011). If the FDA 
                                                 
2 Here, I mean typical development of new drugs as drugs developed from classic small molecule drugs, which 
make up more than 90% of commercial drugs (Bayer AG, n.d.). The processes of developing drugs using substances 
that consist of complex mixtures (e.g., biological drugs, cell therapies) are more challenging (Crommelin et al., 2003) 
and the features (e.g., study size, timeline and percentage of success) will differ with the contents provided in here.  
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review team approves the IND submission, the process moves to the next step: clinical research. 
Clinical research is composed of phase 1, phase 2 and phase 3. Phase 1 studies typically recruit 
20 to 100 healthy volunteers to test the safety and dosage of the potential drug (U.S. Food and 
Drug Administration, 2018). It takes several months or more, depending on the nature of the 
project, to pass through this phase and around 70% of potential drugs go to phase 2. In phase 2, 
the study participants increase to several hundred people and tests are conducted to test the 
efficacy and side effects of the potential drug. Several months to two years are needed to pass 
through this stage and approximately 33% moves to phase 3 (U.S. Food and Drug 
Administration, 2018). Phase 3, which takes as long as four years and as many as few thousand 
participants, tests the efficacy and monitor the adverse reaction attributed to the potential drug. 
Around 25 to 30 percent of tested drugs pass this phase (U.S. Food and Drug Administration, 
2018). When all phases of clinical trials are complete and if the potential drug is proved to have 
efficacy and safety, the drug developer can submit a New Drug Application (NDA) to FDA for 
the approval that allows them to sell the drug to individual customers. After a thorough review, 
FDA decides whether to approve or disapproves NDA. If NDA is approved, the drug can go to 
the market and reach the marketplace. In some cases, post-market drug safety monitoring, which 
is sometimes expressed as phase 4 clinical trial, take place. The prevailing model of biomedical 
product development is provided in Figure 1.  
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Figure 1. The traditional process of biomedical product development  
Source: Fishburn (2013, p. 489) 
 
 Though abovementioned process is probably the most widely taken, there are new 
approaches that aim to accelerate the process of drug development (Knoepfler, 2015). For 
instance, FDA adopted paths to expedite the approval process by using surrogate endpoint as the 
evidence of safety and efficacy (e.g., accelerated approval mechanism), or putting more 
resources for the review (e.g., priority review mechanism) (Knoepfler, 2015). FDA also has 
some experimental regulatory approach such as Fast Track, which aims to speed up the approval 
process of breakthrough therapies that have been proven to have substantial enhancement over 
current therapies with preliminary experiment data (Knoepfler, 2015). Additionally, in some rare 
cases, FDA authorizes the use of unapproved drugs for the patients with terminal illnesses, which 
is referred as ‘compassionate use’ (Knoepfler, 2015; Zettler & Greely, 2014). The patient’s 
physician and drug company both have to agree on the use of the unapproved drug when 
submitting proposal to FDA (Knoepfler, 2015). FDA reviews the process in a case-by-case basis 
9 
and gives approvals in case the proposal shows enough sign of safety and if there are no other 
comparable treatment options for the patient (Zettler & Greely, 2014). 
 
2.1.2. Various stakeholders with heterogenous roles 
 
  The field of biomedicine is a representative field to which the concept of the National 
Innovation System (NIS) can be applied (Niosi, 2011). As there are multiple stages in biomedical 
product development, there are various stakeholders involved. Three major players traditionally 
mentioned in the NIS system, which are government, university, and private firms, all participate 
actively in the field (Niosi, 2011). In addition, there is a unique player in biomedical research 
arena that makes it distinct from other fields of science, which is the hospital (Hicks & Katz, 
1996; Lander & Atkinson-Grosjean, 2011). Though the division of institutions in biomedical 
research arena is continuously changing, having a good understanding on the traditional roles of 
each player would help us understand the complex translation mechanism of biomedical products 
(Lynskey, 2006). Hence, I provide brief descriptions of players in each sector as below.  
 Government. In the case of the U.S., federal government agencies include regulatory 
agencies like FDA and funding agencies like NIH. As described in detail in previous section, 
FDA is the agency that approves the market entry of a drug. It is generally considered to have the 
most rigorous drug approval process in the world, allowing it to function as the global standard 
in many cases (Nam, 2015). Though the high level of requirements from FDA would ensure the 
safety and efficacy of drugs, there is a call from the public for timely delivery of new biomedical 
products that can bring favorable balance of benefits and risk (Califf & Ostroff, 2015). This call 
reflects a variety of factors, including patient frustration with the pace of drug development as 
10 
well as the development of alternative regulatory models, such as Japan’s adoption of expedited 
conditional approval system in regenerative medical therapies3, which allows certain products to 
gain market access with only limited evidence of efficacy. In the similar vein, FDA is adopting 
new regulation tools to accelerate the process of translating discoveries into approvals such as 
accelerated approval system, priority review mechanism and introduction of compassionate use, 
which are described in the prior section (Califf & Ostroff, 2015; Knoepfler, 2015). This trend led 
to the enactment of the 21st Century Cures Act in 2016, which allocates substantial support to 
FDA for rapid drug approval process. This act allows active use of biomarkers, observational 
data and surrogate measure to streamline the drug approval process (Gabay, 2017). 
 NIH oversees discovery research and clinical research (Fishburn, 2013). It is the largest 
source of government funding for biomedical research in the U.S. and the global biomedical 
market (Fishburn, 2013). In 2018, NIH had a total budget of $37.4 billion (National Institutes of 
Health, 2017c). The NIH’s funding is awarded to researchers and institutions across all stages of 
the biomedical research pipeline from idea generation to clinical research (National Institutes of 
Health, 2017c). NIH also has its own laboratories that house around 6,000 scientists. In addition 
to traditional stages of research process, it also supports projects that aim to translate findings 
from basic research into clinical research, which is the focus of this dissertation and will be 
explained in detail later. 
 In the U.S., state governments also play an important role in the medical research 
ecosystem (Feldman, Lanahan, & Lendel, 2014; Nam, 2015). Individual states have adopted a 
wide variety of programs to support scientific research, including biomedical research, within 
their borders (Feldman et al., 2014). These include programs to fund biomedical research to 
                                                 
3 In 2014, the Pharmaceutical and Medical Devices (PMD) Act created an expedited conditional regime and Act of 
the Safely of Regenerative Medicine (ASRM) allowed cell processing to be outsourced (Japan External Trade 
Organizations, 2017). 
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advance promising science and return economic benefits (Feldman et al., 2014; Karmali, Jones, 
& Levine, 2010). For instance, states like California, Connecticut, Illinois, Maryland, New 
Jersey and New York have their own funding programs that support stem cell research (Karmali 
et al., 2010, Alberta, Cheng, Jackson, Pjecha, & Levine, 2015). In some cases, states make their 
own laws or regulations regarding the use of biomedical products. For example, the right-to-try 
bill took into effect first in Colorado in 2014, which allows the use of drugs that passed phase 1 
clinical trials, but without final approval from FDA, for the patients in severe condition4 (Zettler 
& Greely, 2014). We could expect that these conditions that only apply to a small subset of states 
would have an impact on the rate and speed of translation process of biomedical research.  
 Universities. Academic institutions, which are mainly research universities in the U.S 
context, take the role of conducting various kinds of studies including research on basic science. 
In the U.S., research universities started to be established in the 1880s, and there was a massive 
increase in the size from 1990s to 2000s, and now the number of organizations reached about 
350 in 2010 (Fishburn, 2013).  
 One of the major features regarding the structure of biomedical research network is that 
academic institution is the center of the network (Balconi, Breschi, & Lissoni, 2004; Lander, 
2013; Owen-Smith & Powell, 2003, Schummer 2004). Lander (2013) found that universities are 
the key players in the network that connects hospitals, government organizations and private 
firms together. In the similar vein, a study by Schummer (2004) showed that academic 
institutions dominate the biomedical research arena and they mediate the interaction between 
governmental research institutions and the industry. Also, Owen-Smith and Powell (2003) 
showed that academic institutions are the central player in the inter-organizational knowledge 
                                                 
4 This bill expanded to 38 states as of 2017 and was signed into federal law in May 2018 (Brown, Ortiz, & Dubé, 
2018) 
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transfer network in life science. All these studies show that universities are the central locus of 
innovation in biomedical research and suggest that it would be worth examining academic 
institutions carefully in order to understand the general aspects of biomedical research landscape.  
 There are many reasons that universities are the center of the biomedical research 
network. One of the reasons is that universities produce the most advanced technology in 
biomedicine. Together with publicly funded research institutes, universities have been producing 
the technologies in the frontiers (Lynskey, 2006). These technologies led to the production of 
valuable biomedical products and had made universities to be recognized as the leaders of the 
regional innovation system (Lynskey, 2006). The other reason is related to the emergence of the 
new mission of the university, in which the universities take the expanded role of community 
engagement beyond their traditional roles of teaching and research (Lander, 2013). Universities 
are getting more engaged in economic development activities (Lander, 2013). This led academic 
institutions to interact more with external partners, including private sector and governmental 
organizations (Etzkowitz et al., 2008). By having more links with industry, universities could 
learn more about how the industrial product development process works, and what topics are 
important to that product development process (Fries, Glave, & Radick, 2008). This will narrow 
the gap between two sectors and this would lead to more coherent and effective collaboration 
between the two (McElroy, Jones, & Barrault, 2017). 
 Private firms. In the private sector, pharmaceutical companies take major roles in the 
drug development process. The total R&D spending of pharmaceutical companies (PhRMA 
member companies) were $71 billion (Statista, 2019). The pharmaceutical industry is also a large 
employer, employing an estimated 650,000 globally (Fishburn, 2013). Beyond marketing and 
sale of commercial drugs, pharmaceutical firms also conduct research. One of the ways they get 
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engaged in this process is by partnering with academic institutions (Roy & Chaguturu, 2014). 
This kind of partnership benefits both parties as they can exchange resources and make 
translation of ideas easier (Munos, 2014). 
 Other major participants in the private sector are biotech firms, which have been around 
since the 1970s (Fishburn, 2013). They are defined as the companies using biological organisms, 
systems or processes for drug development itself or providing a platform for new drug 
development (Huggett, Hodgson, & Lähteenmäki, 2011). In many cases, biotech firms take 
major roles in basic research and early stages of clinical development (phase 1 and phase 2) 
(Fishburn, 2013).  They take advantage of translational research efforts that universities are 
conducting to enhance their chance of success in the early stage of drug discovery (McElroy et 
al., 2017). Biotech firms raise their funds through partnership deals with pharmaceutical 
companies, public market offerings and private investment (Fishburn, 2013; Huggett et al., 2011; 
Lynskey, 2006).  
 Other important players in the private sector of biomedical research arena are the 
investors, commonly referred to as angel investors and venture capitalists. Angel investors 
typically provide seed money to help the biotech firms move beyond pre-seed or seed stage, 
which typically requires $25,000 to $2 million (Eynott & Fages, 2014). Venture capital firms 
invest at various stages in the product development process, from the early stage of research to 
later stages much closer to commercialization. However, private investors are increasingly 
moving away from early-stage investing and don’t wish to take the risk of investing in 
technologies with uncertain commercial potential. Data shows that only 4% of venture capital 
funds went into early-stage companies in 2013 (Eynott & Fages, 2014). In this regard, it is 
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becoming more difficult for biotech companies to execute successful commercialization of the 
technologies they possess.  
 Hospitals. In the clinical pathway of innovation, biomedical technologies must be tested 
to become a product with commercial value, and hospitals are where the research outcomes of 
the academic institutions can be applied and tested (Lander, 2013). However, the role of the 
hospital is often overlooked when discussing biomedical research system and the network among 
hospitals, universities and their resources are sometimes considered as “hidden research system” 
(Lander & Atkinson-Grosjean, 2011). Even in the non-commercial sector of biomedical R&D 
where the novelty of the research outcomes is important, the role of hospitals can become more 
significant (Lander, 2013). As Dosi (1982) noted, non-commercial organizations like academic 
hospitals may be open to sharing their findings and be more enthusiastic in collaborating with 
others if they think they can benefit from the interaction (Lander, 2013). In this regard, 
considering hospitals as a major player in biomedical research network would overcome the 
approach of the framework that only focuses on the commercial actors (Lander, 2013) and helps 
us better understand the translation process in biomedical research. 
 We can see that there are numerous stakeholders involved in the biomedical research 
pipeline. However, substantial differences between organizations in terms of their goals and 
missions exist and, hence, some obstacles hinder the smooth progress of the drug development 
(Eynott & Fages, 2014). Therefore, the success of biomedical research will depend on how well 
each stakeholder deals with this complex environment of diverse players and how we improve 





2.2. The challenge: decreasing productivity and the ‘valley of death’ in biomedicine 
 
2.2.1. Eroom’s law 
 
 The number of new drugs approved by FDA per billion dollars spent has halved 
approximately every nine years since the 1950s (Scannell, Blanckley, Boldon, & Warrington, 
2012). This decreasing trend of productivity in drug development is represented by the term 
‘Eroom’s law,’ which is the word that arranges the letters of ‘Moore’s law’ backward (Scannell 
et al., 2012). Figure 2 illustrates the decreasing productivity of drug development. We can see 
that since the 1970s the rate of new drug approval is in a decreasing trend or in a constant state 
(shown by bars) despite the exponential growth in total R&D expenditure in drug development 
by the industry (shown by line) (The President’s Council of Advisors on Science and 
Technology, 2012).  The number of the FDA approved drugs, which is the sum of New 
Molecular Entity (NME) and the New Biologic Entity (NBE) approvals, tend to fluctuate without 
any sign of increase. In addition to the non-increasing trend of drug approvals, the number of 
new drug application to FDA is also in a decreasing trend (Borenstein, 2011). If we see the 
change of average number of FDA approvals per 2010 billion dollars spend in pharmaceutical 





Figure 2. Annual FDA approvals and total R&D Expenditures in 2010 dollars  
Note: Calculated with data from FDA and PhRMA 
 
 
Figure 3.Average FDA approvals per 2010 US billion dollars in R&D 
Note: Calculated with data from FDA and PhRMA 
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 The decrease of biomedical R&D productivity is mainly attributed to two main factors, 
which are correlated with each other. The first factor is that lengthy time is needed for the 
translation of the discoveries into the product at the bedside. Morris, Wooding and Grant (2011) 
stated that the average time between the invention of discovery in the basic side of the research 
and the creation of something that is clinically useful is 17 years. By looking at the time needed 
from basic science discovery to the publication of first highly cited human research article, 
Contopoulos-Ioannidis, Alexiou, Gouvias, & Ioannidis (2008) showed that the median value of 
this time lag is 24 years. For some special cases, it may even take around 30 years to go through 
this process (Wilhelm et al., 2016). Also, in recent years, new type of therapies that are different 
from the traditional treatments using small molecule and biologics are emerging (Dodson & 
Levine, 2015). The introduction of this new concept of therapies, like cell therapies, make 
regulatory processes difficult to predict and could lead to a longer development process than 
before (Dodson & Levine, 2015). 
The second related factor is the increasing cost of drug development. Kinch and Hoyer 
(2015) stated that the cost of discovering a new drug in the U.S. has been increasing and is now 
$2.6 billion. Some of the many factors contributing to the rise of the drug development costs are 
unmet medical needs becoming more complex, call for larger group of patients needed for 
clinical trials, stricter rules and more extensive testing, and emergence of rare diseases (Kinch & 
Hoyer, 2015; Nam, 2015; Wild, Huwe, & Lessl, 2013). In addition, novel therapies, such as cell 
therapies, could encounter high cost due to lack of pre-existing tools, reliable production line and 
distribution logistics (Dodson & Levine, 2015). The increasing cost puts investors at risk and 
may encourage risk-averse behavior when making investment decisions. Therefore, private 
funding is moving more towards the safer target (e.g., later stage proof-of-concept), which 
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subsequently led to less progress in the early stage of R&D that is essential to the productivity 
growth (Eynott & Fages, 2014; Kinch & Hoyer, 2015).  
 
2.2.2. Valley of death in biomedical research 
 
 Usually, the early-stage of biomedical research pipeline and later-stage of the 
development do not suffer from extreme investment shortage (Steinmetz & Spack, 2009). The 
entities in public sector (e.g., federal government, foundations and state programs) invest heavily 
in early-stage biomedical research and universities and national laboratories actively participate 
in this stage of R&D (i.e., discovery and basic science). The funding for the later stage of the 
development comes from the private sector (e.g., big pharmaceutical companies, public-private 
partnerships and venture capital firms) and private firms voluntarily take part in the later stage of 
the process (i.e., product development and production). On the other hand, the cash flow between 
these two parts falls dramatically, leading to longer time between basic research and late-stage 
research, which is termed the ‘valley of death.’ (Ciensiski, 2015; Eynott & Fages, 2014; 
Steinmetz & Spack, 2009). The existence of the ‘valley of death’ is attributed to the fact that the 
chance of getting a significant return on research at this stage is not high and it requires a lot of 
investment (Ciensinski, 2015; Eynott & Fages, 2014).  
 The origin of the concept of the valley of death is from studies on innovation in general 
(Butler, 2008; Ciensinski, 2015). It illustrates the gap between basic science and product 
development (Figure 4). The step between basic science and product development is applied 
research, which translates the outcomes from basic research into a commercially valuable 
product (Ciensinski, 2015; Eynott & Fages, 2014). In biomedical research pipeline, the stage of 
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the valley of death is where the preclinical development, early clinical trials and some parts of 
early commercialization take place, which is essential for the FDA approval of biomedical 
products (Steinmetz & Spack, 2009). Due to monetary shortage in these stages, researchers get 
limited access to resources that are essential in technology commercialization procedures (e.g., 
scientific and business expertise, facilities, grant money) (Steinmetz & Spack, 2009). This in turn 
leads to a large portion of outcomes from basic research being not translated into actual products 
with commercial value.  
 
 
Figure 4. Illustration of the “Valley of Death”  
 
Source: Ciensinski (2015) 
 
 As explained, the concept “valley of death” is mainly used to describe the monetary 
shortage. However, the concept is not explained by a single factor (Butler, 2008). It is a 
comprehensive concept that involves various factors that slow down the process of passing 
through the commercialization chasm. For instance, Butler (2008) argues that one of the reasons 
that led to the creation of the “valley of death” is the difference between the incentive system of 
basic scientists and that of clinical scientists. He claimed that for the basic scientists, their 
assessment largely depends on the quantity and the quality of the academic journal papers in 
their field, whereas physicians are assessed largely by other factors like the number of patients 
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they treated. Hence, basic scientists prefer to stay in their comfort zone of conducting research 
that can result in basic science publications and do not wish to participate in works related to 
clinical science (Blümel, 2017; Butler, 2008).  
 Unfortunately, what is evident is that the problem of the “valley of death” is not likely to 
be solved without the intervention from the public sector. As stated in the earlier sections, private 
investors are investing increasingly less on biomedical technologies in early commercialization 
stage to take risk and invest more on the technologies that are proven to have high potential of 
being commercialized (Eynott & Fages, 2014; Kinch & Hoyer, 2015; Moran, 2007). In this 
regard, to solve the problem, the research community needed a new approach with players in the 
public sector taking the leading roles.  
 
2.3. Translational research: A new solution for “valley of death” in biomedical research 
 
2.3.1. The concept of translational research 
 
 To tackle the problem of low productivity in biomedical research, the research 
community sought a new solution. As mentioned in previous sections, a series of studies pointed 
out that remarkable advance in basic biomedical research has not led to significant increase of 
new medicine, and many pointed out the “valley of death” as the core reason for this 
phenomenon. As a result, the concept of translational research attracted the interest of the 
biomedical research community as it had the purpose to fill and bridge the gap between basic 
science and clinical science  (The President’s Council of Advisors on Science and Technology, 
2012). Having started to gain popularity in the 1990s (Lander & Atkinson-Grosjean, 2011), 
translational research has been promoted over the past couple of decades as a potential tool to 
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speed up the slow process of moving research innovations into clinical interventions and 
acceptance5 (Fishburn, 2013; Stevenson et al., 2013).  
 One other reason that led to the emergence of translational research is to answer the 
questions from the society at large. As various societal issues in the society need science for their 
solutions, there has been continuous request from the society that science should get involved 
(Blümel, 2017). Translational research can be seen as a response to this call for societal impact 
of science and it aims to produce knowledge that benefits the patients and ultimately the society 
as a whole (Blümel, 2017). In this regard, we can see that the goal of translational research seems 
clear. Its aim is creating new research outcomes that are closely related to patient needs and 
translating discoveries in the laboratory into new clinical therapies (Fishburn, 2013; Surkis et al., 
2016). The concept and definition of translational research are provided by institutes like NIH, 
Institute of Medicine (IOM), Translational Research Working Group of the National Cancer 
Institute (NCI). They all share the similar aspects and goals of increasing efficiency and reducing 
the time of transfer of fundamental scientific research into clinical research by bridging the “gap 
between the bench to bedside” (Rubio et al., 2010; Han, Williams, & Zuckerman, 2018).  
 The core feature of translational research is that it needs to bring people together for the 
success (Lander & Atkinson-Grosjean, 2011). As translational science span a wide range of 
boundaries of science, breaking down academic barriers, particularly between disciplines, is 
essential in the process (Lander & Atkinson-Grosjean, 2011). Many scholars claim that scientists 
in universities and hospitals should collaborate with the common goal of bridging basic science 
                                                 
5 One specific example of translational research is a study by Bhat et al. (1997) that found binding of fusion genes 
(BCR-ABL) and certain type of protein (c-CBL) only occurs when phosphate (PO43-) is added to acid (amino 
tyrosine) on a protein. Their finding was applied in treating genetic abnormality in chromosome 22 of leukemia 
cancer cell and led to the invention of Tasiga® (Sampat and Pincus, 2015). Another example of translational 
research is a study by Garg and Hassid (1990). They found out that proliferation of cell lines developed from 
disaggregated mouse embryos (BALB/c 3T3) is more active when muscle smoother is not present (CGMP-
independent mechanism). Their finding was applied in solving respiratory failure problem and this led to the 
invention of INOmax® (Sampat and Pincus, 2015). 
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and clinical practice (Lander & Atkinson-Grosjean, 2011). By doing so, the chance of generating 
discoveries that can benefit both basic science and clinical science will increase (Lander & 
Atkinson-Grosjean, 2011).  
 Scholars and practitioners sometimes characterize translational research as consisting of 
multiple stages.  One approach divides translational research into two steps. This approach 
claims that translational research is usually composed of two bidirectional stages (Drolet & 
Lorenzi, 2011; Han et al., 2018; Rubio et al., 2010; Kim, 2013; U.S. National Library of 
Medicine, 2017). The first stage, usually denoted as T1, involves transferring results from early-
stage basic research into clinical research and the second stage, usually denoted as T2, involves 
spreading the use of research outcomes from clinical studies in actual practice and settling in 
local communities (Rubio et al., 2010). The second approach takes translational research as a 
four-stage process (Weber, 2013). These four stages are diagnosis or treatment (T1), evidence-
based research (T2), clinical practice (T3) and verification for actual practice (T4) (Lander & 
Atkinson-Grosjean, 2011). The third approach, presented in the study by Surkis et al. (2016) and 
originally from reports from NCATS and Institute of Medicine, assumes that there are five steps, 
which are basic biomedical research (T0), translation to humans (T1), translation to patients (T2), 
translation to practice (T3) and translation to communities (T4). In this dissertation, I will focus 
on the stages related to the research activities (e.g., T1 in two-stage approach, T1 and T2 in four-
stage approach and T0, T1 and T2 in five-stage approach). 
 
 
2.3.2. Support for translational research in the United States 
 
A brief history 
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 The private sector, represented by biotech firms, has tried to narrow the translational gap 
for a long time but it turned out they failed to accomplish their goal completely (Gittelman, 
2016). Since the early 2000s, NIH realized the problem and started taking action in supporting 
this ‘gap filling’ research (Gittelman, 2016). In the U.S., NIH Director Elias Zerhouni announced 
that the NIH would emphasize translational research as a part of its roadmap in 2003 (Han et al., 
2018). In this roadmap, Zerhouni (2003) claimed that translational research could be a solution to 
solve uncertainty problems in clinical research. In 2005, NIH unveiled its Roadmap 
Interdisciplinary Research Initiatives and announced that the organization would put more effort 
into promoting translational research (Huerta et al., 2005; Lander & Atkinson-Grosjean, 2011). 
After the announcement of related roadmap and initiative in 2003 and 2005 respectively, NIH 
created an award dedicated to supporting translational research named Clinical and Translational 
Research Award (CTSA) in 2006 (Blümel, 2017). The NIH designated twelve institutions per 
year on average in the early period as the recipient of CTSA (Obeid et al., 2014). In 2012, six 
years after the creation of CTSA, an independent organization specialized in managing 
translational research named the National Center for Advancing Translational Science (NCATS) 
was established6. The budget of NCATS has increased from $545 million in 2013 (1.8% of total 
NIH budget) to $742 million in 2018 (2.0% of total NIH budget)7, which is one evidence that 
NIH is in the process of increasing its support for translational research. Figure 5 shows major 
events regarding the NIH’s increasing support for translational research.  
                                                 
6 NCATS was created with the dissolution of the National Center for Research Resources (NCRR) that managed 
CTSA programs. It was founded to deal with the topics like 1) Bridging Interventional Development Gaps (BrlDGs), 
2) Clinical and Translational Science Awards (CTSA), 3) Cures Acceleration Network, 4) FDA-NIH Regulatory 
Science, 5) Office of Rare Disease Research, 6) Therapeutics for Rare and Neglected Diseases (Rockey, 2012). 




Figure 5. Major events of NIH’s support for translational research 
 
The CTSA program 
 
 The CTSA program is the heart of NIH’s effort to support translational research. The 
institutions that receive the CTSA award establish Clinical and Translational Science Centers 
(CTSC)8 and become the member of national NIH CTSA consortium (Butler, 2008), which 
shared $500 million in the fiscal year 2016 (Surkis et al., 2016). The consortium has the shared 
goal to enhance the efficiency and the quality of the translational research (Clinical and 
Translational Science Awards Consortium, n.d.-a). The size of the consortium increased from 12 
in 2012 to 63 in 2015 (Figure 6 and Appendix A). CTSCs’ services are not limited to technical 
support. They also 1) provide infrastructure with multiple uses, 2) provide tools for collaboration, 
3) support pilot programs, 4) provide education and training, 5) provide administrative support 
(Leshner et al., 2013; CTSA Principal Investigators, 2012). To get a better understanding of the 
program, some details of each element is provided below. First two factors are related to both 
clinical and translational research, while other factors are more closely related to translational 
research. 
                                                 
8 CTSCs can be regarded as an enhanced version of the General Clinical Research Centers (GCRCs) that started 
their operation in 1959 in universities and medical centers, which mainly focused on conducting clinical trials 
(Leshner et al., 2013). The budget of 78 GCRC sites in 2005 was $288 million, which is around 1.0% of total NIH 
budget that year (Leshner et al., 2013).   
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Figure 6. Number of organizations with the history of receiving the CTSA award 
 
 Infrastructure with multiple uses. Broad and reusable facilities that can be used in 
multiple disease domains are provided. It has been reported that 5,866 NIH grants in 2010 used 
facilities made with CTSA grant money (Leshner et al., 2013). Centers, such as Clinical 
Research Centers (CRC), which provide facilities for laboratory, nursing care and more, are 
established in multiple sites with the funds in this category (Leshner et al., 2013). CRCs provide 
resources to researchers that plan to conduct clinical studies that span across all stages of drug 
development. CRCs also facilitate drug repurposing studies (CTSA Principal Investigators, 2012) 
 Administrative support. CTSA receiving institutions also provide administrative 
support to streamline research (e.g., to reduce the time for Institutional Review Board (IRB) 
protocol review). For example, electronic sharing resource (e.g., IRBshare) is provided to the 
researchers to reduce the length of time needed for IRB approval award (CTSA Principal 
Investigators, 2012). Also, as a part of administrative support, support on contract negotiation 
and support on the recruitment of clinical trial participants are also provided (CTSA Principal 
Investigators, 2012). 
26 
Provide tools for collaboration. Figure 7 shows the map of where CTSA receiving 
institutions are located. We can see that the centers are located all over the nation with the focus 
on the regions that traditionally stand out in the field of biomedicine (e.g., California, 
Massachusetts, and Maryland). The CTSA program provides tools that help collaboration among 
these organizations and beyond. For instance, a web-based system that helps to locate experts in 
various disciplines (e.g., Profiles Research Network software, VIVO) are established (CTSA 
Principal Investigators, 2012). Also, systems for the data collection and information sharing are 
being operated (e.g., CTSA Intellectual Property Portal, Pharmaceutical Assets Portal) (CTSA 
Principal Investigators, 2012). 
 
 
Figure 7. Map of CTSA-funded institutions  
Source: Clinical and Translational Science Awards Consortium (n.d.-a) 
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 In addition to these technical tools, an initiative called the Trial Innovation Network (TIN) 
was formed within the CTSA program in 2016 to facilitate more collaborations between 
institutions within CTSA recipients (Clinical and Translational Science Awards Consortium, 
n.d.-b). TIN is composed of three key organizational partners, which are 1) the CTSA Program 
Hubs, 2) the Trial Innovation Center (TIC), and 3) the Recruitment Innovation Center (RIC). 
There are three TICs nationwide, based at Johns Hopkins University, the University of Utah and 
the Duke University - Vanderbilt University Medical Center Partnership9 (Slagle, 2016).  
 Support pilot programs. CTSAs typically allocate a portion of their funding to support 
small-scale pilot projects (National Institutes of Health, n.d.). This is to help researchers generate 
preliminary data for grant proposals and develop innovative methods and technologies (CTSA 
Principal Investigators, 2012; Leshner et al., 2013). The process of allocating pilot grants is 
designed to be flexible and simple so that it can provide opportunities to junior researchers and 
help them develop their research abilities (CTSA Principal Investigators, 2012). In 2011, around 
2,000 pilot studies were conducted in various CTSA receiving institutions (CTSA Principal 
Investigators, 2012). 
 Education and training. One of the CTSA award’s aims is to launch new educational 
initiatives to strengthen clinical research capabilities and improve the career of clinical 
researchers (Weber, 2013; Luke et al., 2015). To do so, CTSA provides training programs for 
acting clinical scientists with supplementary KL2 award (CTSA Principal Investigators, 2012; 
Knapke et al., 2015; Surkis et al., 2016). The CTSA program also supports master’s degree 
                                                 
9 Duke University – Vanderbilt University Medical Center partnership is a unique case in the sense that it is the only 
case with multiple leading institutes (Slagle, 2016). The partnership is between Duke Clinical Research Institute 
(DCRI) and Vanderbilt University Medical Center (VUMC), and the grant is planned to last for seven years with 
grant size of $26.5 million (Slagle, 2016). 
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programs in clinical and translational research with TL1 award (CTSA Principal Investigators, 
2012).  
 Each CTSA receiving institution sets priorities for their funding based on their specific 
situation10 but, all in all, the CTSA program aims to change the working environment of the 
whole institution. Activities associated with CTSA awards can support essentially all researchers 
and projects affiliated with the award-receiving institution. CTSA awards do not concentrate on 
certain type of disease or certain group of researchers, but rather aim to reach out to whoever 
needs support. Hence, when analyzing the effects of the CTSA award, it would be reasonable to 
consider all the projects conducted within the institution or all researchers affiliated with the 
institution. 
 
2.3.3. Support for translational research in other countries 
 
       Similarly to the U.S., other countries around the world are also placing an increasing 
emphasis on translational research (Butler, 2008; Blümel, 2017). European countries created 
funding programs dedicated to translational research to improve the capabilities of the research 
system (Blümel, 2017). For instance, in the UK there has been an increase in the budget of the 
Medical Research Council (MRC) in 2010 with the aims to increase support for translational 
research (Medical Research Councils UK, 2017). This was a part of the MRC’s Translational 
Research Strategy that was announced in the same year (Blümel, 2017; Lander & Atkinson-
Grosjean, 2011). Similarly, there is a fund named Scottish Universities Life Sciences Alliance 
                                                 
10 For instance, Georgia CTSA (partnership between Emory University, Georgia Institute of Technology, 
Morehouse School of Medicine, University of Georgia and) mentions on their website that their priorities are 
workforce development, collaboration/engagement, integration, methods/processes and informatics (Georgia 
Clinical & Translational Science Alliance, n.d.). Similarly, Northwestern University’s CTSA program’s three major 
categories of funding are pilot program, team science and career development (Northwestern University, 2019).  
29 
Assay Development Fund (SULSA) (McElroy et al., 2017). It is a £27 million fund established 
by the Scottish Funding Council, which has an aim to unlock the translational potential of new 
biology that meets industry’s needs (McElroy et al., 2017).  
 One thing to note regarding support for translational research in Europe is that European 
countries conceptualize translational research differently compared to the case of U.S. (Blümel, 
2017). In his study that tried to find out the differences in framing of translational research 
between the U.S. and European countries, Blümel (2017) maintained that the U.S. frame existing 
problems related to translational research as professional issues that are closely related to 
individual researchers whereas European countries frame the problem as an organizational issue. 
Blümel (2017) states that the reason for the disparity is due to the difference in their conception 
of science. While the U.S. emphasizes the scientific values in accordance with the scientific 
norms and standards, European countries focus on the problems of organization in the research 
sector when seeking for solutions (Blümel, 2017). In this vein, European projects with the aim to 
address translational research problems focus on changing the structural aspect of the research 
system, such as making new organizations or consortium. A representative example of this 
movement would the creation of European infrastructure for translational medicine (EATRIS). 
EATRIS, created in 2013, is a network of European biomedical translation hubs based on more 
than eighty academic research centers (Blümel, 2017; EATRIS ERIC, n.d.). It is the first 
European Research Infrastructure Consortium in the field of biomedicine (European Commission, 
2017), and it provides high-end facilities and cutting-edge technologies to derisk and add value 
to studies related to translational research (EATRIS ERIC, n.d.).  
 There are similar movements in Asian countries as well. China’s National Center for 
Translational Medicine and several other centers provide facilities and funding opportunities 
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specific to translational research (Williams, 2016). Also, Japan established the Translational 
Research Informatics Center, now the Translational Research Center for Medical Innovation, 
back in 2002 to facilitated the transfer of findings from basic medical research to clinical practice 
(Translational Research Informatics Center, 2003). It promotes academic oriented medical 
innovations by supporting medical researchers for all phases of biomedical study (Fukushima & 
Kimura, n.d.). In Korea, the concept of translational research was introduced in the 2000s and the 
Ministry of Health and Welfare started supporting translational research in 2005 (Kim, 2013). As 
various stakeholders like research universities, government subsidized research institutes, private 
companies and hospitals got aware of the concept, there is a growing interest in this new concept 
of research in Korea (Kim, 2013). However, as the definition of translational research is not 
consistent, similar to other countries, the Korean research community is experiencing a hard time 
supporting and conducting the research (Kim, 2013). However, it is apparent that the research 
community agrees on the importance of such type of research and believes that it will increase 





CHAPTER 3. CHANGE OF COLLABORATION AMONG RESEARCH UNIVERSITIES 




 Chapter 3 of this dissertation focuses on the change in the collaborative landscape of 
biomedical research among the research-intensive universities in the U.S. Promoting 
collaboration between institutions is one of the most important goals of CTSA award (Luke et al., 
2015). NIH aims to accomplish this goal by introducing various tools that could facilitate 
interaction between organizations (Obeid et al., 2014). 
 By using co-authorship of publications as the evidence of collaboration, my analysis aims 
to find out if this effort leads to significant change in the network structure after the initiation of 
the CTSA program. Descriptive analyses of key social network analysis variables (e.g., density, 
centrality) were used to characterize the overall structure of the network. Then, to analyze the 
relationship between CTSA and frequency of interactions between academic institutions more 
systematically, advanced social network analysis regression model, such as Exponential Random 
Graph Model (ERGM) and Temporal Exponential Random Graph Model (TERGM), were used. 
The findings regarding the entire network showed that the biomedical research collaboration 
network is becoming denser and less centralized in general. For the individual institutions, the 
status of taking advantage of the CTSA award led to more collaborations and collaborators.  
 This chapter expects to contribute to the literature on the impact of the CTSA award as 
well as research collaboration in the field of biomedicine in general. The findings could provide 
insight into how the CTSA award should be operated to promote more collaboration between 
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institutions. Also, empirical evidence showing how and to what extent government funding 
changes inter-organizational collaboration patterns could help policymakers set relevant science 
policies more broadly.   
  
3.2. Literature review 
 
3.2.1. Factors affecting research collaboration and their relevance with the CTSA award 
   
 Collaboration in scientific research is widespread and team-based research dominates 
solo research in science (Walsh & Maloney, 2007; Price 1986). Scholars assert that science is a 
social institution where interaction between scientists is crucial to its advancement (Kats & 
Martin, 1997) and will contribute to technological and economic well-being (Mowery, 1998). 
Numerous factors exist that encourage collaboration in science, which can lead to the formation 
of research teams. In this section, I aim to identify the key factors that shape the collaborative 
landscape of biomedical research and that are related to the CTSA award. I will first point out the 
factors that apply to scientific research in general and try to relate them with collaborations 
formed due to the CTSA award.  
 Access to resources. One benefit of scientific collaboration is the sharing of resources 
(Bozeman & Corley, 2004; Katz & Martin, 1997; Gaughan, Melkers, & Welch, 2018). When 
scientists interact with others, they get access to the resources that they would not have access to 
otherwise. These resources are in various forms; tangible resources like equipment, intangible 
resources like professional advice (Gaughan et al., 2018). The CTSA award provides facilities 
with multiple use and administrative support to researchers (CTSA Principal Investigators, 2012). 
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As the researchers affiliated with the CTSA receiving institutions would have access to these 
resources, these researchers would be attractive partners for those who do not have these kinds of 
resource.  
 Financial incentive. Financial factors also affect the formation of research collaboration 
and this feature applies to biomedical field as well. Financial incentive is what government 
programs use to promote collaboration between institutions, sectors and disciplines (Defazio, 
Lockett, & Wright, 2009; Katz & Martin, 1997; Walsh & Maloney, 2007). In some cases, 
government programs provide grants only if the applicants show enough evidence of future 
collaboration plan in their application (Katz & Martin, 1997). This is also true in the case of the 
CTSA award. NIH requires CTSA applicant to provide their plan to collaborate with various 
stakeholders in the health community (National Institutes of Health, 2017b). Therefore, CTSA 
applicants are expected to seek external partners before the application and actually collaborate 
with other organizations during the period they receive the award.  
 Mentorship. Another major factor that impacts research collaboration is mentorship 
(Katz & Martin, 1997). With collaboration with others, scientists can gain advice and get access 
to the expertise of their collaborators when they get mentored (Bozeman & Corley 2004; 
Gaughan et al., 2018). Also, they can form an intellectual companionship with their collaborators 
that can be used in their future research (Katz & Martin, 1997). This is important because past 
collaborators may be more open to sharing their resources than new collaborators (Gaughan et al., 
2018).  
 There is a rising demand of researcher with expertise in translational research and the 
CTSA program has made good progress in educating and training people on translational 
research (Working Group of the NCATS Advisory Council to the Director, 2014). Researchers 
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affiliated with CTSA receiving institutions would have a higher chance of having received 
training on translational research than the researchers affiliated with institutions not receiving the 
CTSA award. Hence, research teams involved in translational research would be seeking 
research collaborators who are members of CTSA receiving institutions to take advantage of 
their learning experience and insight in the translation process (He, Geng, & Campbell-Hunt, 
2009). In this respect, we could expect that scientists belonging to the CTSA receiving 
institutions will be popular as research collaborators.  
 Source of creativity. The fact that scientific collaboration could be a source of creativity 
also affects scientific network formation (Katz & Martin, 1997). As scientific questions are 
becoming increasingly more complex (Bozeman & Corley, 2004; Gaughan et al., 2018; Katz & 
Martin, 1997), many problems cannot be solved with conventional intradisciplinary approach 
and there is more need for combination of various views (He et al., 2009; Katz & Martin, 1997). 
This leads to the need for collaborations that span across various disciplines (Walsh & Maloney, 
2007; Lee & Bozeman, 2005; Luke et al., 2015). As collaboration with other disciplines may act 
as a source of stimulation and creativity, it may help the scientists come up with new techniques 
and subsequently lead them to save time in solving problems (Katz & Martin, 1997). This 
attempt to break down disciplinary silos may lead to strong scientific evidence and provide the 
society a great return (Luke et al., 2015). 
 The CTSA award promotes multidisciplinary research as mentioned in its Funding 
Opportunity Announcement (FOA) (National Institutes of Health, 2017b). The FOA states that 
the CTSA receiving institutions should provide incentives to teams with multidisciplinary 
members. In this regard, research teams that get support from the CTSA award are likely to try to 
bring researchers from various disciplines together. 
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 However, the tools provided from the CTSA program that promote inter-organizational 
collaboration may have unintended consequence that further strengthens intradisciplinary 
collaboration. The CTSA program provides various online tools (e.g., Profiles Research Network 
Software) to support researchers in finding collaboration partners (CTSA Principal Investigators, 
2012). These tools have the aim to help researchers locate experts in various disciplines (CTSA 
Principal Investigators, 2012). However, based on the claim by Van Alstyne and Brynjolfsson 
(1996), the information technology could lead to narrower scientific interactions. They assert that 
using these tools could help the researchers find people and works that really interest them, 
which is likely to be in their own discipline (Van Alstyne & Brynjolfsson, 1996). As a result, the 
phenomenon of balkanization of science by the “topic space” can be strengthened. This feature 
can also be applied to the web-based search tools provided by the CTSA program and more 
monodisciplinary research may take place rather than more multidisciplinary research. 
 
3.2.2. The impact of the CTSA award on research collaboration network 
 
 Few studies have explored how NIH’s support for translational research has changed the 
biomedical research network landscape. Luke et al. (2015) studied the case of the Institute of 
Clinical and Translational Sciences (ICTS) at Washington University, which received CTSA 
from 2007. They studied how the scientific collaborations among the ICTS members change by 
year. By looking at the grant application documents submitted to ICTS, they found out that 
researchers increase their collaboration with others in both project planning and dissemination of 
their research finding. This result holds for two study samples, which are the group with only the 
members who were ICTS members from the first place and the other group including all 
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additional members who joined ICTS during the period of analysis (2007 -2010). Hughes et al. 
(2010) looked at the case of University of Pennsylvania, another CTSA recipients. They 
investigated the Institute for Translational Medicine and Therapeutics (ITMAT) at University of 
Pennsylvania and saw how the collaborative landscape changed using social network analysis 
methods. By looking at co-authorship patterns, they showed that not only the network size 
among ITMAT’s member researchers grew substantially but also the frequency of collaboration 
has increased dramatically. The network structure within University of Arkansas, which started 
receiving the CTSA award in 2009, was analyzed by Bian et al. (2014). By looking at the change 
of collaboration network in research grants of University of Arkansas for Medical Sciences 
before and after receiving the CTSA award, they found out that research teams are becoming 
more multidisciplinary.  
 These studies looked at the impact of CTSA mainly using descriptive analysis on a single 
or small group of organizations. They show that the CTSA award clearly had an impact on the 
intra-organizational research collaboration. However, they did not investigate inter-
organizational collaboration change, which is one of the core goals of the CTSA award. 
Therefore, it would be meaningful to look at the impact of the CTSA award on the collaboration 
network among institutions. By doing so, we could be able to figure out whether the tools11 that 
were introduced by CTSA institutions with the purpose to promote inter-organizational 
collaboration were effective or not. We could also see if various factors affecting research 
collaboration, which are mentioned in the previous section, come into play in shaping the 
network.  
 
                                                 
11 One example is the electronic research network system that provides information on researcher’s status and 
ongoing projects (Obeid et al., 2014). From the survey of CTSA member institutions, Obeid et al. (2014) found that 
this system was effective in fostering cross-institutional collaboration.  
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3.3. Theoretical background and hypotheses 
 
 Scientists choose to collaborate depending on a variety of strategies and motives (Lee & 
Bozeman, 2005; Bozeman & Corley, 2004) and various theories can be applied in explaining the 
factors related to biomedical research collaboration. The first group of theories I want to mention 
is related to resource dependence approach. These resource-based theories can be used to explain 
the phenomena that the ones with more resources tend to have more links than the ones with 
fewer resources (Katz, Lazer, Arrow, & Contractor, 2004). This theory explains the general 
phenomena that research groups with large grants tend to have many collaborators (Bozeman & 
Corley, 2004). One of the theories adopting this approach is the theory of social exchange and 
dependency. This theory claims that people tend to form ties with others that they can exchange 
valuable resources with or get valuable resources from (Homans, 1950). As scientific projects 
are becoming more difficult and the structural complexity of collaboration increase (Walsh & 
Maloney, 2007), scientists need more resources for the successful execution of projects. 
Therefore, the ones that lack resources (e.g., supporting facilities, knowledge on the field) would 
try to form a relationship with others for the successful execution of a project (Walsh & Maloney, 
2007).  
As noted, the CTSA program provides resources for instrumentation, collaboration, training, 
pilot research and administrative support for translational research (Clinical and Translational 
Science Awards Consortium, n.d.-a; Leshner et al., 2013). Hence, based on the social exchange 
theory, the researchers affiliated with institutions having scarce resources, in this case those not 
taking advantage of the CTSA award, would be willing to make ties with CTSA recipients as 
they can benefit from the resources that they do not possess. This would lead to the situation 
where the researchers experience an increase of inter-organizational collaborations with other 
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researchers after their affiliated institutions start taking advantage of the CTSA award. The 
CTSA receiving institutions would also want to form collaborations with institutions not 
receiving the CTSA award based on the self-interest paradigm, which will be discussed later. To 
summarize, we can expect that the CTSA recipients will have more collaborators than the 
institutions not receiving CTSA based on the resource-based theory and I set the following 
hypotheses based on this expectation. 
 
Hypothesis 1: The institutions receiving the CTSA award would have more 
collaborating institutions than the institutions not receiving the CTSA award when the 
impact of the CTSA award gets realized. 
 
Hypothesis 2: The institutions receiving CTSA award would experience higher 
growth in the frequency of collaborations with their partners than the institutions not 
receiving the CTSA awards when the impact of the CTSA award gets realized. 
 
Hypothesis 1 is related to the increase of collaborating partners following the receipt of 
the CTSA award. A binary measure on whether you have a connection with others will be used 
to test this hypothesis. On the other hand, hypothesis 2 is related to the frequency of interaction 
between institutions. Therefore, a weighted measure incorporating the frequency of 
collaborations will be used for testing the hypothesis. When testing either of the hypotheses, we 
need to take into account the time lag between funding and the point when the impact of the 
award gets realized.  
The other theory related to the resource-based approach in collaboration is the theory of 
self-interest paradigm. This theory explains that a tie is formed between two parties if it increases 
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each individual’s interest (Katz et al., 2004). The common interest of those who apply to a grant 
pursue is increasing their chance of being selected as the recipient of the grant. In that regard, in 
case the funder of a grant states that collaborating with certain types of partners would give them 
a higher chance of acceptance, potential applicants would seek for that kind of partners for the 
application. In the case of CTSA program, with the aim to create regional hubs for translational 
research, its FOA (National Institutes of Health, 2017b) requires institutions to provide plans to 
collaborate with a diverse range of partners including local communities, government, non-profit 
organizations and other universities. Therefore, to raise their chance of receiving the grant, 
potential applicants of CTSA would try to make partnership with these parties before they submit 
their applications to NIH. In this respect, self-interest approach can help us understand why 
CTSA institutions reach out to other institutions, which in turn will bring CTSA institutions 
more collaborators in the periphery. Based on this expectation, I developed the following 
hypothesis. 
 
Hypothesis 3: The biomedical research network will become less centralized as the 
institutions taking advantage of the CTSA award interact with institutions not taking 
advantage of the CTSA award more than before. 
     
3.4. Data and methodology  
 
3.4.1. Empirical setting 
 
Co-authorship as the evidence of collaboration 
 Selecting the best indicator to measure research collaboration is a challenge (Katz & 
Martin, 1997; Lee & Bozeman, 2005). As Katz and Martin (1997) noted, research collaboration 
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is an ill-defined field as there are a variety of views on the concept of research collaboration. 
Researchers have been trying to find out the most appropriate measure for research collaboration 
and co-authorship is one of the most widely used measures in measuring scientific collaboration 
(Balconi et al., 2004, Katz & Martin, 1997; Lander 2013; Newman 2004). Co-authorship is an 
undirected measure that takes individual authors or author’s affiliations as nodes and existence of 
coauthored paper as links (Ding, 2011).  
 When doing research on scientific research network, using co-authorship has many 
advantages. Balconi et al. (2004) claimed that it is an ideal quantitative indicator that examines 
the relationship between academic scientists if knowledge exchange occurs in team-working 
experience, which is the case in most collaborative scientific research. Co-authorship is generally 
regarded as an unobtrusive measure of research collaboration (e.g., Qin, Lancaster, & Allen, 
1997) with stability over time and good verifiability (Katz & Martin, 1997). It can also be 
transformed into other measures like the number of authors, the number of institutional 
affiliations and the number of disciplines (Qin et al., 1997) and other social network analysis 
measures.  
 It is true that using co-authorship as the measure of collaboration has some limitations. 
First, co-authorship may not always mean that actual collaboration took place. For instance, 
people who just provided materials, the “guest authors,” or those who just did routine tasks may 
also be listed as one of the coauthors (Stokes & Hartley, 1989; Jabbehdari & Walsh, 2017). 
However, there are clear criteria for authorship for journals in life science, which is focus of my 
study. For instance, International Committee of Medical Journal Editors (ICMJE) has its own 
guideline on authorship and it is adopted by 600 biomedical journals (Jabbehdari & Walsh, 
2017). Their guideline states that to be listed in the coauthor list a person should have substantial 
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contribution to the work, should have taken critical role in drafting or revising the work and 
should have participated in the final approval of the work (International Committee of Medical 
Journal Editors, 2019). This kind of guidelines could reduce the concern about the existence of 
the “guest authors” and increase the reliability of the co-authorship data. Secondly, co-authorship 
can only capture official collaborations. Research collaboration can take various forms that don’t 
leave any records such as discussions in meetings. By nature, these kinds of informal 
collaborations cannot be captured by co-authorship. However, we should note that all other 
indicators, not only the indicators based on co-authorship, cannot capture unofficial collaboration 
easily. Very time-consuming job, like interviewing all researchers, would be needed to capture 
undisclosed relationship regarding research collaboration. Given the scope of my research, using 
this kind of approach in measuring collaboration is almost impossible. Hence, even using co-
authorship has some limitations I will be using this “codified markers of collaboration” (Park, 
Yoon, & Leydesdorff, 2016, p. 1017) as the evidence of collaboration in my study. 
 
Study sample  
 In this study, the population of interest is 115 Carnegie Highest Research Universities 
(Carnegie R1 universities) in The Carnegie Classification of Institutions (Indiana University 
Center for Postsecondary Research, n.d.). Two factors led me to choose R1 universities as the 
study sample. The first factor is the size of the treated group and the controlled group. As seen in 
Table 1, there are 47 universities in the R1 university group that have experience of receiving the 
CTSA award. In addition, there are eight other R1- universities that have official partnership 
with the CTSA receiving institutions. This leaves us with 60 institutions that are not affected by 
the CTSA award, which can be used as the comparison group. This means there are almost the 
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same numbers of institutions in both the treatment group and the control group if we take R1 
universities as the study sample.  
 









R1 Universities 47 (40.9%) 11 (7.0%) 60 (52.2%) 115 (100%) 
R2 Universities 5 (4.7%) 5 (4.7%) 97 (90.7%) 107 (100%) 
Note: The full list of Carnegie R1 universities in each leadership type can be found in Appendix A 
 
The second and more important factor that led me to take R1-university group for the 
analysis is related to the comparability of the treatment and the control group. To have high level 
of internal validity of research, we need to have appropriate comparison group that has similar 
features with the treatment group (Campbell & Stanley, 1963). The most preferred case would be 
introducing a control group that has same attributes with the treatment group before the treatment 
takes place. However, it is impossible to have that kind of pair in a quasi-experimental setting 
like my study. Hence, in this situation, I should try to get the control group that is as similar as 
possible to the treatment group.  
As expected, there is a clear difference in the values regarding R&D attributes for R1 
universities and High Research Activity University (R2 universities) (Table 2). For instance, 
average R&D expenditures in Science and Engineering (S&E) for R1 universities are 6.6 times 
larger than that of R2 universities. Also, per-capita S&E research staff is four times larger for R1 
universities than R2 universities. This suggests that R1 universities and R2 universities are 
fundamentally different in terms of the research capacity. If I included R2-universities in the 
study sample, I would be comparing a large number of R1 universities receiving the CTSA 
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award to a large number of R2 universities not receiving the CTSA award. This will lead to a 
large bias of the result as these two groups might have differed even without the impact of the 
CTSA award. This would lower the internal validity of the research and limit the strength of the 
claims I could make on the causal relationship between the CTSA award and the dependent 
variables of my analyses.  
 












R1 Universities 411,742 604 202 277.9 0.4 
R2 Universities 62,821 51 37 144.7 0.1 
Note: * indicates units in $1,000 
Source: Indiana University Center for Postsecondary Research (n.d.) 
 
Including only R1 universities in my sample means that I aim to look at the collaboration 
between universities that have high research ability, which was the approach Owen-Smith and 
Powell (2003) chose in their study on patenting activities of universities. Regarding the field of 
science, I restricted it to life science and related fields. To do so, I only looked at the grants from 
NIH and their outcomes. Using outcomes from grants has the advantage of capturing the 
dissemination of knowledge and findings from grant-supported projects (Ihli, 2016). For the 
period of analysis, I chose the years between 2001 and 2015. This means that I have enough 
years before the initiation of CTSA, which is five years, and after the initiation of CTSA, which 
is nine years. The organizations that received CTSA after the first year of the start of CTSA 
would have fewer years after the event but more years before the event. Therefore, for some 
analyses, I normalize the period taking the year of designation as the base year. I didn’t use the 
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most recent years (e.g., 2016 and 2017), in my analysis because there should be some time lag 
for the outcome of projects to be realized. Also, it takes some time to capture all outcomes (e.g., 
publications from NIH projects) in the NIH reporting system. 
 The status of being impacted by the CTSA award will be the criteria for dividing the 
treatment group and the control group. The institutions that received CTSA award will be in the 
treatment group whereas the institutions that didn’t will be members of the control group. One 
issue to address in identifying the institutions in the treatment group is the appropriate 
classification of partnering institutions of the CTSA award receiving institutions. NIH promotes 
CTSA receiving institutions to partner with other institutions and encourages them to share their 
resources with their partners (Llewellyn et al., 2019). In this regard, some CTSA receiving 
institutions make official partnership with other institutions with the purpose to make the best 
use of the award, which make them multi-hub institutions (Llewellyn et al., 2019). As the 
partnering institutions also have access to the resources, methods, and other tools that could 
accelerate the research process (Llewellyn et al., 2019), I also include the partnering institutions 
in the treated group. The basic rules that were applied in identifying the partnering institutions 
are as follows.  
 
• Classify an institution as CTSA-partner if that institution never received the CTSA award but 
made official CTSA partnership with any of the CTSA receiving institution (CTSA-leader) 
that would not have been formed without the award.   
• The CTSA partnership is considered official if 1) CTSA-leader institutions self-identified 
partnership with CTSA-partner on their hub website or their grant abstracts, 2) there is 
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leadership or principal investigator from both CTSA-leader and CTSA-partner listed on their 
hub website or their grant abstracts 
• The universities that would have been connected even without the effect of the CTSA award 
(e.g., universities in same state university system) were not considered to have an official 
CTSA partnership   
 
Figure 8 shows the change in the size of the treated group and the controlled group by 
year12. We can note that the size of both the treatment group and the control group will change 
by year. Before the CTSA program started (e.g., year 2003), all Carnegie R1 universities are 
classified as a member of the control group. The number of institutions in the treatment group 
increases as the CTSA program progresses (e.g., 35 in 2008 and 55 in 2015).  
 
 
Figure 8. Change of the sizes of the treatment group and the control group by year 
 
                                                 
12  Full list of institutions by CTSA-leader type can be found in the Appendix A. 
46 
Data construction 
 The primary data source for my research is from NIH Research Portfolio Online 
Reporting Tools13 (RePORTER). As part of NIH’s “open government” initiative and Public 
Access Policy, NIH provides information on all projects it funded through RePORTER (National 
Institutes of Health, 2018; Surkis et al., 2016). CTSA receiving institutions also have obligations 
to report publications that received support from the CTSA program’s services, resources, 
training programs and pilot projects (Surkis et al., 2016). I used ExPORTER (National Institutes 
of Health, 2017a)14, which is part of the RePORTER system that contains downloadable version 
of the data, to download the dataset I needed. I first downloaded them in Comma Separated 
Value (CSV) format and transformed the data into the format that can be imported into the 
statistical programs I used for my analysis. The dataset from ExPORTER has a number of 
variables related to the projects including core project number, the fiscal year of the project, total 
cost, support year, administering institution, affiliation of principal investigator and so forth. I 
used core project number to link the information of the projects with the publication outcomes.  
 To get the collaboration network between organizations multiple steps had to be taken. 
The first step is getting the list of projects that are conducted by Carnegie R1 universities 
between 2001 and 2015 (Carnegie R1 Projects). To do this, I download CSV files that contain 
information on projects supported by NIH from NIH ExPORTER (National Institutes of Health, 
2017a). Then, I search for projects where the principal investigator (PI)’s affiliation was one of 
the 115 Carnegie R1 universities. I found out there were 139,066 projects, which is the count of 
unique core project number throughout the period. 
                                                 
13 Source: https://projectreporter.nih.gov/reporter.cfm 
14 Source: https://exporter.nih.gov/ExPORTER_Catalog.aspx 
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The second step is extracting journal articles that are generated from Carnegie R1 
Projects (Carnegie R1 Publications). For this task, I downloaded another set of CSV files from 
NIH ExPORTER (National Institutes of Health, 2017a) that contain PubMed IDs of articles in 
one column and acknowledged NIH projects in another column. Using this file, I identified and 
extracted a group of matches between PubMed ID and NIH core project number. I found out that 
there were 840,464 publications with Digital Object Identifier (DOI), which means 6.04 
publications with DOI were produced per project on average. Here, we need to keep in mind that 
only the articles that cite NIH projects properly can be captured in this dataset (Han et al., 2018). 
Articles that do not acknowledge any grant number or acknowledge a different grant number, 
whether it was intentional (e.g., for the better assessment of specific project) or unintentional 
(e.g., by mistake), could not be properly included in the dataset.  
As the third step, bibliometric information of Carnegie R1 Publications is downloaded 
from Web of Science (WOS) via access through Georgia Tech Library. WOS is chosen as it 
contains comprehensive data of nearly 12,000 high impact journals (Lander, 2013; Clarivate 
Analytics, 2018) and it covers journals in all fields of interest (e.g., science, social science and 
arts and humanities) for over 100 years (Clarivate Analytics, 2018). In addition, it offers citation 
indexes that can be used in various applications, which will also be used in the later section of 
this dissertation.  
As the fourth step, I identified organizations that participated in the publication of the 
articles (Carnegie R1 co-authoring organizations). I assumed that if the researchers appeared in a 
coauthor list of a same publication, the organizations that these researchers are affiliated with 
collaborated15, which is the approach that studies looking at inter-organizational collaboration 
                                                 
15 One issue of this approach is that if an author lists two or more organizations as his or her affiliations, those 
organizations would be considered as collaborating institutions. In this dissertation, I do count them as collaboration 
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use frequently (e.g., Lander, 2013). In this step, different ways of referring to the same 
organization need to be merged. For example, Columbia University and Columbia University in 
New York City must be merged into Columbia University. This job of merging institution names 
was conducted using self-made thesaurus for use in VantagePoint.  
For the last step, I made the collaboration network composed of only 115 Carnegie R1 
universities. I created this network by dropping non-Carnegie R1 universities from the network 
matrix that is composed of all Carnegie R1 universities and Carnegie R1 co-authoring 
organizations. The final outcome is the collaboration network matrix of 115 Carnegie R1 
universities, which will be used as the dependent variable in my analysis. Figure 9 illustrates the 




Figure 9. Flow chart of making collaboration network between Carnegie R1 universities 
 
                                                                                                                                                             
institutions as I agreed with the claim by Lander and Atkinson-Grosjean (2011) and Swan et al. (2007). They 
asserted that this kind of scientists are ‘boundary spanners’ who take the role of sharing knowledge between their 
affiliated organizations. 
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The programs I used for my analyses are Vantage Point, R, STATA and Microsoft Excel. 
With Vantage Point, I extracted bibliometric information that is needed for the analyses. The 
factors that were extracted are DOI, author affiliation, publication year and Web of Science 
Category. Furthermore, Vantage Point’s co-occurrence matrix function was used to create 
network matrices. In some cases, I created thesauruses that can be used in jobs related to 
classifications and merging observations. R was used to construct social network data, calculate 
social network measures (e.g., density, centralization, centrality) and run network regression 
analyses. For some descriptive analyses and regressions, STATA was used. Microsoft Excel was 
used to get basic statistics and for some data visualization.  
 
3.4.2. Measures and variables 
 
 Social network analysis (SNA) provides us with insights on the relationship between 
multiple individuals or entities (Gaughan et al., 2018). The scientific relationship is one of the 
topics that the SNA approach is well-suited to analyze (Katz et al., 2004; Luke et al., 2015) 
Macro-level network measures 
Network density. Network density is calculated by the number of actual ties divided by 
the number of possible ties (Hanneman & Riddle, 2005). The value is same as the ratio of 
existing adjacencies divided by the number of possible pairs in the network (Hanneman & Riddle, 
2005). The density gives us insight on how close the entities in the network are to each other and 
the value is associated with the speed of information diffusion in the network (Hanneman & 
Riddle, 2005).  
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Network centralization. Many variables provide a general picture of a network and 
centralization is of one of them. Centralization measures how focused a network is on few core 
nodes (Haythornthwaite, 1996). The network with high value of centralization represents highly 
centralized network, which means that there is small number of core nodes that are connected to 
a large portion of other nodes (Haythornthwaite, 1996). In this case, these core nodes act as the 
hubs of the whole network and they have more power compared to non-hub nodes (Hanneman & 
Riddle, 2005).  
 
Micro-level network measures 
Centrality measures. Four centrality measures, which are degree centrality, closeness 
centrality, betweenness centrality and eigenvector centrality, are the variables that I will use in 
my descriptive analysis. These measures provide us information on key features of the 
collaborative landscape (Hanneman & Riddle, 2005, Katz et al., 2004). For instance, with these 
measures, I would be able to figure out how central an institution is in the collaborative network 
and get a sense of their position in the network (Hanneman & Riddle, 2005). Table 3 provides 
the concept and features of four centrality measures I used. 
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Table 3. Concepts of centrality measures 
Variables Concept and features 
Degree 
Centrality 
· How many institutions that an institution has direct collaboration with 
· Large value represents high prestige and prominence  
Closeness 
Centrality 
· The extent to which an institution is directly or indirectly connected to the rest 
of the nodes in the network 
· Measured using the sum of distance to others from an ego and it indicates how 
fast can an institution reach others in the network 
Betweenness 
Centrality 
· How much an institution has links with others who are not directly connected 
and become the direct route between two alters in the network 
· High value means less dependency on others and having more power 
Eigenvector 
Centrality 
· How well an institution is connected to other well-connected institutions 
· Focusses on the global structure of the network rather than the local structure 
of the network 
Note: Descriptions mainly from Hanneman & Riddle (2005) 
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Variables for regression models 
Independent variable. As I am interested in the impact of receiving CTSA on 
collaboration formation and change, I used the dummy variable related to receiving CTSA as my 
key independent variable and called it CTSA. The number of CTSA receiving Carnegie R1 
universities rose from eight in 2006 to fifty five in 2016. Therefore, the binary independent 
variable 𝒙𝑖|𝑗(𝑡) will have the value of 0 for all organizations till 2005 and eight organizations will 
start to have the value of 1 from 2006. The number of organizations having the value of 1 for this 
variable will increase to 21 in 2007 and reach its highest value of 55 in year 2012. The full list of 
the CTSA receiving institutions can be found in the Appendix A.  
Control variables. Various attributes of the organizations were used as the control 
variables, which is denoted as  𝑺𝑖𝑗(𝑡). First, from the Carnegie Classification of Institutions of 
Higher Education website (Indiana University Center for Postsecondary Research, n.d.) whether 
an organization has a medical school (Medical), whether an orgnization is controlled by a 
private party (Private) and the state of the organization (State) is obtained. Secondly, R&D 
expenses in the life sciences (R&D) were obtaned from National Science Foundation (NSF) 
Higher Education Research and Development Survey (National Science Foundation, n.d.-b). The 
field selected to get this value was “Life sciences, all.” and I took the sum values of all affiliated 
institutions of the corresponding universities. Thirdly, NSF Survey of Graduate Students and 
Post-doctorates in Science and Engineering (GSS) (National Science Foundation, n.d.-c) was 
used to calculate the number of researchers in life science for each organization (Researcher). 
With the raw data from NSF GSS, I added the number of graduate students, post doctoral 
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students and non-faculty researchers in life sciences16 to get the value of a total number of 
researchers in life science. Table 4 shows the list of control variables and how they were coded.  
 
Table 4. List of control variables used in the analytic model 
Name Code Source 
Medical 
0: Does not grant medical degrees 
1: Grants medical degrees 
Carnegie Classification of 
Institutions of Higher 
Education website17 
Private 
0: Public university  
1: Private university 
State 
1: AL, 2: AK, 3: AZ, 4: AR, 5: CA,  
6: CO, 7: CT, 8: DE, 9: DC, 10: FL,  
11: GA, 12: HI, 13: ID, 14: IL, 15: IN,  
16: IA, 17: KS, 18: KY, 19: LA, 20: ME,  
21: MD, 22: MA, 23: MI, 24: MN, 25: MS,  
26: MO, 27: MT, 28: NE, 29: NV, 30: NH,  
31: NJ, 32: NM, 33: NY, 34: NC, 35: ND,  
36: OH, 37: OK, 38: OR, 39: PA, 40: RI,  
41: SC, 42: SD, 43: TN, 44: TX, 45: UT,  
46: VT, 47: VA, 48: WA, 49: WV, 50: WI, 51: WY 
R&D R&D expenditures in life sciences 
NSF Higher Education 
Research and Development 
Survey (HERD)18 
Researcher 
Number of graduate students, post-docs and non-faculty 
researchers in life science  
NSF Survey of Graduate 
Students and Post-doctorates 
in S&E (GSS)19 
 
                                                 
16 Fields included are biomedical engineering, agricultural sciences, biological sciences, health science and 
neuroscience. 
17 Source: http://carnegieclassifications.iu.edu/downloads.php 
18 Source: https://www.nsf.gov/statistics/herd/pub_data.cfm 
19 Source: https://www.nsf.gov/statistics/srvygradpostdoc/pub_data.cfm 
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3.4.3. Models  
 
 To analyze the relationship between the variables and collaboration formation between 
institutions, I used the Exponential Random Graph Model (ERGM), which is widely used 
approach on statistical modeling of networks (Robins, Pattison, Kalish, & Lusher, 2007; 
Schaefer & Marcum, 2017). ERGM assumes that a given network is one possible form of 
random network and provides the probability of a tie conditional on all other possible networks 
(Schaefer & Marcum, 2017). ERGM derives parameter values that could reproduce the given 
network assuming that the network is at equilibrium (Schaefer & Marcum, 2017). EGRM is a 
cross-sectional model, which mean that it can only deal with variables for a single point of time 
(Leifeld, Crammer, & Desmarais, 2018) 
I ran a total of 15 ERGM models, one for every year between 2001 and 2015. With these 
15 models, I checked the change of the coefficients over time. The equation of the ERGM model 
using weighted values for the collaboration is as follows. 
𝑤𝑖𝑗~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜇𝑖𝑗) (1) 
log(𝜇𝑖𝑗(𝑡+3)|𝐺𝑖𝑗(𝑡+3)
𝑐 ) = 𝛽1 + 𝛽2𝒙𝑖|𝑗(𝑡) + 𝛽3𝑺𝑖𝑗(𝑡) (2) 
, where i is a receiver effect and j is a sender effect. 
 The left side of the equation measures the rate of collaboration between i and j for year 
t+3. Year t+3, not t, is used to account for the time between receipt of the CTSA award and when 
resulting changes might be observed. I assume that it takes about three years between the time an 
institution receives the CTSA award and the appearance of any visible changes. This assumption 
is based on the finding by Ihli (2016). In her study on the lag time between the award of the grant 
from NSF and publication of the articles acknowledging the grant, which is called 
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acknowledgment lag, Ihli (2016) found out that highest count of the lag-time was three years. 
Though there would be some differences between NSF grant and NIH grant, I assume that they 
would share many features and believe it is reasonable to take this approach as most 
characteristics of this lag would not differ much between two government funding agencies.  
One advantage of the ERGM is that it can incorporate homophily effect in the model. 
Homophily effect explains the tendency of a one forming a tie with the ones with similar 
characteristics (Katz et al., 2004; McPherson, Smith-Lovin, & Cook, 2001; McFarland, Moody, 
Diehl, Smith, & Thomas, 2014). This results in individuals with similar attributes interacting 
with each other more often than with other individuals without similarity (McFarland et al., 
2014). Homophily effect has been widely studied in various topics such as friendship, advice, 
work, support and information transfer (McPherson et al., 2001). In the context of biomedical 
research, we can expect that the scientists affiliated with institutions that receive grants with 
similar attributes will tend to collaborate with each other more so than with the ones not 
receiving them. In this respect, the homophily effect of the CTSA award will also be tested in the 
model.  
We can also expect that the organizations located in similar regions, or close-by regions, 
will tend to collaborate frequently. This claim can also be linked to the relationship between 
geographical proximity and rate of collaboration. Many studies found out that people tend to 
work with the ones who are physically close to them (e.g., Bozeman & Corley, 2004). Bozeman 
and Corley (2004) found out that researchers tend to work frequently with the people in their 
own working group. This could be linked to the claim that the ones in the same region will 
collaborate more frequently than the ones not in the same region, which will also apply to 
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biomedical research. Hence, I also plan to test the homophily of regions, which is analyzed in 
state level.   
 Beyond the analysis with cross-sectional ERGM, I also test the relation between variables 
using the temporal network regression model. To analyze across-time change of the network 
formation, I used Temporal Exponential Random Graph Model (TERGM). TERGM is an 
extension of the ERGM that account for temporal characteristics of the network formation and it 
can take care of time dependence over a series of networks (Leifeld et al., 2018). This model 
divides the dependencies into within-time change and across-time change (Shaefer & Marcum, 
2017). Regarding the across-time change, the model tests the effect of the past network on the 
current network (Shaefer and Marcum, 2017; Leifeld et al., 2018). The model can also test 
whether there is a dependence between ties over time, which is called “memory terms” (Shaefer 
and Marcum, 2017; Leifeld et al., 2018, p. 4). These terms will be described more in detail in the 
result section with interpretation on actual coefficients. One limitation of TERGM is that it can 
only account for binary feature of the links as social network packages have not gotten to the 
level to deal with weighted outcomes. This means that the dependent variable is based on the 




3.5.1. Descriptive analysis 
 
Macro-level network measures 
 To analyze change of the overall features of the whole collaboration network among all 
115 Carnegie R1 universities, I checked the trend of density and centralization. As shown in 
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Figure 10, the density measure of binary network increased from 0.412 in 2001 to 0.820 in 2015 
showing an overall increasing trend. It means that in 41.2% of possible ties between Carnegie R1 
universities were present and the portion increased to 82.0% in 2015. This means that Carnegie 
R1 universities tend to collaborate more with each other over time.  
On the other hand, the centralization measure showed a decreasing trend, and the value 
dropped from 0.446 in 2001 to 0.183 in 2015. As the centralization measure is in a decreasing 
trend,  we can claim that the whole network is becoming less centralized and this confirms that 
my hypothesis 3 holds. This means that the number of universities acting as the hub of the 
network is increasing. In the early years, there may have been a small number of Carnegie R1 
universities monopolizing the collaborations with other Carnegie R1 universities. However, in 
later year the number of institutions that act as hubs, with a lot of cooperation with other 
Carnegie R1 universities, has increased.  
 
  
Figure 10. The trend of density and centralization of the whole network 
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 To figure out the reason that led to this change, I divided the whole network into 1) a sub-
network that is only composed of the institutions that ever took advantage of the CTSA award 
(CTSA-evers) and 2) another sub-network that is only composed of the institutions that never 
took advantage of the CTSA award (CTSA-nevers), which are the institutions that stay in the 
control group until 2015. Figure 11 and Figure 12 show the change of density and centralization 
of two sub-networks. For the first sub-network, we can see that there were slight changes in the 
density. The change for this variable was only around 0.10 during the whole period between 
2001 and 2015. On the other hand, if we check the change of the density for the second sub-
network, we can see that there was a substantial increase, from 0.15 in 2001 to 0.60 in 2015. 
These findings indicate that the increase of density is due to both the increase of collaboration 
among institutions in CTSA-ever group and collaboration among CTSA-never institutions, but 
the change is mainly due to the increase of collaboration among CTSA-never institutions. It can 
be seen that CTSA-never institutions have a larger increase in the number of collaborations than 
the CTSA-ever group. 
 If we look at the centralization measure, we can see that the measure is not decreasing in 
the second sub-network, but decreasing in the first sub-network. Therefore, we can claim that the 
decrease of centralization in the whole network is mainly due to the decrease of centralization 
between institutions that took advantage of the CTSA award. From the finding, we can expect 




Figure 11. Centralization and density for the network between CTSA-ever institutions 
 
 
Figure 12. Centralization and density for the network between CTSA-never institutions 
 
 To investigate this issue further, I looked at the frequency and portion of collaborations 
having CTSA-ever group institution as partners or CTSA-never group as partners. The trend of 
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frequency having calendar years as the x-axis are shown in Figure 13 and Figure 1420. Figure 15 
and Figure 16 shows the trend of the portion of collaborations. The solid line and dashed lines 
represent the mean values and the shaded areas show the range between 25 percentile value and 
75 percentile value. The vertical line shows the year when the CTSA program started, which is 
2006. From the figure, we can see that the collaboration frequency with CTSA-ever institutions 
is increasing at a faster rate than the collaboration frequency with CTSA-never institutions. We 
can note that even the CTSA-never group institution is collaborating more with CTSA-ever 
group institutions and CTSA-ever group institutions barely collaborative with CTSA-never 
group institutions. The portion of collaboration with CTSA-never group institutions is less than 
20% of the total collaboration that CTSA-ever institutions have. 
 
 
Figure 13. Collaboration frequency with CTSA-evers 
 
                                                 
20 The graphs with normalized years as the x-axis are in the Appendix B. These graphs show similar pictures with 
the graph having calendar year as the x-axis. 
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Figure 14. Collaboration frequency with CTSA-nevers 
 
 




Figure 16. Collaboration portion with CTSA-nevers 
 
Micro-level network measures 
 Figure 17 through Figure 20 show the trends of four kinds of centrality measures, which 
are degree centrality, closeness centrality, betweenness centrality and eigen-vector centrality, of 
institutions in CTSA-ever institutions and CTSA-never institutions21. Degree centrality and 
closeness centrality increased for both treatment group (CTSA-ever institutions) and control 
group (CTSA-never institutions). This result indicates that institutions in both the treatment 
group and the control group experienced an increase in the number of collaborations, as expected.  
If we look at the change in the betweenness centrality, we can see that there is a 
decreasing trend for the treatment group whereas the institutions in the control group are not 
experiencing any big change. If we look at eigen-vector centrality value, there is a slightly 
decreasing trend for the CTSA-ever group and there is clear increasing trend for the CTSA-never 
group. This means that institutions that took advantage of the CTSA award are increasing their 
                                                 
21 The graphs with normalized-years as the x-axis are in the Appendix B. 
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number of collaborations with the institutions in the periphery. On the other hand, the CTSA-
never group institutions are getting more connected with the institutions that have many links of 
its own.   
 
 
Figure 17. Degree centrality trend of institutions in CTSA-ever group and CTSA-never group 
 
 
Figure 18. Closeness centrality trend of institutions in CTSA-ever group and CTSA-never group 
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3.5.2. Network regression  
 
  To test whether the CTSA led to higher number of collaborators, which is Hypothesis 1, 
I ran ERGM models with binary dependent variable from 2009 to 2015. One of the assumptions 
in my analyses is that it would take three years for the impact of the CTSA award to get realized. 
Hence, my first year of analysis is 2009 as the first year that institutions started taking advantage 
of the CTSA award is 2006. Table 5 shows estimation of seven ERGM models with unweighted 
rate of collaboration as dependent variable. The coefficients of CTSA have significantly positive 
value for all years. This means receiving CTSA lead to more number of collaborators and 
hypothesis 1 holds. For instance, in 2015, CTSA increases the log odds of institutions to form a 
tie with other partners by 0.49622.  
 If we look at the coefficient of the control variables, we can note that the effect of the 
R&D expenditure (R&D) and being private school (Private) have minimal or insignificant effect 
in making more collaborators. However, it turned out that having medical school leads to higher 
number of collaborating institutions. In all models, the coefficients of Medical were larger than 
that of CTSA. This finding indicates that the effect of having medical school has a larger impact 
in terms of creating more collaborators than the CTSA award.  
Regarding the homophily effect, the result shows that the coefficients of two factors 
considered, the status of taking advantage of the CTSA award and being located in same state, 
have positive values with significance in 0.01 level. This means that having same status 
regarding the receipt of the CTSA related resources and being located in same state lead to more 
collaborations. 
                                                 
22 The coefficients of CTSA related variables from the models that include endogenous network formation factors 
(e.g., preferential attachment) also showed similar values (not shown here).  
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Table 5. ERGM estimations with binary dependent variable between 2009 and 201523 
Variables 2009 2010 2011 2012 2013 2014 2015 
Main effects        
 CTSA 0.344*** 0.296*** 0.307*** 0.437*** 0.387*** 0.485*** 0.496*** 
 Researcher 0.279*** 0.269*** 0.324*** 0.545*** 0.491*** 0.516*** 0.424*** 
 R&D 0.005*** 0.005*** 0.005*** 0.004*** 0.003*** 0.003*** 0.004*** 
 Private 0.009 0.072 0.056 0.219*** 0.113* 0.075 0.000 
 Medical 0.585*** 0.460*** 0.465*** 0.614*** 0.540*** 0.520*** 0.477*** 
Homophily Effects        
 CTSA 0.281*** 0.369*** 0.332*** 0.437*** 0.302*** 0.401*** 0.302*** 
 State 1.714*** 1.259*** 1.396*** 1.708*** 1.606*** 1.459*** 1.393*** 
Constant -2.608*** -2.263*** -2.254*** -2.697*** -2.161*** -2.153*** -1.679*** 
 
 
To test hypothesis 2 of my analysis, which is related to the impact of the CTSA award on 
the rate of collaborations, I ran ERGM models with weighted collaboration rate as dependent 
variable between 2009 and 2015. The results are shown in Table 6. From the results from models 
for all seven years, we could find that receiving CTSA has a significant impact on the rate of 
collaboration as the coefficient of CTSA is statistically significant for all years and it suggests 
that my hypothesis 2 holds. For instance, in 2009, the expected number of collaborations that the 
CTSA-ever institution has is exp⁡(0.291) = 1.338 times higher than that of CTSA-never 
institutions holding all other variables constant. In 2015, the strength of ties that a CTSA-ever 
                                                 
23 Diagnostics of goodness-of-fit of models are presented in the Appendix C. It seems like the simulated networks 
predict the observed network reasonably well as 1) the shapes of the observed shared partners frequency are similar 
to those of the simulated shared partners frequency and 2) the large portion of the observed value fall within the 
acceptable range of the simulated values.  
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institution has was exp⁡(0.287) = 1.332 times stronger when compared to a CTSA-never 
institution, holding all other variables constant24.  
It was also interesting to note that all the control variables had statistically significant 
impacts. The R&D expenditure had very minimal impact whereas number of researchers, being a 
private school and having medical school had substantial impacts on increasing collaboration 
frequency. One finding that is noteworthy is the impact of medical school. We can see that the 
coefficient of having medical school is higher than that of receiving CTSA for all seven years. 
For example, in 2010 the coefficient of Medical is 0.685 while the coefficient of CTSA is 0.315. 
This means that having medical school leads to exp⁡(0.685) = 1.862 times more collaborations, 
whereas receiving the CTSA award only leads to exp⁡(0.315) = 0.856 times more collaborations 
when all other variables are kept constant.   
 The CTSA homophily effect is also significantly positive. This means that receiving the 
CTSA award leads to more collaborations with other CTSA recipients. That is, there is a 
tendency that institutions in CTSA-ever group are collaborating more with the CTSA-ever group 
institutions. In the previous section that explained micro-level network measure, the change of 
eigen-vector trend showed that CTSA-ever institutions had expanded their collaborating 
institutions to periphery institutions. With the result that CTSA homophily effect is always 
positive, we can make more advanced claim that CTSA-ever institutions have not been 
increasing interaction with CTSA-never institutions, but with have been increasing interaction 
with CTSA-ever institutions that were not in the very core of the network. This means that 
institutions that started to act as network hubs belong to CTSA-ever group, not CTSA-never 
group, even if they are in the periphery of the network. As expected, being in the same state has 
                                                 
24 The coefficients of CTSA related variables from the models that include endogenous network formation factors 
(e.g., transitivity) also showed similar values (not shown here). 
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significantly large impact on creating more collaborations. In fact, the state homophily effect is 
larger than any other effects tested. 
 
Table 6. ERGM estimations with weighted dependent variable between 2009 and 2015 
Variables 2009 2010 2011 2012 2013 2014 2015 
Main effects        
 CTSA 0.291 0.315 0.252 0.312 0.297 0.290 0.305 
 Researcher 0.282 0.270 0.252 0.258 0.218 0.224 0.190 
 R&D 0.002 0.002 0.002 0.002 0.002 0.002 0.002 
 Private 0.278 0.278 0.329 0.326 0.270 0.283 0.286 
 Medical 0.691 0.685 0.647 0.741 0.675 0.604 0.616 
Homophily Effects        
 CTSA 0.237 0.228 0.212 0.228 0.191 0.235 0.199 
 State 1.269 1.102 1.131 1.051 1.033 0.990 0.926 
Constant -1.963 -1.723 -1.625 -1.580 -1.283 -1.154 -0.909 
 
Table 7 shows the estimations of the TERGM model. Model 1 is estimated without time-
related variables and Model 2 is estimated with time-related variables. For both models, we can 
see that the main effect of the CTSA is positive with significance at the 0.01 level. As TERGM 
can only handle binary dependent variables, this means that institutions affected by the CTSA 
award are increasing their number of collaborators even when the temporal effects are 
considered. This result provides additional support to hypothesis 1 of my analysis. The impact of 
being a private school (Private) and having medical school (Medical) both have significant 
impact on institutions making more collaborators. Also, having same status regarding the receipt 
of the CTSA award (CTSA homophily effect) and being in the same state (State homophily 
effect) lead to more collaborators. All these results are consistent with the results of the yearly 
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ERGM estimations. The fact the constant has negative value indicates that the observed network 
is sparser than the model we can get from random models.  
 Regarding the time-related factors, both the tie memory variable and time memory are 
positive with significance. Tie memory having positive value, which is the case of my 
estimation, means that tie (or non-tie) at one time point lead to tie (or non-tie) on the next time 
point (Leifeld et al., 2018). This means the institutions are more likely to form ties with the 
institutions they collaborated with in the past, while not forming ties with institutions they 
haven’t collaborated with. Therefore, positive coefficient of the Tie memory also means that the 
network is stable (Leifeld et al., 2018). The Time variable also had a positive value. This means 
that the number of connected pairs of institutions is increasing over time. This finding is 
consistent with the increasing trend of the whole network’s density (Figure 10).  
 
Table 7. Estimation result of the TERGM for 2009-2015 
Variables 
Model 1 
(without time-related covariates) 
Model 2 
(with time-related covariates) 
Main effects   
 CTSA 1.296 1.068 
 Researcher 0.004 0.338 
 R&D 0.351 0.003 
 Control 0.075 0.111 
 Medical 0.476 0.421 
Homophily Effects   
 CTSA 1.089 1.033 
 State 1.459 1.127 
Time-related   
 Tie memory  0.677 
 Time  0.100 
Constant -2.895 -2.881 
Note: All coefficients are significant in 0.01 level 
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3.6. Conclusion  
 
In this chapter, I looked at how the CTSA award changed the landscape of biomedical 
research collaboration network. The first notable finding is that that biomedical research 
collaboration network is becoming denser. This result is in line with the findings by Powell, 
White, Koput, and Owen-Smith (2005) in that the biomedical research collaboration is becoming 
denser. One of the key goals of translational research is to break down barriers between 
institutions and promote interaction among them (Obeid et al., 2014). The CTSA award portfolio 
has programs that provide tools to promote active collaboration between institutions. One 
example is the Research Network System, which provides information on researchers and 
coauthorship activities affiliated with various institutions. (Obeid et al., 2014). With this kind of 
tools, CTSA tries to help researchers find their potential collaborators and acquire information on 
resources and methodologies (Obeid et al., 2014). It may bring the researchers affiliated with 
institutions with these tools to collaborate more with each other. Subsequently, this could bring 
more collaboration of CTSA institutions with other institutions that will lead to a denser network 
as a whole. The results from ERGM and TERGM confirms this claim and they indicate that 
receiving CTSA awards lead institutions to have more collaborators (Hypothesis 1 holds) and 
make more frequent interactions with the collaborators (Hypothesis 2 holds).  
 The second notable finding is the overall network is becoming less centralized 
(Hypothesis 3 hold), meaning institutions that didn’t take the role of network hubs in the past are 
starting to take this role. The descriptive analysis of eigen-vector centrality and ERGM 
estimation results indicate that it is the CTSA-ever institutions that are becoming new hubs, not 
the institutions in the CTSA-never group. Though it was shown that having homophily feature of 
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receiving the CTSA award leads to more collaborations and a larger number of collaborators, the 
main effect of the CTSA award is stronger. Hence, CTSA receiving institutions have 
significantly more collaborators and collaborations than the institutions that never received the 
CTSA award. The reason why the CTSA-never institutions have limitation in attracting more 
collaboration may be explained by factors like lack of useful resources (Bozeman & Corley, 
2004; Katz & Martin, 1997), not being able to provide mentorship (Katz & Martin, 1997) and 
not being the source of creativity (Katz & Martin, 1997). The unpopularity of CTSA-never 
institutions compared to CTSA-ever institution may also mean that resources, which could 
provide direct benefits, are more attractive than increasing the probability of being selected as 
CTSA recipient in the future.  
 Although this chapter advances our understating of the impact of the CTSA award on 
research collaboration, it has some limitations. Most of all, the analytical approach of this 
chapter is subject to endogeneity concerns. Indeed, the institutions affected by CTSA award may 
be the ones that have preferred characteristics in terms of collaboration (e.g., more links with 
other institutions) before being selected as the CTSA recipient. I tried to alleviate this concern by 
applying lag between the start of the CTSA award and the time when the collaboration is taking 
place. Also, CTSA partnering institutions, which don’t necessarily have high propensity of 
receiving the CTSA award, are included in the treatment group which may reduce the selection 
bias problem. Also, I also moved beyond cross-sectional analysis and conducted temporal 
analysis, which could alleviate the endogeneity problem to a certain extent. However, the 
endogeneity concern is not fully addressed, and it allows me to discuss only the strong 
association of the CTSA award on the collaboration network, not the perfect causal relationship 
between the two.  
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 The ultimate goal of the CTSA award is to translate findings from the laboratory into 
products that benefit patients and have commercial value (Han et al., 2018; Weber, 2013). The 
development of new drugs, medical devices, or other therapeutics is the ultimate measure of 
successful translation. However, as noted in the previous chapters, it takes too long to make these 
products from scientific discoveries (Morris et al., 2011; Contopoulos-Ioannidis et al. 2008), for 
them to be an attractive measure for use in the assessment of the translation process. Patents are 
another potential measure that may serve as an indicator of successful translation, but the lag 
time for patents to issue along with uncertainty about which patents will be used commercially 
complicate the use of this measure. On the other hand, it takes much less time for publications 
describing novel research to appear, with more than 80% of publications being published within 
six years from the year of grant directly related to that publication (Ihli, 2016). This makes 
measures related to publications attractive for the evaluation of projects that support translational 
research. Although publications have less commercial value compared to patents and drugs, 
publications can be used to understand the dissemination of research and their forward citation 
data can be used to understand the usage of the publications across the academic discipline 
(Llewellyn et al., 2019). In this respect, there have been quite a lot of attempts to develop an 
index measuring translational feature of publication using their bibliometric information (e.g., 
Weber, 2013; Han et al., 2018; Fontelo & Liu, 2011; Surkis et al., 2016). However, thus far, 
there has been no measure that acquired broad consensus from the research community. Hence, 
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in this chapter, I propose a novel index that measures translational feature of publications, which 




 Federal funding has supported translational research through the CTSA award for more 
than a decade (Weber, 2013). As these efforts have continued and represent a substantial 
investment, it is important to assess the effectiveness of this endeavor. Several studies have tried 
to assess various aspects of the impact of CTSA. For instance, some studies focussed on the 
research productivity and scholarly impact of publications with bibliometric data. Schneider et al. 
(2017), for example, used bibliometric tools to measure the impact of articles that CTSA 
institutions published. They found out that six CTSA institutions they analyzed experienced an 
increase in publication counts and forward citation counts. Another example is a work by 
Georgia CTSA Alliance (Llewellyn, Carter, Rollins, & Nehl, 2018), which looked at articles 
citing CTSA hub awards. They found that the publications supported by CTSA programs are 
cited more and this characteristic strengthens when a publication is from multi-institutional 
CTSA hubs. Other topics like clinical trial enrollment (Liu et al., 2013) and the success rate of 
receiving NIH grants (Knapke et al., 2015) have also been examined. These studies found that 
the CTSA award had a positive impact on the number of patients enrolled in clinical trials and 
probability of getting a NIH grant funding, respectively (Liu et al., 2013; Knapke et al., 2015). 
 It is important to investigate the factors mentioned above for the assessment of the CTSA 
program. However, the most important factor in the assessment of CTSA is whether it achieved 
its ultimate goal of changing the research community towards more translational research. To the 
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best of my knowledge, only one study has examined this issue (Weber, 2013). Using Medical 
Subject Headings (MeSH), Weber (2013) divided publications into three groups, which are 
publications on animals (group A), publications on cells (group C) and publications on humans 
(group H). Then, he made a triangle with A, C and H as three points. After that, he placed points 
that represent individual collections of publications (e.g., group of publications on biology) 
inside the triangle and tracked the location of points by time. If they noticed that a point of 
specific publication collection is moving towards the H point, they assumed that field is 
becoming more translational. One of the results they found is that a collection of articles that has 
the topic related to “Cloning, Organism” is moving towards the H-point, which means that this 
group of publications is becoming more translational over time. They also introduced the concept 
of “generations” of translation lag. They defined an article as a first-generation article if it was 
cited directly by group-H paper, as a second-generation article if a non-H group article that cites 
non-H group article got cited by group-H paper and so forth. The study by Weber (2013) 
provides one perspective on what has happened in the research community on translational 
research. However, the measurement used in the study is complex and not easy to follow and this 
concern should be addressed for the result to be accepted widely.  
For the accurate evaluation of the CTSA program, we need to use right measure of what 
translational research is. Besides the study by Weber (2013), there have been few other attempts 
to come up with a measure of translational research. For instance, Surkis et al. (2016) made a 
checklist that can be used in categorizing publications into a specific stage in the five-stage 
process of translational research (T0 to T4). Then, they created a machine learning algorithm to 
categorize publications within these five stages. Due to low frequency of T1, T2, T3 and T4 
articles relative to T0 articles, they combined T2 with T3 articles and T4 with T5 articles during 
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the classification. The authors claimed that their algorithm showed very good performance and 
reliability in all groups of articles. Another example using MeSH keywords for the classification 
of translational work is a study by Han et al. (2018). They classified a publication as “primary 
translational research” if it was related to field related to clinical science25 (Han et al., 2018, p. 5). 
The authors also introduced a category named “secondary translational research” and classified a 
paper into this group if a paper was not associated with clinical study but got citations from 
papers that deal with clinical issues (Han et al., 2018). Using this approach, they showed that 
13.4% of CTSA supported articles published in the field of behavioral and social science could 
be classified as translational research. 
In some studies, methods not related to MeSH keywords were used for the classification 
of translational publications. For instance, Fontelo & Liu (2011) introduced a web application 
filter that can be used to retrieve articles that have potential clinical applications. They created 
this filter by manually reviewing words and phrases that appear in articles published in clinical 
and translational science journals. A study by Grant, Cottrell, Cluzeau, and Fawcett (2000) 
looked at the citation link between publications and clinical guidelines. They assumed that 
publications cited by clinical guidelines have an impact on the field of health. Based on the type 
of journal in which an article was published, they classified cited publication as 1) clinical 
observation, 2) basic, 3) clinical mix, or 4) clinical investigation. Their result showed that 
publication in “basic” category is not cited much (8%) by clinical guidelines.   
 Looking at previous studies, we can easily notice that the research assessment field has 
not standardized on a single indicator to measure the translational feature of research articles and 
the attempts to develop and improve measures are still ongoing (Blümel, 2017; Surkis et al., 
                                                 
25 Few examples include clinical study, clinical trial, phase 1 clinical trial, phase 2 clinical trial, phase 3 clinical trial, 
phase 4 clinical trial, controlled clinical trial, practice guideline, observational study and randomized controlled trial 
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2016). Hence, when a researcher wants to conduct research on the change of translational feature, 
he or she should select an existing measure or develop a novel measure that fits the context of the 
planned research well. I made the latter choice in my study and described this measure in the 
sections that follow.   
 
4.3. A new measure: the TS score 
 
 To measure how translational a publication is, I am proposing a new index that is related 
to the share of forward citations from clinical science a non-clinical article receives. This 
measure aligns with the method of using disciplines of journals of the citing article to 
characterize features of the cited article (Qin et al., 1997; Grant et al., 2000). Two big steps are 
required to calculate the new measure. As the first step, I categorized journals into four 
disciplines, which are clinical science (Clinical), non-clinical science (Non-Clinical), 
multidisciplinary (Multi) and non-science and engineering (Non-S&E). This categorization is 
done by using Web of Science Category (WOSC) and NSF classification of fields of study 
(National Science Foundation, 2018). In Web of Science, each journal is assigned up to five 
WOSCs based on the topics covered by the journal. Each WOSC can be matched with fields in 
the NSF classification of fields of study using the name similarity. After the name matching, I 
classify the Web of Science category of journals into clinical science and non-clinical science. 
Specifically, when a field was listed in science and engineering section (e.g., biomedical 
engineering) I classified it as non-clinical science and, when the field was listed in health section 
(e.g., pediatrics), I classified it as clinical science. As a journal can have up to five WOSCs, a 
journal could have a mix of non-clinical science WOSCs and clinical science WOSCs. In my 
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study, I classified a journal as clinical journal if the journal has only clinical WOSCs. The fields 
that were not listed under science and engineering or health were classified into 
Multidisciplinary science or Other Science (e.g., social science)26. Figure 21 illustrates the 
concept of the first step. 
 
 
Figure 21. Classifying publications into the ones with and without translational feature based on 
journal discipline of forward citing publications 
 
As the second step, the Translatedness score (TS score) is calculated using the simple 







Using the portion of cross-disciplinary citation builds on the approach that Luke et al. 
(2015) adopted. In their study on the cross-disciplinary collaboration of an individual CTSA 
receiving institution, Luke et al. (2015) introduced the cross-disciplinary density ratio, a measure 
calculated by dividing the density of cross-disciplinary collaboration by the density of within-
disciplinary ties. However, the focus of their study was not on articles but on the composition of 
research teams. 
 The intuition behind the TS scores is that if an article published in a basic science journal 
has translational feature, it is likely that it receives a large portion of forward citations from 
                                                 
26 Details on the classification of Web of Science Category into four disciplines are shown in the Appendix D. 
78 
journals published in the clinical sciences. Therefore, there will be a baseline TS score to judge 
whether an article has translational feature or not. This approach would provide me with the 
number of translational publications each institution produces every year and I could track the 
change of this count variable to evaluate how much an institution is impacted by the CTSA 
award. 
 
 4.4. Verification tests on the measure 
 
 When a new measure is developed, we need to assess how credible the measure is. In this 
regard, I’ve conducted some tests that can give support to the reliability and validity of the 
measure.  
 
4.4.1. Reliability tests 
 
 What is essential for a quantitative measure to have high reliability is the stability over 
time (Golafshani, 2003). A measure’s time stability is related to similarity of measurements 
within a given period of time, which could ensure repeatability and replicability of a measure 
(Golafshani, 2003). In this regard, we need to check if the TS score has stable value over time in 
order to claim that it is a reliable measure. For each publication, enough number of forward 
citations should be accumulated for the share of forward citations from clinical science to reach a 
stable status27. As the forward citation counts will increase over time, the TS score of an article 
                                                 
27 For instance, if a publication received first two citations from non-clinical field, its TS score will be 0. If its third 
forward citation is from clinical side, its TS score will rise from 0 to 0.33. On the other hand, if the forward citations 
count of a publication is large enough the TS value would not change much with one additional forward citation 
from rare discipline. For instance, let’s assume a situation where an article received 100 forward citations and all of 
them were from non-clinical publications. If its 101st forward citation comes from clinical side, its TS score will 
only increase from 0 to 0.01. 
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will stabilize only after certain years has passed since the publications of the article. This means 
that forward citation counts and time since publication, which is correlated with each other, are 
two factors to consider in determining the stabilization of the TS score. In this respect, I took the 
following steps to find out when the TS score gets stabilized28.  
1. Check the TS score of each publication by year and figure out how many years are 
needed for the TS score to stabilize, which I call stabilizing year. 
2. Extract groups of papers with a certain number of forward citations (i.e., 1 through 10) 
and calculate the TS scores of each publications-group. This group of TS scores will be 
named as TS scores at starting year.  
3. Calculate the change of TS scores of each publication-group by year (i.e., N years) for the 
years after stabilizing year (calculated in step 1), which I name TS scores after N-year. 
4. Check the correlation of TS scores at starting year (acquired in step 2) and TS scores 
after N year (acquired in step 3). If the correlation is larger than 0.7 for all TS scores at 
starting year - TS scores after N-year pairs, we could assert that the TS score was stable 
from the starting year.  
To perform step 1 through 4, I used a sample of 286 non-clinical publications that were 
published in 2003 and acknowledged NIH grants with a PI from Emory University. The 
cumulative counts of total forward citations and forward citations from the clinical science 
journals that occurred between 2004 and 2015 were used to calculate the TS score. Figure 22 
shows the change of TS score by year for some publications. These are some examples of 
publications that received forward citations for almost all years (11 or more years) during the 
                                                 
28 Ideally, it’s better to track the TS score by the change of the forward citation counts. However, I was only able to 
get end-of-year values of forward citation counts and the values were not the number that increment by one. Hence, 
I had to use the method presented below.   
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period of interest29. There are various forms of change regarding the TS score. Some publications 
have similar TS score from the beginning till the end (e.g., ID 272, ID 415), some publications 
start from very low TS score value but increase as time passes (e.g., ID 36, ID 195) and some 
publication starts with high TS score in the early years and decrease over time (e.g., ID 13, ID 
267). TS score of some papers that fluctuate in the early years (e.g., ID 24, ID 269). However, 
we can note that, in almost all cases, the value of TS scores doesn’t change much after 2007, 
which is marked as the vertical line in each graph. Having these results, we can claim that the TS 
score of a publication reaches its stable value four years after a paper is published. It means that 
we need to wait around four years to classify a basic science publication into one with high 
translational feature or the one with small or no translational feature.  
 
Figure 22. Change in TS score by year for some non-clinical publications 
                                                 
29 More examples can be found in the Appendix E. 
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Table 8 shows the result of step 2 through step 4 of my reliability test. If we look at the 
case of publications with only one forward citation, which is a sample with 63 cases, the 
correlation of the TS scores at the starting point and four years and five years after the starting 
point is 0.730 and 0.721, respectively. However, the correlation between starting point’s TS 
scores and six-year after starting point is 0.634, which is below 0.7 threshold. Furthermore, the 
correlation value stays below 0.7 if we increase the post-year to 7 and 8. Hence, having only one 
forward citation doesn’t give us a stable TS score, as expected. This is also the case for the 
publications with two citations. The correlations are smaller than 0.7 threshold for all starting 
point and post starting point pairs. For citations with three citations, the correlation values are all 
larger than 0.7, which seems to be a coincidence. For the groups of papers that start with four 
citations, the correlation values are smaller than 0.7 in most pairs (all pairs except starting point 
and after five years pair). The tendency of having correlation value smaller than 0.7 stops as the 
forward citation count at start point increases to 5. For the group of publications that received 5 
or more forward citations, the correlation value is larger than 0.7 for all pairs. Therefore, we 
could claim that the publications with five or more forward citations have stable TS score values.  
 
 
Table 8. Correlation between TS score of the starting point and TS score after four or more years 
Forward citation counts 
at starting year 
Correlation between TS scores at the start and corresponding years 
Sample 










1 0.730 0.721 0.634 0.589 0.550 63 
2 0.661 0.504 0.533 0.512 0.462 62 
3 0.794 0.799 0.770 0.732 0.727 71 
4 0.690 0.707 0.637 0.645 0.622 81 
5 0.786 0.745 0.789 0.793 0.808 69 
6 0.836 0.792 0.785 0.770 0.743 59 
7 0.827 0.807 0.800 0.810 0.812 74 
8 0.904 0.891 0.879 0.874 0.849 50 
9 0.878 0.865 0.853 0.833 0.831 64 
10 0.915 0.923 0.918 0.931 0.937 55 
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4.4.2. Validity tests 
   
A. Calculating the TS scores with another approach: Publication discipline classified 
based on the affiliation of the first authors 
 
Validity of an indicator is related to the question that determines whether an indicator is 
measuring what it intended to measure (Golafshani, 2003). The validity in quantitative research 
like mine is associated with truth, actuality and accuracy (Golafshani, 2003). The TS score I am 
proposing is based on the classification of disciplines of journals. If the new TS scores calculated 
through another method have similar values (high correlation with my original TS score), the 
validity of the measure will increase. There have been some other measures that examine 
citations outside the category an article was published in, mainly for assessing the 
multidisciplinarity of articles (e.g., Morillo, Bordons, & Gómez, 2001; Ortega & Antell, 2006; 
Porter & Chubin, 1985). One of the approaches that these studies used is taking the first author’s 
affiliation to categorize papers into different disciplines (Ortega & Antell, 2006). This 
assumption is based on the accepted practice in academia, especially in life science, that first 
authors of publications are assumed to have the largest contribution on the paper (Carpenter, 
Cone, & Sarli, 2014, p. 1162). Drawing on these articles, I recalculated TS score using the 
discipline classification of the first author’s affiliation to help assess the validity of my measure. 
For this analysis, I classified forward citing publications with the first author affiliated with 
clinical science department as clinical science publications and classify articles as non-clinical 
publications otherwise. Figure 23 depicts the concept of classifying publications based on the 
first author’s affiliation. 
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Figure 23. Classifying publications into the ones with and without translational feature based on 
first author’s affiliation 
 
The steps that I took to conduct this validity test are explained below:  
1. Select a sample of publication for the analysis. My selection is journal articles that were 
published in non-clinical science journal in 2003 that acknowledge any NIH grant that 
have PI from Emory University with forward citation counts between 11 and 42. This 
gave me a sample of 114 articles. 
2. Gather the bibliometric information of the articles that cited the publications in my 
sample. This gave me a total of 2,089 forward citing articles. 
3. Classify disciplines of forward citing publication based on the full address of the 
affiliation of the first authors. There were around 2,000 unique affiliations, which I 
classified manually30. 
4. For each article, calculate the share of forward citing publications that have first author’s 
affiliation classified as clinical department.   
                                                 
30 There were some issues to consider when classifying publications into clinical papers and non-clinical papers, 
which led me to do the classification manually. First, the department information didn’t exist in some listings (e.g., 
Univ St Andrews, St Andrews KY 16 9ST, Fife, Scotland; RAND Corp, Santa Monica, CA 90401 USA). In these 
cases, I couldn’t make decision on the discipline of the author’s affiliation. Second, the orders that university name, 
department or school name and city are listed were different between articles. Though the department information 
was listed second in most cases, it was listed first in some cases. Third, the details of the affiliation were different 
across publications. For instance, some publications provided very detailed information (e.g., Sch Med & Dent, Dept 
Biostat & Computat Bio) whereas some publications only provided information on school level (e.g., Sch Life Sci & 
Technol). To be conservative on classifying a publication into clinical paper, I classified the publications into 
clinical article only if there were clear and enough information of the discipline. For instance, I didn’t classify a 
publication as clinical if the most detailed information of the first author’s affiliation is school of medicine. This is 
because, in many universities, school of medicine is composed of departments conducting basic science work (e.g., 
department of microbiology). In this vein, I only classified a publication as a clinical paper only if sub-division of 
the school is closely related to the clinical field of research (e.g., Department of Pediatrics). This approach would 
give me lower values for the TS scores. 
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Table 9 compares summary statistics for two different approaches, one based on the 
journal classification of forward citing articles and the other based on the affiliations of first 
authors in forward citing articles. We can see that the value of the TS score based on first 
author’s affiliation (first row) is larger than the TS score calculated based on journal 
classification (second row). A total of 81 articles out of 144 articles (71.1%) in my sample had 
larger TS scores when the first author's affiliation-based approach was used. Figure 24 shows the 
distribution of TS scores calculated using two different approaches. We can see that the TS 
scores calculated using the first author’s affiliation has larger mean value and are more dispersed, 
as expected. Most importantly, the correlation value between two TS scores is 0.748, which is 
larger than 0.7 threshold. Hence, we can claim that TS score based on journal classification has 
gained validity in some sense.  
 
Table 9. Correlation between TS scores calculated with different methods 
Approach of classifying discipline 
of forward citing article 
Mean Std Dev Min Max 
Correlation with TS score 
based on journal classification 
Based on journal classification 0.092 0.119 0 0.553 1.000 
Based on first author affiliation 0.172 0.164 0 0.684 0.748 




Figure 24. Distribution of TS scores calculated using different approaches 
 
B. Checking the TS scores of publications that result in patents 
 
 If a publication is cited by one or more patents, it suggests that the publication has a 
translational feature, or is at least relevant to industrial use (Meyer, 2000). A direct knowledge-
transfer from basic research to technological outcome could be reflected in patent’s citation of 
basic science publication (Huang, Yang, & Chen, 2015; Meyer, 2000; Sung, Wang, Huang, & 
Chen, 2015). US patents list nonpatent references (NPR) on their front pages and the citation link 
between publications and patents can be identified using the NPR list (Meyer, 2000). Drawing on 
this evidence of patenting and translation of research, I aim to test the validity of my TS score 




Prospective approach of publication – patent citation analysis 
 
As the first step to test the validity of the TS score using prospective approach of 
publication-patent citation analysis, I selected a group of basic science publications. My selection 
was, as in reliability tests, the set of 286 non-clinical articles published in 2003 that received 
support from NIH and had a PI affiliated with Emory University. I searched the DOI of these 286 
articles in LENS.ORG (http://www.lens.org)31. The Lens returned information of 217 of them 
giving me the retrieve rate of 75.9%. Not all publication information is retrieved as the Lens 
database doesn’t cover all scholarly databases, but only covers three datasets (PubMed, Crossref 
and Microsoft Academics)32.  
Table 10 shows the summary of the statistics for publication groups with and without 
patent citation. Among the total sample of 217 publications, 144 publications (66.4%) didn’t 
receive any patent citation and 73 publications (33.6%) had at least one patent forward citations. 
We can see that the average TS score of the publications without any patent citation (0.111) is 
smaller than the average TS score of publications that result in at least one patent (0.156). The t-
test also showed that the mean value of the TS score of the former group is smaller than the 
mean TS score of the latter group in 0.05 significance level (Pr value: 0.013). This result 
provides additional support that the TS score is a valid measure of the translational feature of 
publications. 
 
                                                 
31 LENS.ORG is an open public website managed by Cambia, an independent non-profit organization, that provides 
linkages between scholarly works, patents and biological sequences (LENS.ORG, n.d.). Its patent database covers 
patent datasets from the USPTO, European Patent Office, WIPO and IP Australia and its scholarly dataset includes 
PubMed, Crossref and Microsoft Academics (LENS.ORG, n.d.). With the collaboration with NIH Pubmed and 
Crossref teams, the Lens linked publications’ Digital Object Identifier (DOI) with NPL in their patent database. 
Hence, using DOI of publications, we could check if the publications were cited by patents or not. 
32 Using Pubmed ID instead of DOI for the search may give me higher retrieve rate. However, it would be hard to 
track the forward citations links of publications with only Pubmed ID but without DOI. 
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Table 10. TS score comparison between publications resulting and not resulting in patents 
Group of publications Obs Mean Std Dev Min Max 
All publications 217 0.126 0.139 0 0.611 
Publications without patent citation 144 0.111 0.126 0 0.610 
Publications with patent citations 73 0.156 0.158 0 0.611 
 
Retrospective approach of publication – patent citation analysis 
 
For a test on the validity of TS-scores using a retrospective approach of publication-patent 
citation analysis, I started with group of patents, rather a group of publications. To complete this 
validity test, I used the following approach: 
1. Using patent ID - NIH project ID link CSV file downloaded from NIH RePORTER, 
acquire the list of patents issued during 2001 -2015 that acknowledge any NIH project 
that have Emory University affiliated PI (List 1).  
2. Using “otherreferences” file downloaded from PatentsView (2018), extract bibliometric 
information (e.g., author, title, journal names) of “Non-patent citation” of List 1 patents 
(List 2). 
3. Using bibliometric information obtained from step 2, manually search for non-patent 
citations using Google Scholar and Web of Science to get their DOIs (List 3). 
4. Extract publications in List 3 that are from basic science journals (List 4). 
5. Get forward citing publication list of DOIs in List 4 (List 5). 
6. Calculate TS scores of DOIs in List 4 using the Web of Science Category classification 
of List 5 publications.  
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The result from step 1 gave me a sample of 177 patents (List 1). This group of patents had a 
total of 186 non-patent citations (List 2), of which 88 were scholarly publications (List 3). 
Among 88 scholarly publications, 68 of them were published in basic science journal based on 
my classification rule using the Web of Science category and NSF Classification of fields of 
study (List 4). 68 basic science publications received 29,503 forward citations (List 5), which 
were divided into clinical publications and non-clinical publications based on the Web of 
Science category and NIH classification of fields of study. Table 11 shows the summary of all 
basic science publications (sample size 68) and group of publications that received more than 
five forward citations (sample size of 66). This validity test benefits from focusing on 
publications that have been cited in patents but lacks a natural comparison group.  A matching 
approach could potentially be used to develop a comparison group but that was beyond the scope 
of this dissertation. Hence, I compared the mean value of this group with the average TS score of 
the whole group of publications33 that will be used in my analysis in chapter 5. The mean values 
(0.135 and 0.140) were larger than the average value of the whole group of publications, which 
was 0.117. Hence, this finding could be used as additional evidence of the validity of the TS 
score I am proposing. 
 
Table 11. Summary of TS scores of Emory University’s non-clinical publications that result in 
patents 
Group Obs Mean Std Dev Min Max 
All publications 68 0.135 0.163 0 0.624 
Publications with more 
than 5 forward citations 
66 0.140 0.163 0 0.624 
 
                                                 
33 All articles published during 2001 - 2015 with support from NIH grants that have PI affiliated with from 115 
Carnegie R1 universities 
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C. Several examples of the TS scores of publications that result in drug 
 
 One very clear way to determine whether a publication has translational feature or not is 
checking if the publication leads to the development of a drug. Scholars have focused on this 
characteristic of publications and tried to find articles that result in drugs. For instance, Sampat 
and Pincus (2015) used a machine learning technique to match publication, patents and drugs. 
They did this to figure out how publications from Academic Medical Centers (AMC) are used 
and found that about half of FDA approved new molecular entities (NME) between 2000 and 
2009 are associated with publications from NIH-funded AMC projects. Another study by Li et al. 
(2017) linked publications with patent associated with approved drugs. They found that around 5% 
of NIH grants result in publications that are cited by patents related to marketed drugs.  
If the TS scores of basic science publications on abovementioned lists turn out to be high, 
it will give additional support to the validity of the measure. I wasn’t able to get a full list of 
publications that result in drugs as the studies looking at publication-drug link mentioned above 
did not provide enough details for the exact replications. However, I was able to get some 
examples of publications that end up in drugs from the supplementary material of Sampat and 
Pincus (2015). In the supplementary material, they provided a list of 15 publication-patent-drug 
link examples. With the information, I calculated the TS scores of all four publications on the list 
that were published in non-clinical science journals based on my classification rules. Table 12 
shows the value of TS scores of these publications. We can see that, in general, the TS scores 
have high values with the largest value of 0.552. The average TS score of these publications is 
0.393. This value is much higher than the mean value of total population of papers that will be 
used in my analysis in chapter 5, which is 0.117. Though the number of publications analyzed is 
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very small, this finding gives additional support of the validity of the TS score I have developed 
and proposed. 
 
Table 12. TS score of non-clinical science publications that result in drugs 




Bhat et al. (1997)  0.552 
Entereg Alvimopan 
Bagnol, Mansour, Akil and 
Watson (1997)  
0.528 
Inomax Nitric Oxide Garg and Hassid (1990)  0.345 
Velcade Bortezomib Rock et al. (1994)  0.149 
Note: Table recreated from a table in supplementary appendix of Sampat and Pincus (2015) 
 
4.5. Conclusion  
 
 In this chapter, I introduced the TS score, a novel measure to assess the translatedness of 
a non-clinical publication. The measure is calculated using the share of clinical forward citations 
among all forward citations a non-clinical article receives. This is based on the assumption that if 
a non-clinical article is cited by an article in clinical science journal, a knowledge flow from 
basic science to clinical science is taking place. The measure borrows concepts from previous 
studies using journal discipline of forward citing articles (Qin et al., 1997), distinguishing basic 
research and clinical science (Grant et al., 2000; Narin, Pinski, & Gee, 1976), and using cross-
disciplinary density ratio (Luke et al., 2015; Porter & Chubin, 1985).  
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Several considerations make the TS score both novel and strong. First, the measure is 
relatively simple and easy to understand. Potential users only need to know the concept of 
forward citation and the classification of journal disciplines based on fields of study. Second, the 
measure can be used easily. Previous measures on translational feature of publications used 
machine learning technique (e.g., Surkis et al., 2016), complex application of MeSH keywords 
(Weber, 2013; Han et al., 2018) or filters created by manual review of articles (Fontelo & Liu, 
2011). All these approaches may have good precision, but it would be difficult for the common 
user to understand and, hence, require supplementary training. On the other hand, the TS score is 
straightforward in the sense that it uses very few concepts in the calculation. Also, the 
calculation process could be automated easily as long as there is consensus on the classification 
rule of journals into clinical group and non-clinical group. Third, my preliminary assessments 
suggest the measure is both reliable and valid. My reliability tests showed that if a publication 
received five or more forward citations, the TS score of the publication reaches a stable value. 
Results from the validity tests that compared my TS score with the TS score calculated using the 
first author’s affiliation of forward citing publication and that checked the TS score of 
publications that result in patents or drugs also showed positive results. All in all, the TS score I 
am proposing has many strengths and I expect that this measure has the potential to be used 





CHAPTER 5. IMPACT OF NIH’S CTSA AWARD ON TRANSLATIONAL RESEARCH 




Creating research outcomes that have translational nature is the ultimate goal of NIH’s 
support for translational research (Han et al., 2018; Weber, 2013). In this chapter I aim to test the 
hypothesis whether the CTSA award has led to a change in the number of publications that have 
translational feature. To classify publications into those with and without translational 
characteristic, the TS score that is proposed in the previous chapter will be used. A non-clinical 
science publication will be considered as having translational feature if its TS score is above 
certain threshold. To compare the translational research performance of Carnegie Highest 
Research Universities, all NIH supported basic science journal papers published by these 
institutions between 2001 and 2015 are analyzed. Difference-in-difference methodology with 
institution matching will be used to test the difference between the treatment group, which are 
institutions that received CTSA awards, and the comparison group, which are institutions that 
did not receive or participate in CTSA awards.  
It may be the case that a variety of factors mediate the relationship between the CTSA 
award and the translational publication counts of institutions. Hence, in addition to assessing the 
relationship between the CTSA award and the production of translational outcomes, I aim to 
examine the process through which this relationship is formed. NIH emphasizes inter-
organizational collaboration and multidisciplinary research as very important factors for the 
successful execution of the CTSA program (National Institutes of Health, 2017b; Obeid et al., 
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2014). Hence, I plan to assess if these two factors affect the relationship between the CTSA 
award and the increase of translational research outcomes of institutions. For the test of 
mediation, a combination of methods proposed by Barron and Kenny (1986) and Preacher and 
Haye (2004) were used. I expect that the study will provide insight into the effects of the CTSA 
program and provide implications on the government policy related to translational research. 
 
5.2. Theoretical background, previous studies and hypotheses 
 
5.2.1. The direct relationship between the CTSA award and translational outcome  
 
Research outcomes should be benchmarked to supporting program’s intended aims 
(Corredoira, Goldfarb, & Shi, 2018) and the ultimate goal of the CTSA award is to produce 
research outcomes that link the outcomes from basic science to clinical use (Han et al., 2018). 
My first research question for this chapter addresses this fundamental goal of the CTSA program. 
I want to find out whether receiving the CTSA award led institutions to create more research 
outcomes that transfer the research outcome from the basic side to the clinical side. For this 
assessment, I focus on the creation of journal articles that are translational in nature34. To change 
the feature of the whole institution at large towards more creation of translational research 
outcomes, we need to understand what are the factors that could lead to the change. Hence, I try 
to identify and discuss the factors that could take the role of changing the scientist’s research 
behavior, which would subsequently lead to the change of the overall nature of the research 
community.  
                                                 
34 The reasons why I chose publications, not other measure like patents, for the assessment are provided in chapter 4. 
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The theory that connects many of the factors related to potential changes in researcher’s 
behavior is the incentive theory. Incentive theory maintains that people would be willing to 
adjust their behaviors that would bring them more benefits (Balconi et al., 2004). If a scientist 
thinks that certain type of research would not provide them any benefit, he or she will not 
participate, even with intervention from the external forces (Brint, 2005). The following 
paragraphs list and explain the factors that may have effect on incentivizing scientist to conduct 
more translational research. 
 Meeting environmental demand. Scientists try to adapt to environmental demands 
(Bessant et al., 2001). As members of the society, scientists should continuously pursue the roles 
that the society or the affiliated institutions require and try to meet their needs (Wowk et al., 
2017). Scientists take the role of “supplying” knowledge and information to the society and this 
should correspond with the “demand” of the society (Sarewitz and Pielke, 2007). In that regard, 
in the era of more emphasis on the commercial use of scientific outcomes (Brint, 2005), referred 
as “Model 2 knowledge production” in the study by Gibbons, Nowotny, Schwartzman, Scott and 
Trow (1994), scientists may change their research behavior towards more production of research 
outcomes that have practical uses. To achieve this goal, scientists may get more involved in 
translational research rather than being engaged in the traditional field they have been working 
on. This is also related to the self-interest theory in the sense that people would have a preference 
in the research type that provides them enough resources for research. As noted in previous 
chapters, the support for translational research continues to grow in terms of budget size, which 
leads to an increase of related resources. This trend could make translational research become 
more popular than before and attract more scientists. 
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Financial benefit. There are various types of benefit that scientists will react to and one 
of them is the financial benefit (Van Rijnsoever & Hessels, 2011). The question of whether 
financial benefit, represented by external funding, can lead scientists to change their research 
behavior to the form that they are not used to is very important in science policy. The answer to 
this question is crucial as various institutions and funding agencies have been trying to lead the 
scientists to conduct scientific research towards the direction they want. If scientists only stick to 
the research patterns they are accustomed to and are reluctant to change their research behavior 
even with financial incentive, making programs and providing grants that aim to make this 
change would have limited effects. The CTSA program, like many other NIH programs, goes 
through reassessment process every five years (Kaiser, 2017). Hence, the scientists involved in 
the CTSA program would tend to follow the requirements of the NIH for the renewal of the 
program. The most comprehensive requirement that the NIH provides to the CTSA receiving 
institutions is to conduct more translational work (Han et al., 2018). As a result, scientists, 
especially those in the leadership of individual institutions’ CTSA program, would be conducting 
translational research while their institutions are receiving the CTSA award.  
Duration of research. The third type of benefit related to researcher’s incentive is the 
expectation on the duration of the research. Academic researchers would prefer to be engaged in 
the field that they can participate throughout their career, not the ones that are not expected to 
last long. Therefore, if they consider the movement towards translational research is temporary, 
they would stick to their original research field (Luke et al., 2015). However, several factors 
suggest that the support for translational research will last for an extended period. First, the 
emergence of support for translational research did not happen suddenly. It was a result of the 
long-lasting recognition of the problem of the “valley of death” (The President’s Council of 
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Advisor on Science and Technology, 2012). In this respect, public authorized institutions like 
NIH, IOM and even the Congress recognize the importance of translational research (Rubio et al., 
2010; Han et al., 2018). Also, it has been more than two decades since it gained attention from 
the research community as a solution to the decreasing productivity of biomedical research 
(Lander & Atkinson-Grosjean, 2011). Given this circumstance, support for translational research 
is expected to last for a long time and scientists would also be aware of the fact.  
 Recognition. One of the factors related to intrinsic motive of scientists that result in the 
change of scientist’s research behavior is the recognition. Recognition of a scientist among his or 
her colleagues is important as it is closely related to promotions such as receiving tenure and full 
professorship (Butler, 2008; Van Rijnsoever & Hessels, 2011). Therefore, academic researchers 
would not be willing to participate if certain type of research if it does not have a positive effect 
on their recognition (Van Rijnsoever & Hessels, 2011). As translational research is relatively 
new to the entire biomedical field, questions remain about whether it will have positive or 
adverse impact on the recognition. As there is uncertainty, we can expect that scientists may not 
actively engage in translational research.  
   
Table 13. The expected direction of the impact of factors on the change of scientist’s behavior 
towards translational research 
Factor Direction of the change towards translational research 
Meeting environmental demand Positive 
Financial benefit Positive 
Duration of research Positive 
Recognition Not clear 
   
 Table 13 shows the summary on the expected direction of impact of the factors related to 
the change of scientists’ behavior towards translational research. The counts of publications with 
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translational feature will increase, decrease or don’t change depending on the relative influence 
of each factor mentioned in Table 13. Though the direction of the impact regarding recognition 
factor is unclear, the remaining factors are expected to have positive impacts towards more 
translational work. Hence, I am proposing following hypothesis.  
 
Hypothesis 1. Academic institutions receiving CTSA award will produce more 
translational publications than the ones not receiving CTSA award. 
 
5.2.2. The indirect relationship between the CTSA award and translational outcome  
 
One issue with Hypothesis 1 is that the relationship mentioned in the hypothesis cannot 
stand alone. Many other factors could affect the relationship between CTSA award and research 
outcomes. In addition to traditional covariates, such as the research capacity of institutions or the 
existence of medical schools, important point to consider when analyzing the relationship 
between the CTSA award and translational publication count is to consider the mediating role of 
the factors related to inter-organizational collaboration and multidisciplinarity of institutions. 
 
Inter-organizational collaboration as potential mediator35 
 
Universities possess imperfect information and this shortage leads to an inefficient and 
unorganized form of the institution, which makes them seek partners. Powell, Koput, & Smith-
Doerr (1996) urged that network will bring benefits to all stakeholders in the field of 
                                                 
35 More details about the characteristics, impact and trend of inter-organizational collaboration related to biomedical 
research, especially on the CTSA award, can be found throughout chapter 3.  
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biomedicine. They urged that the network will bring more access to knowledge for all parties in 
the network and help them perform better. It is reasonable to expect that these resources will help 
scientists enhance their research productivity (Katz & Martin, 1997; Gaughan et al., 2018). The 
elements of collaboration that have positive effect on research productivity include division of 
labor, research capacity or complementary skills, intellectual stimulus, new skills learned from 
the collaborators, access to equipment (Lee & Bozeman, 2005; Owen-Smith & Powell, 2003). 
There has also been an emphasis on research collaboration by NIH and one of the major 
goals of translational research is to foster collaboration between institutions (Obeid et al., 2014). 
This is based on the wide-spread belief that collaboration will bring many benefits such as access 
to resources and mentorship (Bozeman & Corley, 2004; Katz & Martin, 1997; Katz et al., 2004). 
Many studies also showed empirical evidence that groups with more ties with other groups have 
higher performance than the ones with fewer ties (Katz et al., 2004). Despite this evidence, we 
should remember that increasing collaboration is not the ultimate goal of the CTSA program. 
Rather, it’s just part of the process of creating more research outcomes that have translational 
feature. In this regard I am proposing following hypothesis with the depiction of the hypothesis 
presented in Figure 25.  
 
Hypothesis 2. Intensity of inter-organizational collaboration of institutions mediates 
the relationship between receiving CTSA and production of translational outcomes. 
 
 
Figure 25. The depiction of Hypothesis 2 
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Multidisciplinarity of research as potential mediator 
 
Emphasis on multidisciplinary research has attracted the interest of the research 
community for the last few decades (Qin et al., 1997; Wang et al., 2017). This can be explained 
with wide-spread belief that assembly of knowledge from various disciplines would lead to 
solutions to complex problems (Baumwol, Mortimer, Huerta, Norman, & Buchan, 2011; Van 
Rijnsoever & Hessels, 2011). Scientists felt the need for more combination of knowledge from 
diverse disciplines to fully answer important questions that traditional approach on science 
cannot provide (Aboelela et al., 2007). Studies on multidisciplinary research started as early as 
the 1950s by sociologists, psychologists and science historians (Qin et al., 1997) and have found 
that the major benefits of multidisciplinary research include its ability to spark creativity and 
make scientific breakthroughs (Rafols, Leydesdorff, O’Hare, Nightingale, & Stirling, 2012; 
Heinze, Shapira, Rogers, & Senker, 2009; Hemlin, Allwood, & Martin, 2004; Stevenson et al, 
2013), support innovation (Gibbon et al., 1994) and help address societal problems (Lowe & 
Phillipson, 2006; Rafols et al., 2012; Wowk et al., 2017).  
 Thanks to positive perception, various parties provide support for multidisciplinary 
research. Government is the key player in supporting multidisciplinary research. For example, 
NSF considers multidisciplinary research as a major tool in tackling complex science issues and 
solve societal problems (Wagner et al., 2011). In the similar vein, NIH identified 
multidisciplinary research as their priority in their Roadmap and considered it as a crucial factor 
in producing new knowledge (Aboelega et al., 2007). Various funding instruments for 
multidisciplinary research are being applied at the university level (Van Rijnsoever & Hessels, 
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2011). In particular, both NSF and NIH supported universities in making large multidisciplinary 
research groups and building research centers for them36 (Brint, 2005).  
In line with the support from the government, there have been movements by the 
universities on their own. As a part of the academic revolution, universities are making programs 
fostering multidisciplinary collaboration and trying to become new foci of this new concept of 
research (Brint, 2005). During the period of increasing ties with the commercial actors (Brint, 
2005), universities are taking a new approach of introducing programs that promote 
multidisciplinary collaboration such as making research umbrella groups and setting new 
initiatives. Brint (2005) mentioned that universities are also creating graduate programs dealing 
with multidisciplinary research and showed that over eighty percent of the universities in his 
survey pool introduced cross-disciplinary graduate programs.  
The CTSA program has also put an emphasis on promoting multidisciplinary and 
provided support in making multidisciplinary teams with the hope that it can help research teams 
to come up with solutions for smooth flow from basic science and clinical science (Luke et al., 
2015). NIH thinks that combining skills and approaches used in various disciplines can 
accelerate the translational process and help solve the puzzle of complex problems related to 
disease (Zerhouni, 2006). However, the relationship between receiving CTSA and increase of 
                                                 
36 For instance, many research centers funded by NIH, which has much larger funding on the support for 
interdisciplinary research than NSF, such as Center for Evidence-Based Practice in the Under Deserved, 
Interdepartmental Neuroscience Center are labeled as doing interdisciplinary research (Aboelega et al., 2009). These 
centers try to integrate knowledge from various disciplines to broaden the scope of investigation and remove the 
potential roadblocks for the interdisciplinary collaboration (Aboelega et al., 2007). A more representative example 
of NSF’s interdisciplinary center would be Engineering Research Center (ERC). ERCs are interdisciplinary, multi-
institutional centers that links academic institutions, private companies and government to narrow the gap between 
academia and industrial engineering applications (National Science Foundation, n.d.-a). ERC program is similar to 
CTSA program in that it has the purpose of expanding the use of research outcomes from the academia. However, 
these two programs are different in several aspects. First, ERC focuses various fields such as security, health, energy 
and manufacturing (National Science Foundation, n.d.-a) whereas the CTSA program focusses on only field of life 
science. Second, while ERC program is associated with workforce in engineering, the CTSA program is more 
related to researchers in basic science and clinical science. Thirdly, ERCs are multi-institutional by nature (National 
Science Foundation, n.d.-a) but having partnering institutions is not mandatory for CTSA hubs. 
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multidisciplinarity of research is mixed. In the study by Luke et al. (2015), it was shown that the 
academic researchers who were part of a CTSA institution from the first place got more involved 
in cross-discipline collaboration than they used to after they joined CTSA related center. 
However, in their same study, Luke et al. (2015) showed that if they add the ones who joined the 
CTSA institution in the study sample, the overall tendency of cross-disciplinary collaboration 
decreases. The authors mention that there are two reasons for this trend. First, they claim that all 
publications, which were used to calculate the co-authorship trend, might not have been captured 
because of the time lag between funding and publication. Secondly, they maintain that the ones 
who join the institutions later would be junior researchers and they may tend to stick to their own 
discipline in their research. This is because what researchers need early in their career is 
recognition in their own field and they would try to make more publications on their own field.  
The point I would like to make here is that the ultimate goal of CTSA is supporting 
research that produces translational outcomes, not multidisciplinary outcomes. Increasing 
multidisciplinary may help the researchers produce more translational outcomes but we have to 
keep in mind that those two goals are not the same. For the case of CTSA, the ultimate goal of 
the award is to produce non-clinical research outcomes that have clinical use or that links the 
research outcomes from basic science to the clinical side of the research pipeline. Increasing 
multidisciplinarity may have a positive impact in accomplishing this goal, but it is not same as 
achieving this goal. Therefore, multidisciplinarity should be considered as a mediator of the 
relationship between CTSA and translational research outcomes. In that regards, I propose the 
following hypothesis, which can be summarized as “Multidisciplinarity is a mean to reach the 
ultimate goal of translatedness.” Figure 26 shows the depiction of this hypothesis. 
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Hypothesis 3. The multidisciplinarity of institutions mediates the relationship 
between receiving CTSA and production of translational outcomes. 
 
 
Figure 26. The depiction of Hypothesis 3 
 
 
5.3. Data and methodology 
 
5.3.1. Empirical setting  
 
 To test the hypotheses, I took institutions as the unit of analysis. As institution is the unit 
of analysis, the variables will be aggregated in institutional level. Some variables will use the 
sum of counts (e.g., number of publications with translational feature), whereas for some 
variables the average value will apply (e.g., multidisciplinarity).  
I assume that the impact of the CTSA award appears after a few years and apply a three-
year lag based on the finding by Ihli (2016). That is, in case an institution received the CTSA in 
year t, the impact of the CTSA award will be reflected in the articles that are published in year 
t+3. In this respect, the variables related to publications (e.g., collaboration density based on co-
authorship, multidisciplinarity based on backward citation of publications) should be calculated 
in year t+3 to see the impact of the CTSA award in year t.  
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  One disadvantage of using this approach is that the sample size may not be large, which 
equals the multiplication between the number of Carnegie R1 universities (115 institutions) and 
the number of years in the period of analysis (15 years), which is 1,725. However, the sample 
size is still much larger than what Cohen (1988) suggested as the necessary sample size to run a 
multiple regression, which is 764. The status of the institution receiving CTSA will be 
independent variable and the inter-organizational collaboration intensity and multidisciplinary 
score of the institutions will be mediating variables. The empirical setting of my analysis is 
depicted in Figure 27.  
 
 
Figure 27. The empirical setting of my analysis in chapter 5 
 
5.3.2. Data and variables 
 
5.3.2.1. Dependent variable 
 
The dependent variable of my analysis is the counts of journal articles that possess 
translational feature. After an article is published, we would be able to track its use in the 
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research community by looking at its forward citations (Llewellyn et al., 2019). The forward 
citation can take place from the year that an article is published and the total number of citation 
an article receives will increase over time. However, in contrast to the total counts of forward 
citation, the TS score will have a stable value after a certain period of time37. Considering this 
feature, I plan to use the TS score to check if an article has translational feature.  
I plan to categorize an article as having a translational feature if TS score is above 0.150. 
This choice of the threshold is based on the validity tests presented in chapter 4. The validity 
tests showed that publications that are cited by patents had the average TS score value of 0.156 
when prospective approach was applied, and 0.140 if retrospective approach was used. Also, 
among the four examples of basic science publications that result in drugs, the article by Rock et 
al. (1994) had the lowest TS score and the value was 0.149. Considering these values are all 
around 0.150, it seems reasonable to set the threshold value as 0.150. As the unit of analysis for 
this section is institution, the count of basic publications with TS score above 0.150 for each year 
will be used as the dependent variable. As the publication count variables are usually not 
normally distributed as in Gaughan et al. (2018), I will be using not only Ordinary Lease Square 
regression but also Poisson regression in my analysis.  
 
5.3.2.2. Independent variable 
 
 The independent variable is a dummy variable on whether an institution received the 
CTSA award or not. I take the treatment group as the institutions that received the CTSA award 
and the comparison group as the institutions that didn’t take advantage of the CTSA award. As in 
                                                 
37 As presented in chapter 4, my reliability test shows that it takes around four years for a TS score to reach its stable 
value. 
105 
chapter 3, institutions that partnered with institutions receiving the CTSA award are considered 
as a member of the treated group. An institution that was selected as the CTSA receiving 
institution or partnered with the CTSA receiving institution at year t would have the value of 1 
from year t. The institutions that never took advantage of the CTSA program will have zero 
value for the independent dummy throughout the period of analysis. 
 
5.3.2.3. Mediating variables 
 
Inter-organizational collaboration intensity38 
The first mediating variable I will include is the intensity of collaboration. As discussed, 
many studies found out that collaboration has a significant impact on scholarly productivity (e.g., 
Lee & Bozeman, 2005). Centrality measures provide key characteristics of institutions regarding 
their position in the network (Hanneman & Riddle, 2005). Hence, I use centrality of the 
institution as the variable measuring inter-organizational collaboration. Among four centralities 
calculated in chapter 3, I will be using degree centrality as the first mediator of the model. 
Degree centrality is chosen as the CTSA program promotes direct relationship between 
institutions and it is what measures this feature.  
 
Multidisciplinarity 
One very big challenge in fostering multidisciplinary research is difficulty in defining and 
measuring multidisciplinarity precisely (Qin et al., 1997). Qin et al. (1997) gave a list of 
characteristics that multidisciplinary research possesses such as it having members using 
different approaches to solve problems, having members influenced by other members on 
                                                 
38 More details on the measures related to inter-organizational collaboration can be found in chapter 3. 
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performing a task and integrating the analytical strength of disparate scientific disciplines. 
However, it is very hard to come up with an indicator that incorporated all these factors and there 
is no agreed-upon measure of multidisciplinarity (Qin et al., 1997). This leads to different 
measurements, assessment tools and evaluation processes (Wagner et al., 2011). However, from 
the list in Qin et al. (1997), we can see that knowledge integration is the must-include factor 
when defining or assessing multidisciplinarity of research (Wagner et al., 2011). 
 Though there is no unified measure on multidisciplinarity, scholars have been conducting 
research on multidisciplinarity using the measures they deem most appropriate. A large portion 
of studies use quantitative measure in measuring multidisciplinarity and bibliometric measures 
are the most developed and widely used quantitative measures (Ihli, 2016; Wagner et al., 2011). 
The simplest measure is assessing multidisciplinary research is the number of disciplines 
involved, which is based on the co-occurrence of author affiliations, keywords or headings 
(Schummer, 2004). One type of this co-occurrence approach is counting the papers co-authored 
by the people from more than one disciplines as in Shummer (2004). Schummer (2004) claimed 
that the co-occurrence approach could capture the cognitive and social aspects of relationship 
and exchange of knowledge between corresponding disciplines. However, this approach is not 
widely used as it is very tough to get affiliation information without errors (Wagner et al., 2011). 
As I mentioned in chapter 4, there is inconsistency in the information related to author’s 
affiliation. There are differences in the information the author’s affiliation contains, and the order 
in which the information is listed is very diverse. Also, we could not know exactly what 
discipline a researcher is engaged in just with the department name of his or her affiliation, as 
discussed in chapter 3.  
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Another widely used bibliometric measure is based on the citations of the paper (Wang et 
al., 2017). For instance, Wang et al. (2017) used the composition of citation categories to 
measure the multidisciplinarity of papers, which were later averaged by institutions in order to 
get the multidisciplinarity of a research system. Qin et al. (1997) used a similar method and 
counted the number of disciplines cited by a paper to calculate multidisciplinarity. To address the 
issue of difference in the size of the disciplines, relative measures or ranking measures are 
sometimes used (Wagner et al., 2011). In some cases, citations from disciplines outside the 
journal that a paper was published in are used as an indicator (e.g., Porter & Chubin, 1985). This 
approach is based on the assumption that when scientists cite sources outside their discipline, 
science-information interaction takes place (Qin et al., 1997).  
All in all, we can see that there is no measure that can be used universally in all situations 
(Wagner et al., 2011). As in claim by Martin and Irvine (1983), among multiple sources and 
measures on multidisciplinarity, we need to make a selection on what is most appropriate based 
on the context of the research. Here, my choice on the measure of multidisciplinarity is average 
Shannon Diversity of publications based on the backward citation of each article averaged into 
institution-year level. The reason why Shannon diversity of backward citation of each 
publication is used is that it is essential to take into account citation categories when measuring 
multidisciplinarity of publications (Rafols et al., 2012; Wang et al., 2017). To calculate the 
Shannon Diversity of each publication, following equation will be used. Here, Pi is the portion of 
cited articles published in WOSCi. 
1 − ∑ 𝑝𝑖𝑙𝑜𝑔𝑝𝑖𝑖 , 
(4) 
 
After Shannon Diversity of each publication is calculated, it will be averaged into 
institutional-year unit. This approach is taken as individual publications can be considered as 
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elements of a research system and the average of a group of publication could provide unbiased 
measurement of multidisciplinarity (Wang et al., 2017).  
 
5.3.2.4. Control variables 
 
Research capacity (Researchers and R&D in life science) 
One major factor that has a significant role in changing research performance of an 
institution is the research capacity of the institution. Research capacity of an organization, 
expressed as absorptive capacity in some contexts, affects the level of change in research 
performance due to change in collaboration level (Owen-Smith & Powell, 2003). The study by 
Owen-Smith and Powell (2003) included scientific capacity, which is measured as the 
publication counts, in their model measuring the relationship between collaboration and research 
patenting performance of academic institutions. We can expect that institutions having high 
research capacity would have higher research performance. Research capacity of an institution 
can be measured by research budget and the number of researchers (Cockburn & Henderson, 
1998). In this regard, I will include both the size of biomedical research budget and number of 
researchers in life science as control variables. 
 
Medical school 
In biomedical research, whether an institution has a medical school or not also affects the 
relationship between collaboration and productivity (Owen-Smith & Powell, 2003). Owen-Smith 
and Powell (2003) claimed that research conducted in medical school is close to commercial 
needs and can contribute to increase in commercial products. In this regard, I included the 
existence of medical school as another control variable. If a university has a medical school, it is 
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more likely that the translational process will be smoother (Owen-Smith & Powell, 2003). As 
mentioned in study by Hicks and Katz (1996), hospital is an important entity in the process of 
biomedical research. There are also reports on the significant role of hospitals in biomedical 
research pipeline (Lander & Atkinson-Grosjean, 2011).   
 
Institutional control 
 The last control variable I included is institutional control. Institutional control, whether 
an institution is public or private, has been studied widely (Dundar & Lewis, 1998). Some 
studies showed that being a private school lead to higher research productivity as private schools 
put more emphasis on research than teaching and other services (Dundar & Lewis, 1998; Jorand 
et al., 1988). As I’m taking one kind of research productivity as my dependent variable, though it 
is different with traditional measures like mere count of publication, the institutional control 
factor could have the potential to affect the result of my analysis. Table 14 shows the description 
of the variables that will be used in my analysis. 
 
Table 14. Descriptions of the variables used in the analysis 





Number of articles published in non-clinical science journal 
that has TS score higher than 0.150. 
Independent 
variables 





The frequency of collaboration with all other institutions 
measured by co-authorship (degree centrality) 
Multidisciplinarity 
How multidisciplinary an intuition is based on the 
multidisciplinarity of articles it published 
Control variables 
Researcher Sum of biomedical researchers in life science 
R&D Size of the research budget in life science 
Medical school Whether an institution has a medical school 





Difference-in-difference regression  
 
 Using longitudinal data with repeated measure can help us test the causal relationship 
between variables (VanderWeele & An, 2013), which will be used in my analysis. With the 
longitudinal data, I will be using multivariate regression that compares the values before the 
intervention and after the intervention. To do so, I will be using the difference-in-difference 
method. This approach may help address endogeneity to a certain degree. The empirical equation 
for the analysis is as follows: 
 
𝑌𝑖(𝑡+𝑠) = 𝛼 + 𝛽 ∙ 𝐶𝑇𝑆𝐴𝑖 + 𝛾 ∙ 𝑃𝑂𝑆𝑇𝑖(𝑡) + 𝛿 ∙ 𝐶𝑇𝑆𝐴𝑖 ∙ 𝑃𝑂𝑆𝑇𝑖(𝑡) + 𝑋𝑖𝑡
′ ∙ 𝜹
+ 𝐹𝐸𝑖 + 𝐹𝐸𝑦 + 𝑖(𝑡) 
(5) 
where i is a project and t is time. 
 𝑌𝑖(𝑡+𝑠) is the count of translational publications for year t+s. Year t+s, not t, will be used 
as it takes some time from the start of the project to get the result of a project. This variable is a 
count variable that is not normally distributed as in Gaughan et al. (2018). Hence, I will test not 
only Ordinary Least Square (OLS) model, but also the Poisson regression model for the analysis. 
𝐶𝑇𝑆𝐴𝑖 is the dummy variable of my interest, which is the status of receiving CTSA.  
𝑃𝑂𝑆𝑇𝑖(𝑡) is after-treatment dummy, which has a value of 1 if the period is after the 
treatment occurred. For the institutions in the control group which did not receive the CTSA 
award during the period of analysis, I need years that these institutions would have started 
receiving the CTSA award. I could just select a single year (e.g., 2008) and set this as 
hypothetical CTSA-starting year for all institutions that never took advantage of the CTSA 
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award. However, this approach would have minimal influence in reducing the selection bias 
problem. Hence, to get these hypothetical years, I used propensity score matching method. First, 
I looked at the of content of FOA of NIH’s CTSA award (National Institutes of Health, 2017b). 
Then, I figured out factors that may influence NIH’s selection of CTSA receiving institutions. 
With these factors, I calculate the propensity score of the institutions receiving CTSA using a 
logit model. Then, I matched CTSA non-receiving institutions and CTSA receiving institutions 
based on these scores using nearest neighbor approach. Then, I assigned hypothetical CTSA 
receiving year to the institutions that never took advantage of the CTSA award. The common 
support option was not applied as I need imaginary treatment year for all institutions. As a result, 
institutions that only have hypothetical CTSA receiving year will also have value of 1 for this 
variable when the period is after its hypothetical CTSA receiving year. 
The interaction term 𝐶𝑇𝑆𝐴𝑖 ∙ 𝑃𝑂𝑆𝑇𝑖(𝑡) is the variable of interest. If the coefficient of this 
term has significanlty positive value, we could maintain that the Average Treatment Effect (ATE) 
of the CTSA award on the increase of 𝑌𝑖(𝑡+𝑠) would be positive. As noted in previous section, 
various control variables (𝑋𝑖𝑡
′ )  (e.g., collaboration frequency, biomedical research budget) will 
also be used in the equation. Fixed effects on institutions (𝐹𝐸𝑖) and years (𝐹𝐸𝑦) will be applied 
in the equation to control for heterogeneity between institutions and years that is not captured by 
the control variables. 
 
Mediation tests 
 To test the mediation effect, a method proposed by Baron and Kenny (1986) will be used 
with slight modification. In their seminal paper on mediation analysis, they introduced four 
conditions that have to be met for the mediation effect to be present. These conditions were 
based on the estimations from three regression models. First estimation is based on the result of 
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the model that regresses dependent variable on independent variable. From this model, we could 
get coefficient of independent variable, which is labeled as c. The first condition for the 
mediation effect to be present is this coefficient c being significant. The second condition comes 
from the second model that regresses the mediator on the independent variable. The second 
required condition is that the coefficient of independent variable in this model, which is labeled 
as a, should be significant. The third model regresses the dependent variable on both the 
independent variable and the mediator. This third model would give the coefficient of the 
independent variable, which is c’, and the coefficient of the mediator, which is labeled as b. The 
third requirement for the mediation effect to be present is that the absolute value of coefficient c’ 
should be smaller than the absolute value of c, which is from the first model that regress the 
dependent variable on the independent variable. The fourth condition is related to the indirect 
effect, which is |c|-|c’| or a·b. Preacher and Hayes (2004) suggested that this value should be 
significant using the bootstrapping method. I used 10,000 iterations for the bootstrapping to see 
whether zero is not in the interval of the indirect effect value. All four conditions mentioned 
above, summarized in Table 15, should hold for the mediating role of the mediator to be present.  
 
Table 15. Required conditions for medation effect to be present 
Regression model Condition 
 
• Condition 1: c should be significant 
• Condition 2 (optional): a should be significant 
• Condition 3: |c’| should be smaller than |c| 
• Condition 4:  The value of indirect effect, 
which is |c|-|c’| or a·b, should be significant 






5.4.1. Institution matching 
 
 To calculate the propensity score on how likely an institution would take advantage of the 
CTSA award, I looked at the FOA of NIH’s CTSA award (National Institutes of Health, 2017b) 
and identified four major criteria that may have impacted the selection of the CTSA recipients. 
Then, I linked these criteria with the factors that may have influenced the selection of the CTSA 
hubs.  
The first criterion is related to the sharing of resource and research finding. In its FOA, 
NIH states that CTSA receiving institutions need to disseminate the solutions they found. In 
addition, collaborative leadership and communication are what NIH requires to the CTSA hubs. 
This means that the CTSA recipients should be in the positions that make them easy to act as a 
leader and share their resources with others. Hence, network centrality measure would be related 
in the assessment of the application and it should be included as one of the factors to calculate 
the propensity score of institutions taking advantage of the CTSA award.  
There is one more reason that the network centrality measure should be included. The 
treated group in my analysis included institutions that officially partnered with CTSA hubs. We 
can easily expect that the CTSA hubs would establish an official partnership with the institutions 
that they have close relationship with. It is likely that the institutions with high value of network 
centrality would be the ones that have close relationship with many institutions, including CTSA 
hubs. Hence, having a high network centrality value would increase the probability of becoming 
a CTSA partnering institution. As the index of network centrality, I used degree centrality, which 
was calculated in chapter 3. 
114 
The second factor that may affect the selection of the CTSA institution is whether an 
institution has a medical school or not. NIH’s FOA on the CTSA award requires (National 
Institutes of Health, 2017b) CTSA hubs to participate in research related to pediatric, geriatric 
and fields related to special population. As studies on these fields are conducted widely in 
hospitals and medical schools, it is likely that having a medical school would have positive 
impact of an institution being selected as a CTSA recipient. Therefore, I included the existence 
of a medical as one of the factors for calculating the propensity score and the information was 
obtained from NSF Higher Education Research and Development Survey (HERD).  
The third potential factor is the racial diversity of the researchers. In the FOA, NIH 
encourages the institutions to diversify their students and faculty populations. Hence, having 
higher race diversity of people conducting research could have an influence on the selection of 
the CTSA award. To get the value for the race diversity, I used race composition of graduate 
students, post-doctoral researcher and non-faculty researchers in NSF Survey of Graduate 
Students and Postdoctorates in Science and Engineering (GSS). I calculated Shannon diversity of 
the race composition, which was consisted of Hispanic, American Indian/Alaskan, Asian, Black, 
Native Hawaiian/Pacific and White. 
The statement that is related to the fourth potential factor in the NIH’s FOA (National 
Institutes of Health, 2017b) is “assembly of multidisciplinary translational teams.” As mentioned 
in previous sections, multidisciplinary research has been promoted by government agencies like 
NIH and the CTSA award is not an exception. To obtain multidisciplinarity of institutions, the 
average multidisciplinarity of articles published by the institution was used. As explained 
previously, multidisciplinarity of each publication was calculated using Shannon diversity of 
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disciplines that appear in backward citation of publications. Table 16 shows the summary of 
factors that are potentially used by NIH when selecting CTSA receiving institutions. 
 
Table 16. CTSA selection rules and potential factor affecting the selection 
No. Selection rules in NIH’s FOA 
Potential factors 
affecting the selection 
1 
“CTSA hubs are expected to develop, demonstrate, and then disseminate 
solutions to roadblocks to the efficiency and effectiveness of clinical and 
translational research. Plans for collaborative leadership and communication 
should consider the inclusion of a diverse range of internal and external 




“CTSA hubs should have plans to enhance the participation in research of 
pediatric, geriatric, and other special populations, and in some instances make 
them the focus of study. CTSA hubs should aim to include underserved 
populations, address health disparities, and approach cultural factors as a 
variable to be examined when developing translational innovations.” 
Having medical school 
3 
“This program encourages institutions to diversify their student and faculty 
populations and thus to enhance the participation of individuals currently 
underrepresented in the biomedical, clinical, behavioral and social sciences 
research enterprise, as described in NOT-OD-15-053.” 
Race diversity of the 
researchers 
4 
“Strategic goals under such a vision may include increased incentives for 
teamwork, facilitation of the assembly of multidisciplinary translational teams, 
promotion of collaborative efforts, and increased knowledge and awareness of 
what works best in team science.”  
Multidisciplinarity of 
organization’s work 
Source: FOA of NIH’s CTSA award (National Institutes of Health, 2017b) 
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With four potential factors affecting the selection of the CTSA hubs, I calculated the 
propensity sore of all 115 Carnegie R1 universities using logistic regression. Then, I matched the 
institutions based on the nearest-neighbor option39. For some institutions, it was matched with 
more than one institution. For instance, Boston College, University of Texas at Arlington and 
Clemson University, which all had propensity score below 0.02 was matched with University of 
Wisconsin in Milwaukee, which has the lowest propensity score among the treated group (0.018). 
On the other hand, some institutions in the treated group are not matched with any of the 
institutions in the control group. This is because the highest propensity score of any institution in 
the control group is 0.792 and the institution with this score (University of Connecticut) is 
matched with its nearest neighbor, which is University of Utah with the propensity score value of 
0.796. Hence, other institutions in the treatment group with propensity score larger than 0.796 
are not matched with any other institutions in the control group. Table 17 shows the size of the 
groups based on the CTSA starting year, whether it is actual or assigned through institution 
matching.  
 
Table 17. Group size based on CTSA starting year 
 
Starting year Actual CTSA Hypothetical CTSA Total 
2006 9 5 14 
2007 12 6 18 
2008 14 20 34 
2009 5 1 6 
2010 9 22 31 
2011 4 1 5 
2012 1 1 2 
2013 1 3 4 
 
                                                 
39 Full list of institutions with matching results can be found in the Appendix F.  
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5.4.2. Descriptive analysis 
 
Summary of the data 
 To get the sense of the characteristics of institutions, the summary of variables of two 
groups, the institutions that received the CTSA award (CTSA-ever) and the institutions that 
never received the CTSA award (CTSA-never), are presented in Table 18. For the data summary 
and all other analysis, only publications with five or more forward citations were considered 
when calculating the TS score to maximize reliability of the measure and results (See chapter 
4.4.1.B for more details). In general, the CTSA-ever group has larger values for most of the 
variables than the CTSA-never group. For instance, the average number of non-clinical science 
publications per institution-year is 345.46 for the institutions in the CTSA-ever group while the 
value is 96.58 for the CTSA-never group. Differences also exist in the control variables like 
biomedical R&D expenditure and biomedical researcher counts. Hence, it is essential to include 
these variables as the covariates to help address omitted variable bias. One fortunate fact is that 
the variables related to forward citation of publications (e.g., mean forward citations, mean 
forward citations from clinical science and mean TS score) are not that different between two 
groups. For example, the number of forward citations a paper receives has an average value of 
53.53 for the publications from the CTSA-ever group and 46.31 for the publications from the 
CTSA-never group. Also, the difference of the mean counts of forward citation from the clinical 
side is 2.88, which is not that large compared to the difference of the variables in the covariate 
group. As there is no big difference in this value between two groups, the average TS score 
values of two groups would not differ much.  
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Table 18. Data summary with comparison of CTSA-evers and CTSA-nevers40 
Variable 
Institutions that ultimately took advantage of CTSA Institutions that never took advantage of CTSA 
Obs Mean Std.dev Min Max Obs Mean Std.dev Min Max 
Non-clinical science publications 825 345.46 251.65 2 1659 900 96.58 76.25 1 424 
Mean forward citations (per paper) 825 53.53 21.04 13.03 145.06 900 46.31 24.39 8.88 220.41 
Mean forward citations from clinical 
science (per paper) 
825 7.87 3.83 0.67 30.15 900 4.86 3.33 0 28.13 
Mean TS score (institution-year unit) 825 0.13 0.04 0.03 0.23 900 0.10 0.05 0 0.27 
R&D (million $) 825 310.29 202.11 2.51 882.69 900 93.47 78.50 0.90 373.77 
Researcher ( 825 17.09 11.15 0.60 85.11 900 8.23 5.05 0.75 26.61 
Medical 825 0.83 0.38 0 1 900 0.34 0.47 0 1 
Private 825 0.45 0.50 0 1 900 0.15 0.36 0 1 
Degree centrality 825 171.46 41.08 14 228 900 113.62 50.63 4 220 
Multidisciplinarity (institution-year unit) 825 2.02 0.12 1.60 2.35 900 25108 0.16 1.29 2.49 
Race diversity 825 1.60 0.25 0.80 2.27 900 1.60 0.28 0.50 2.38 
 
The trend of translational publication counts 
 For my analysis, the publication counts with TS score over certain threshold is used as 
the dependent variable. As I mentioned in previous section, a TS score of 0.150 will be used as 
the threshold for determining whether a publication has translational feature or not. To have 
better understanding of the value, I looked at the change of counts of non-clinical publications 
that have TS score above this threshold, which I call translational publications hereafter (Figure 
28). In the figure, the average translational publication counts of institutions for the treated group 
(CTSA-ever) is indicated as solid line while the control group (CTSA-never) is indicated as 
dashed line. The shaded areas show the range of 25 and 75 percentiles values for each group. 
The year when the CTSA program started is 2006 is indicated by a vertical line on the graph. As 
we can see, the value for the CTSA-ever group is larger than the value of the CTSA-never group 
                                                 
40 Data summary and correlations between variables having all Carnegie R1 universities in the sample are shown in 
Appendix G. 
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for all years. Also, CTSA-ever group is in an increasing trend while CTSA-never group is not. 
This finding suggests that not all institutions are producing more translational publication than 
before, but only the institutions that ultimately received the CTSA award are. 
 
 
Figure 28. Trend of translational publication counts by calendar year 
 
Figure 28 provides general picture on how the translational publication counts of 
institutions change over time, but it provides limited information on the impact of the CTSA 
award. This is because the year when each institution starts receiving the CTSA award differ. 
Hence, to get a better picture on how the CTSA award affects the change of the translational 
publication outcomes, I made a new trend graph taking years normalized by the years of CTSA 
receipt as the x-axis (Figure 29). Actual years of CTSA receipts were used as the reference year 
for the CTSA-ever institutions and hypothetical CTSA receipt year drawn from propensity score 
matching of institutions (see Appendix F for details) were used for institutions in CTSA-never 
group. From the graph, we can see that the treated group is in an increasing trend while the value 
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for the controlled group shows no increasing trend. Table 19 shows the mean translational 
publication counts before and after the receipt of the CTSA for both the treated and the 
controlled group. The number of translational publications that institutions in the treated group 
produced increased by 59.84, whereas the controlled group only increased by 8.42. This means 
that the change of mean translational publication counts at the institutions that received the 
CTSA award is 51.42 larger than the change of the mean production of translational publications 
by the institutions that never received the CTSA award.  
 
 
Figure 29. Trend of translational publication counts based on institution-matching without 
caliper option 
 
Table 19. Mean translational publication counts before and after CTSA for all institutions 
  Pre-CTSA Post-CTSA Difference 
CTSA-ever group 94.38 154.22 59.84 
CTSA-never group 21.98 30.40 8.42 
  Difference-in-difference value 51.42 
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One thing to note in Figure 29 is that the increasing trend of translational publication 
counts is present even before the CTSA award starts to appear. This may suggest that there may 
be systematic difference between the treated and the comparison group. This result was 
predictable beforehand as the top-tier universities in biomedical science are also CTSA recipients 
and there may not be good comparable institutions in the CTSA-never group. To address this 
concern, I went further and applied a more stringent matching method, which is applying caliper 
value of 0.05 in the matching process. This means that if the value of propensity score of an 
institution differs from propensity score of any other institutions in the comparison group by 0.05 
or higher, that institution is not matched with any other institution and not used in the analysis. 
Dropping unmatched institutions would provide us with comparison group more similar to the 
treatment group and give me more ability to make the causal claim about the impact of the 
CTSA award.   
If I apply the caliper option, 24 institutions are dropped, of which most of them are the 
institutions with high propensity scores41. These institutions, who are in the CTSA-ever group 
are dropped as they don’t have any comparable institutions that have high enough propensity 
scores as them. Dropping these institutions in the analysis would, on the one hand, reduced the 
size of the sample. However, the total number of observations, which is 1080, is still much larger 
than 764 observations that are needed to run multivariate regression (Cohen, 1988). Figure 30 
shows the trend of translational publication counts by year after applying new institutional 
matching result. We can see that the pre-treatment trend line of two groups got more parallel. 
This could mean that the institution-matching method was somewhat more effective and the new 
treatment group and the new comparison group are now more similar to each other. In this 
                                                 
41 Few examples are Emory University, Johns Hopkins University and Harvard University, which are all leaders in 
biomedical research in terms of research capacity and research performance.  
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respect, I will use the model with this matching method as one of the models in my analysis. One 
more thing to note is that there is a sudden rise of the translational publication counts for the 
treatment group right after the CTSA award come into effect, whereas there is no notable change 
happening for the control group. Table 20 shows the mean translational publication counts before 
and after CTSA recipient based on the new institutional matching method. When compared with 
the values in Table 19, the change of the pre-post difference reduced substantially for the treated 
group (24.47), while there is only slight change for the control group (0.12). This is because 23 
universities with very high expected propensity of receiving the CTSA have been dropped for the 
new analysis and these institutions produce large number of translational publications. Even 
without these top-tier universities, the difference-in-difference value of translational publication 
counts is positive with the value of 26.81. 
 
 




Table 20. Mean translational publication counts before and after CTSA based on institution 
matching with 0.5 caliper option 
  Pre-CTSA Post-CTSA Difference 
CTSA-ever group 62.34 97.45 35.11 
CTSA-never group 22.05 30.35 8.30 
  Difference-in-difference value 26.81 
 
5.4.3. Estimation results 
 
Test on Hypothesis 1: DID regression 
 
 Table 21 shows the estimations of the difference-difference regression models based on 
propensity score matching without caliper option42. The result table shows two extreme cases, 
the ones without any control variables and the ones with all control variables. Both the result of 
the model based on OLS regression and Poisson regression is shown. Regarding fixed effects, 
models either have only year fixed effect or both year fixed effect and institutional fixed effect. 
Year fixed effect is included in all models as the growth of the support for translational research 
differs by year, mostly in an increasing trend, and other variables have limited power capturing 
this change.  
The most important thing to note is that the difference-in-difference variables (CTSA X 
POST) are all positive at 0.01 significance level. The value of the coefficients gets smaller as 
control variables are included for the OLS models. It means that the control variables also have 
explanatory powers in explaining the difference of translational publication counts between the 
treated group and the controlled group. Another thing to note is that the coefficients of CTSA are 
                                                 
42 As applying caliper in institutional matching only gives us the ability to explain smaller set of comparable CTSA 
recipients, estimation of models without caliper option in institutional matching were also conducted. The results are 
shown in Appendix H and these model estimations generally have similar results with the result shown in main text, 
which is a sign of robustness of the result in the main text.  
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also positive with significance in models without institutional fixed effects. This means that 
being a CTSA receiving institution itself leads to a greater number of publications with 
translational feature. Using model 7, for example, we can see that CTSA recipients have 
approximately 2.20 (= exp(0.808)) more translational publications per year before the impact of 
the CTSA award come into effect and 2.32 (=exp(0.045+0.808)) more translational publications 
during the post-treatment period, holding all other variables constant. One more important thing 
to note is that the coefficients of POST are not significant when all control variables are included 
for the OLS model. This means that the translational publication counts for institutions not 
receiving the CTSA award does not experience an increase of translational publications after the 
hypothetical CTSA receiving year, which is confirmed by the trend graphs shown above (Figure 
28, 29 and 30).  
 If we look at coefficients of the control variables, we can see that the researcher counts 
(Researcher) and R&D expenditure (R&D) have significant impact on the translational 
publication counts, although the impact of R&D expenditure is minimal compared to other 
factors. One interesting thing to note is that having medical school (Medical) has mixed effects. 
This may be interpreted as the universities with medical schools doesn’t always lead to more 
production of non-clinical publications with translational feature. This finding could indicate that 
schools with medical school produce clinical papers, rather than creating basic science 
publications, in the first place, which are not captured in the dependent variable. Another 
interesting fact is that being a private school (Private) also shows mixed results. It has 
significantly positive impact in OLS model, but insignificant effect for the Poisson model. 
Therefore, we couldn’t make clear claim whether being private school leads to more production 
of translational research outcome.  
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Table 21. Estimation of main difference-in-difference regression models (dropping unmatched 
institutions) 
 
 OLS Poisson OLS Poisson 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA X POST 13.71*** 13.65***   0.04* 0.04*   8.63*** 8.70***   0.05*   0.05* 
CTSA 50.66*** - 1.07*** - 25.64*** - 0.81***      - 
POST  -3.72*  -3.77**  -0.03    -0.03   -1.58  -1.69  -0.04  -0.04 
Researcher       7.29***   5.50**   0.05*   0.04 
R&D       0.17*** 0.15*** 0.00***   0.00* 
Med school        1.39  -6.67*   0.19**   0.07 
Private     17.73*** -   0.01      - 
Multidisciplinarity      15.69**  15.09** 1.00*** 1.01*** 
Centrality      0.08***    0.04 0.00*** 0.00*** 
Constant 19.14*** 36.59*** 3.09***  -34.54***   -9.09   0.58*  
Observation 1080 1080 1080 1080 1080 1080 1080 1080 
R2 0.342 0.115   0.736 0.615   
Pseudo R2 
    0.019 0.137        0.074 0.153 
Year FE YES YES YES YES YES YES YES YES 
Institution FE NO YES NO YES NO YES NO YES 
Note: *** p < 0.01, ** p < 0.05, * p < 0.10 
 
With consistency in the significance and sign of the DID variable’s coefficient, we may 
assert that the CTSA award did lead to the increase production of basic science publications with 
translational feature. There may be various reasons for this increase. One thing we can think of is 
the increase of publications that got direct support from the CTSA award. These are the 
publications that acknowledge the CTSA award’s grant number on their papers, which probably 
have high TS scores. Figure 31 shows the trend of average TS score of three groups of papers, 
which are publications from CTSA-never group, publications from CTSA-ever group and 
publications that acknowledge direct support from the CTSA award. On average, publications 
that got support from the CTSA award have larger TS score than other two groups of 
publications. If we check the portion of publications that acknowledge the CTSA award, we can 
easily check that it is in increasing trend (Figure 32). In some universities such as University of 
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Chicago and University of Cincinnati, the portion increase to the value higher than 20% in 2015 
(see Appendix I for more details).  
 
 
Figure 31. Average TS score by publication group 
 
 
Figure 32. Change of the portion of CTSA award acknowledging publications by year 
127 
 To examine this question, I identified all publications that received direct support from 
the CTSA award and, thus, might, have higher TS scores. This job was done to conduct new 
analyses that do not include these publications in the dependent variable, which could help us 
have better understanding of the impact of the CTSA award. If the estimations from the new 
models show similar results with the previous ones, we may claim that the CTSA award had an 
impact across the whole biomedical research environment of the universities and even changed 
the nature of publications that are not directly affected by the CTSA award. If the results find 
that there is no significant difference-in-difference effect when excluding CTSA supported 
articles, we may conclude that the CTSA award only changed the aspects of the publications that 
got direct support from the award but was not making the institution broadly more translational.  
 Table 22 shows estimation results of difference-in-difference Poisson regression models 
excluding publications with direct CTSA support. We can see that the coefficients of the 
difference-in-difference variables (CTSA X POST) now become insignificant. This finding 
suggests that the impact of the CTSA award is only valid on the publications that received direct 
support from the award. Therefore, we would not be able to make a claim that the CTSA award 
changed the whole institutions in a way that also influenced studies that didn’t get its support.  
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Table 22. Estimation of difference-in-difference regression models excluding publications with 
direct CTSA support 
 
 (1) (2) (3) (4) 
CTSA X POST        -0.03 -0.03              0.00            0.00 
CTSA 1.06***    0.82***  
POST        -0.01 -0.01             -0.02            -0.02 
Researcher                0.06**             0.05* 
R&D                0.00             0.00 
Med school                0.19**             0.08 
Private                0.00  
Multidisciplinarity    1.06*** 1.07*** 
Centrality    0.00*** 0.00*** 
Constant 3.10***               0.48  
Observation 1080 1080 1080 1080 
Pseudo R2 0.016 0.109 0.079 0.127 
Year FE YES YES YES YES 
Institution FE NO YES NO YES 
Note: *** p < 0.01, ** p < 0.05, * p < 0.10 
 
Test on Hypothesis 2: Mediation test on inter-organizational collaboration 
 Table 23 shows the summary of the estimation results that take degree centrality of 
institutions based on inter-organizational collaboration as the mediator. The tests were conducted 
separately by year with 3-year lagged values applied for the treatment dummy (CTSA) and other 
control variables (Researchers, R&D, Medical, Private). To confirm that the potential mediator 
takes the mediating role, all four conditions must be satisfied. We can see that the mediation 
effect is not present in the early years from 2009 to 2013. This is mainly because condition 2 is 
not satisfied in these years, which means that the impact of the CTSA award on the degree 
centrality is not significant during this period. This leads to the situation where indirect effect not 
having a significant value and condition 4 not being satisfied.  
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On the other hand, when it comes to year 2014 and 2015, the mediating role of the degree 
centrality of institutions starts to appear. This finding may indicate that the inter-organizational 
collaboration rate starts mediating the relationship between the CTSA award and translational 
publication counts when the CTSA program finds its feet. We could expect that it would take 
some time to stack the inter-organization collaborations that would really help the increase of 
translational outcomes and this is confirmed by my findings. 
 






indirect effect to 
the total effect Condition 1 Condition 2 Condition 3 Condition 4 
2009 YES NO YES NO No NA 
2010 YES YES YES NO No NA 
2011 YES NO YES NO No NA 
2012 YES NO NO NO No NA 
2013 YES YES YES NO No NA 
2014 YES YES YES YES Yes .0017 
2015 YES YES YES YES Yes .0022 
Note: More detailed result with actual value of coefficients can be found in Appendix J 
 
Test on Hypothesis 3: Mediation test on multidisciplinarity of institutions’ publications 
 Table 24 shows the result of mediation tests taking multidisciplinarity as meditators from 
2009 to 2015. As shown, condition 2 is not satisfied for all years, which means the CTSA award 
doesn’t impact the change of multidisciplinarity score of institutions significantly. This may be 
because there is no clear difference of multidisciplinary of institutions between the institutions 
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that took advantage of the CTSA award and the ones that are not affected by the CTSA award 
(Figure 33).  
 






indirect effect to 
the total effect Condition 1 Condition 2 Condition 3 Condition 4 
2009 YES NO YES NO No NA 
2010 YES NO YES NO No NA 
2011 YES NO NO NO No NA 
2012 YES NO NO NO No NA 
2013 YES NO NO NO No NA 
2014 YES NO NO NO No NA 
2015 YES NO NO NO No NA 
Note: More detailed result with actual number can be found in Appendix J 
 
 






 In this chapter, I assessed the impact of the CTSA award by taking the number of 
translational publications as the outcome. A publication was considered as a translational 
publication if it has the TS score above 0.150, the threshold value that is drawn from my validity 
tests of the measure. Results from difference-in-difference regression models with various 
specifications showed that the CTSA award leads to increase of translational publication counts 
in institution level. However, it was shown that the CTSA program only affected the publications 
that got direct support from the program but didn’t change entire institutions towards more 
translational research. This may seem like a limitation of the CTSA award, but if we see it in a 
different way, this could mean that the award has a substantial effect on the affected publications. 
Hence, if the program spreads throughout the institutions and more researchers start taking 
advantage of the program, it may change whole organization’s characteristics related to 
translational research. 
 Mediation tests of two factors that NIH emphasizes for the successful operation of the 
CTSA program, which are inter-organizational collaboration rate and multidisciplinary of 
institutions, showed different results. It was shown that the inter-organizational collaboration rate, 
measured as degree centrality of the institutions, mediates the relationship between the CTSA 
award and translational publication counts five years after the CTSA program started. The main 
reason why inter-organizational collaboration rate did not have mediation effect during the early 
period was that the CTSA award did not lead to the change of the degree centrality of institutions. 
This result suggests that the CTSA award did not lead to the creation of collaboration that had 
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positive impact on the translational research at the beginning of the CTSA program. The newly 
created links might not have brought helpful resources to the institutions such as complementary 
skills or access to useful equipment (Bozeman and Corely, 2004; Katz & Martin, 1997; Gaughan 
et al., 2018; Owen-Smith & Powell, 2003).  
The mediating role of the institution’s multidisciplinarity did not appear during the whole 
period of analysis. Again, the reason why the mediation effect is not present is that the CTSA 
award did not lead to the change of multidisciplinarity of institutions. In my analysis, the 
multidisciplinarity of institutions is calculated based on the composition of backward citations of 
publications. Hence, CTSA award having no impact on the multidisciplinarity of institutions can 
be interpreted as CTSA award not having a significant impact on changing researcher’s citing 
patterns. The trend of multidisciplinarity score of institutions is increasing (Figure 33), maybe 
due to the positive perceptions of the multidisciplinary research (Baumwol et al., 2011; Van 
Rijnsoever & Hessels, 2011) and the need of knowledge from various fields for answering 
complex problems (Aboelela et al., 2007). However, the CTSA award was not the main factor 
that caused the change. The online tools that the CTSA program provided with the aim to 
promote multidisciplinary research (e.g., Profiles Research Network Software) might not have 
worked well. Rather, it is possible that these tools might have only helped the researchers to find 
partners in their own disciplines, which is claimed by Van Alstyne and Brynjosfsson (1996). 
 There are some limitations of my analysis that is used in this chapter. First, as mentioned 
previously, the selection bias issue is not fully addressed. The institutions that were selected as 
the CTSA award recipients could be the ones that put more effort on translational works and 
might have increased their translational outcomes even without the CTSA award. I tried to 
alleviate this issue by using difference-difference regression after matching institutions, 
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assuming lagged effect of the CTSA award, dropping the institutions with very high propensity 
scores of receiving the CTSA award to check robustness of results and so forth. However, due to 
the nature of quasi-experimental research design setting as my study, the endogeneity problem 
may still be present. To address the endogeneity problem further, I may need to apply more 
precise institutional matching technique. Getting to know the real factors affecting NIH’s 
evaluation on the selection of CTSA recipients or the actual evaluation scores of each institution 
during the NIH’s selection process would help me get more accurate matching of institutions.  
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CHAPTER 6. DISCUSSION 
 
6.1. Summary of findings 
 
 With the aim to bridge “the valley of death” in biomedicine, NIH has been increasing its 
support for translational research since the early 2000s. A clear indication of this effort is the 
creation of the CTSA award that provides infrastructure with multiple uses, tools for 
collaboration, education and administrative support and other resources to facilitate translational 
research. Since the CTSA program has been in operation for over a decade, it is important to 
understand whether and to what extent the program has achieved its intended goal. In this respect, 
I first examined whether the award had a positive impact on increasing collaboration among 
institutions, which is one of the major factors that NIH emphasizes for the successful operation 
of the program (National Institutes of Health, 2017b). In addition, I analyzed whether the CTSA 
awards helped institutions publish more articles that were translational in nature, another key 
goal of the program (Han et al., 2018).  
 My first analysis focused on the impact of the CTSA award on the collaboration network 
among Carnegie R1 universities, which are academic institutions with high research capacity. 
Using co-appearance on the author affiliation list of publications as evidence of inter-
organization collaboration, I calculated various measures related to the collaboration network of 
biomedical research. These measures were used in my descriptive analyses and as variables in 
network regression model (e.g., ERGM) estimations. The results showed that the biomedical 
research collaboration is becoming denser and less centralized as the impact of the CTSA award 
gets realized. Institutions that received CTSA awards had more links with other Carnegie R1 
universities than institutions that did not receive CTSA awards. However, the findings suggest 
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that the institutions that took advantage of the CTSA program are not interacting more with the 
institutions that never took advantage of the CTSA award. Rather, these institutions increase 
their collaboration with only the ones that ultimately took advantage of the CTSA award. This 
finding may not correspond precisely with NIH goals, as NIH would prefer major universities to 
have a wide range of partners, not just other elite institutions (National Institutes of Health, 
2017b).  
 My second analysis examined the relationship between the CTSA award and the change 
of the translational publication counts. I aimed to examine the relationship between the CTSA 
award and the production of translational publications and see if two major factors that the 
CTSA award emphasizes (inter-organizational collaboration and multidisciplinary research) 
mediate the relationship. A unique measure – TS Score – was proposed and used to assess 
whether a publication was translational or not. The TS score is defined as the portion of forward 
citations from clinical science among all forward citations that a non-clinical publication receives. 
A new measure was proposed as there was no easy-to-use measure widely used that fits my 
research design. The TS score was shown to be reliable if a publication received five or more 
forward citations. Also, several tests using a group of publications were conducted to test the 
validity of the measure.  
 To classify a publication into publications with translational feature and one without, I 
had to set the threshold TS score value. Based on the results of validity tests, I selected 0.150 as 
the threshold value, which means that I considered publications with TS score higher than 0.150 
as translational publications. As my unit of analysis was institution, my dependent variable was 
the number of non-clinical science publications with TS score larger than 0.150. The result of 
difference-in-difference regression with institution matching showed that there is a direct impact 
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of the CTSA award on the increase of translational research outcomes. However, this impact 
disappeared if the counts of publications that got direct support from the CTSA award were not 
included in the counts of the publications. This suggests that the CTSA award had changed the 
nature of the publications that are influenced by the award, but it didn’t change the nature of 
biomedical research at these institutions more broadly. 
Regarding the mediating effect, at the beginning of the CTSA award, neither the rate of 
inter-organizational collaboration rate nor the multidisciplinarity of institution’s publications had 
significant mediating role on the relationship between the CTSA award and the translational 
publication counts. However, inter-organizational collaboration rate started mediating the 
relationship between these two factors five years after the CTSA program started. This finding 
may indicate that institutions are starting to create inter-organizational collaboration in a way 





The first analysis of this dissertation shows how the collaboration network of biomedical 
research has been changing over time. I found that receiving the CTSA award is associated with 
increasing the number of collaborators and the rate of collaboration. This result may suggest that 
the CTSA award brought helpful resources to the institutions that took advantage of the award. 
According to the resource dependency theory, more resources could lead institutions to have 
more collaborations, which is confirmed by my analysis. Regarding the theory of self-interest 
paradigm, my result only partly supports it. The CTSA award did lead institutions to seek more 
partners but it turned out that they mainly focus on expanding collaboration with high-tier 
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universities. This could mean that benefit that can be gained by collaborating more with low-tier 
universities, which is future financial benefit provided by NIH by being selected as a CTSA 
recipient, is smaller than the potential benefits that can be obtained by working with higher-level 
universities. However, the result from my second analysis indicates that even this kind of 
collaboration pattern change didn’t lead to an increase of translational publications until recently.  
The findings from my second analysis show that the CTSA award led to an increase in 
the number of translational outcomes, which was the result that NIH desired. However, the result 
is not in the form that NIH really wanted. My results showed that the CTSA award only 
influenced the publications that got direct support from the award. Even if a group of 
publications were produced in the institutions that took advantage of the CTSA award, their 
nature of translatedness didn’t change much if it is not directly affected by the award. This 
means that the CTSA program failed to change the research environment of entire institutions 
toward more translational research.  
 The limited impact of the CTSA award could be interpreted in two ways. First, the 
impact of the CTSA award may not be large enough to induce broader systematic change. 
Though the absolute size may be large, the portion of the grant among total research 
expenditures at recipient universities may not be large enough to influence the whole institution. 
For instance, of the total sponsored funding of Emory University in 2016, only about 6% were 
related to the CTSA program (Georgia Clinical & Translational Science Alliance, n.d.). Also, as 
shown in previous chapter, the average portion of publications that acknowledge the CTSA 
award on their publications is only around 6% in 2015 (Figure 32). The second explanation for 
the limited effect of the CTSA award could be related to lack of time for the impact of the CTSA 
award to appear. It is true that it has been more than ten years since the CTSA program started, 
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but it is possible that we need more time to see the impact of the CTSA award to appear. It may 
take a great deal of time for the factors related to the change of translational publication counts to 
change. As noted previously, it took five years to change the collaboration patterns of institutions 
toward a form that could help translational research. Other factors may also require as much or 
more time to change to a form that could help fasten the translational process.  
 To overcome this limitation, various measures can be made. First, CTSA recipients could 
try to spread the program more widely within the institution and introduce the resources from the 
CTSA program more to the researchers. If more researchers get to know about the CTSA award, 
the number of studies getting direct support from the CTSA award will increases. As shown, the 
publications that received direct support from the CTSA award have high TS scores on average. 
Therefore, the number and portion of translational publications, based on my definition using the 
TS score, will increase as more studies get direct support from the CTSA award. Also, more use 
of the CTSA program by scientists may change the whole institutional research culture towards 
more translational research friendly environment to a certain degree, which is the form that NIH 
ultimately wants (Han et al., 2018). The second approach could be increasing the size of the 
workforce who specialize in translational research. Education and training programs are major 
parts of the CTSA program (Weber, 2013) and the current approach of training researchers 
related to translational research is focused on educating acting clinical scientists (Weber, 2013; 
Luke et al., 2013). However, it is very hard to bring scientists in basic science silo and scientists 
in clinical science silo together (Butler, 2008; Blümel, 2017). Hence, even a scientist in 
particular discipline have some knowledge in another discipline, he or she may not collaborate 
with people in another discipline. If it is hard to make scientist from two groups work together, it 
may be effective to train researchers who can dedicate their work to tasks related to translation of 
139 
outcomes from the non-clinical science into clinical setting. If the number of dedicated 
researchers in translational research increases, the translational process can proceed faster even if 
scientists specialized in basic science and clinical science stay in their own field 
  
6.3. Limitation and suggestion for further studies 
  
Though the values of the coefficients in model estimations are statistically significant and 
the result supports the proposed hypotheses, my study, like all research, has room for 
improvement. In my concluding section, I would like to propose some approaches that I or others 
could use to confirm, strengthen confidence in, and build upon my results. First of all, I could not 
make a strong claim that endogeneity problem is fully addressed. It is possible that the 
organizations receiving CTSA may be the ones that will be more connected with other 
organizations regardless of the CTSA award. As these organizations are mostly high-tier 
organizations in the field of biomedicine, they could have received more collaboration request 
from their potential partners than the organizations that didn’t receive the CTSA award. Also, 
these institutions could be the ones that are putting more effort on increasing translational works 
than the institutions not affected by the CTSA award. This may have caused selection bias of the 
samples and resulted in the bias on the estimators. I tried to alleviate this issue by matching 
institutions and applying difference-in-difference regression method. However, there is still more 
that can be done for the improvement.  
One of the ways to alleviate the endogeneity issue further is developing a better 
comparison group. In case I know the factors that actually affect NIH’s selection on CTSA 
recipients, I would get more precise propensity score of institutions and this could lead to better 
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institutional matching results. Also, I may also find a good instrumental variable on the list, 
which is the variable that affects the selection of the CTSA receiving institutions but doesn’t 
affect the change of my dependent variables (e.g., collaboration rate, translational publication 
counts). In this case, I could adopt two-stage least squares (2SLS) regression analysis, which has 
a profound effect on solving the endogeneity problem. What is more helpful in getting better 
institutional matching result is getting a list of institutions that applied for the CTSA program 
each year. The institutions that applied but failed to get the award can be classified as 
comparative institutions to the CTSA recipients for the specific year of application. It would be 
even better if I get to know what scores each institution received during NIH’s evaluation 
process regarding the selection of CTSA recipients. In this case, I could do institutional matching 
by pairing institutions that have close scores. If the number of institutions around the threshold 
score point that determines the selection of CTSA receiving institutions are large enough, I may 
also apply regression discontinuity method for the analysis.  
Regarding the mediation analysis, one major limitation is that I conducted year-by-year 
analysis rather than applying longitudinal perspective. My approach of applying lags between the 
impact and the effect could avoid reverse causality between variables to a certain degree, but the 
estimators in this cross-sectional setting could still be biased (Maxwell, Cole, & Mitchell, 2011). 
To conduct longitudinal analysis on mediation, other methods such as Structural Equation 
Modelling (SEM) should be used (Maxwell et al., 2011). SEM can apply longitudinal framework 
and it can be used for causal inference in various settings (Maxwell et al., 2011). Thus, for 
further study, I may adopt longitudinal SEM to get more reliable results on the mediation of two 
major factors that NIH puts a lot of emphasis on.  
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 Finally, conducting more robustness tests could help increase the reliability of the results 
from my analyses. I’ve tried to test my results with various settings including dropping 
unmatched institutions and using different dependent variables. However, performing more 
analyses under additional model specifications could increase the robustness of my results. First, 
I may test my result with other settings regarding time-related variables. I may apply different 
time interval between the impact and effect, which is three years in my current setting. Also, to 
test the placebo effect of the CTSA award, different year can be applied for the years of 
treatment. Secondly, I could use other values for the threshold TS score that is used in classifying 
publications into translational publications and non-translational publications. My current 
approach is using the threshold value of 0.150, which is based on my validity tests of the TS 
score in a small group of publications. However, it is possible that I get different threshold value 
if I conduct the validity tests with another sample of publications. In the process, I should keep in 





APPENDIX A. List of CTSA hubs and their partnering institutions 
Start year  CTSA-lead institution (CTSA-hub) CTSA-partnering institution 
2006 
Columbia University*  
Duke University*  
Mayo Clinic  
Oregon Health & Science University Kaiser Permanente's Center for Health Research  
Rockefeller University  
University of California At Davis*  
University of California San Francisco  
University of Pennsylvania* 
The Children's Hospital of Philadelphia, the 
Wistar Institute, the University of the Sciences in 
Philadelphia 
University of Pittsburgh* Carnegie Melon University* 
University of Rochester*  
University of Texas Health Science Center at 
Houston 
 
Yale University*  
2007 
Case Western Reserve University*  
Emory University* 
Georgia Institute of Technology*, University of 
Georgia* (partnership started in 2017), 
Morehouse School Medicine 
Johns Hopkins University*  
University of Chicago* 
Rush University, Advocate Health Care, Loyola 
University, Illinois Institute of Technology 
University of Iowa*  
University of Michigan At Ann Arbor*  
University of Texas Sw Med Ctr/Dallas  
University of Washington* 
Fred Hutchinson Cancer Research Center, Seattle 
Children's Hospital 
University of Wisconsin Madison* Marshfield Research Clinic 
Vanderbilt University* Meharry Medical College 
Washington University in St. Louis* 
University of Missouri*, St Louis University, 
BJC healthcare 
Weill Medical Coll of Cornell Univ*  
Memorial Sloan-Kettering Cancer Center, the 
Hospital for Special Surgery, New York-
Presbyterian Hospital, Hunter College 
2008 
Albert Einstein College of Medicine   
Boston University*  
Harvard University*  
Indiana University* 
Purdue University*, the University of Notre 
Dame*  
Northwestern University*  
Ohio State University*  
Scripps Research Institute  
Stanford University*  
Tufts University Boston* 
Massachusetts Institute of Technology*, Rand 
Corporation  
University of Alabama at Birmingham*  
University of Colorado Denver Colorado State University* 
University of North Carolina Chapel Hill* 
North Carolina State University* (partnership 
started in 2018), RTI International, North 
Carolina Agricultural and Technical State 
University 
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University of Texas Hlth Sci Ctr San Ant  
University of Utah*  
2009 
Icahn School of Medicine at Mount Sinai  
Medical University of South Carolina  
New York University School of Medicine*  
University of Arkansas Med Scis Ltl Rock*  
University of Cincinnati*  
University of Florida* 
Florida State University* (partnership started in 
2015) 
University of Illinois at Chicago*  
University of Texas Medical Br Galveston  
2010 
George Washington University* (Children's 
National Medical Center) 
 
Georgetown University* 
Howard University, MedStar Health Research 
Institute, Oak Ridge National Laboratory, and the 
Washington Veteran’s Affairs Medical Center  
Medical College of Wisconsin 
University of Wisconsin-Milwaukee*, 
Bloodcenter of Wisconsin, Children's Hospital of 
Wisconsin, Froedtert Hospital, Marquette 
University, Milwaukee School of Engineering, 
Milwaukee VA Medical Center  
University of California Irvine*  
University of California San Diego*  
Univ of Massachusetts*  
University of New Mexico*  
University of Southern California*  
Virginia Commonwealth University*  
2011 
Pennsylvania State Univ*  
University of California Los Angeles* 
Cedars-Sinai Medical Center, Charles R. Drew 
University of Medicine and Science  
University of Kansas* 
Kansas City University of Medicine and 
Biosciences, St. Luke's Health System/University 
of Missouri-Kansas City 
University of Kentucky*  
University of Minnesota Twin Cities*  
2012 University of Miami*  
2013 Dartmouth College  
2014 None  
2015 Wake Forest University   
2016 State University of New York At Buffalo* 
Population Health Collaborative, Kaleida Health, 
Erie County Medical Center, Roswell Park 
Comprehensive Cancer Center, HEALTHeLINK, 
and VA Western New York Healthcare System 
 
Notes:  
1. Institutions with asterisks (*) are Carnegie R1 universities 
2. Institutions with bold names are institutions that are ultimately included in the treatment group 
3. Otherwise stated, CTSA partnership started in the year the CTSA hub started receiving the CTSA award 
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APPENDIX B. Networks measures with x-axis as normalized years 
 
 
Figure B1. Collaboration frequency with CTSA-evers 
 
 





Figure B3. Collaboration portion with CTSA-evers 
 
 




Figure B5. Degree centrality trend of institutions in CTSA-ever group and CTSA-never group 
 
 






































Figure C1. Goodness-of-fit assessment of binary ERGM from 2009 to 2015 
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APPENDIX D. Classification of basic science, clinical science, multidisciplinary science, 
and other science based on NSF’s classification of fields of study 
# Counts Web of Science Category 
Non-
Clinical 
Clinical Multi-disc Non-S&E Name on NSF list 
1 115402 
Biochemistry & Molecular 
Biology 
X    Biochemistry 
2 86350 Neurosciences X    Neuroscience 
3 65035 Cell Biology X    Cell Biology and Anatomy 
4 55905 Multidisciplinary Sciences   X  NA 
5 47710 Oncology  X   Oncology 
6 41626 Immunology X    Immunology 
7 37356 Genetics & Heredity X    Genetics, General 
8 37293 
Public, Environmental & 
Occupational Health 
 X   Occupational Health and Industrial Hygiene 
9 31937 Psychiatry  X   Psychiatry 
10 30352 Pharmacology & Pharmacy  X   Pharmacy (PharmD [United States] PharmD, BS/BPharm [Canada]) 
11 29829 Endocrinology & Metabolism  X   Endocrinology and Metabolism 
12 28471 Physiology X    Physiology, General 




X    Biochemistry 
15 23257 
Medicine, Research & 
Experimental 
 X   Medicine (MD) 
16 23140 
Radiology, Nuclear Medicine & 
Medical Imaging 
 X   Nuclear Radiology 
17 22414 Chemistry, Multidisciplinary X    Chemistry, Other 
18 22399 Microbiology X    Microbiology, General 
19 21071 
Cardiac & Cardiovascular 
Systems 
X    Cardiovascular Science 
20 19993 Biophysics X    Biophysics 
21 19358 Infectious Diseases  X   Infectious Disease 
22 18593 
Biotechnology & Applied 
Microbiology 
X    Microbiology, General 
23 18444 Hematology  X   Hematology 
24 18320 Peripheral Vascular Disease  X   Vascular Surgery 
25 17960 Virology X    Virology 
26 15271 Surgery  X   General Surgery 
27 14767 Pediatrics  X   Pediatrics 
28 13974 Psychology, Clinical X    Clinical Psychology 
29 13493 Psychology X    Psychology, General 
30 13300 Engineering, Biomedical X    Biomedical/Medical Engineering 
31 12892 Developmental Biology X    Developmental Biology and Embryology 
32 12744 Ophthalmology  X   Ophthalmology 
33 12189 Medicine, General & Internal  X   Internal Medicine 
34 11732 Substance Abuse    X Substance Abuse/Addiction Counseling 




X    Biomathematics and Bioinformatics, Other 
37 11305 Respiratory System  X    Pulmonary Disease 
38 11018 Chemistry, Organic X    Organic Chemistry 
39 10869 Toxicology X    Toxicology 




 X   Gastroenterology 
42 10263 Chemistry, Medicinal X    Medicinal and Pharmaceutical Chemistry 
43 10149 Behavioral Sciences    X Behavioral Sciences 
44 10104 Nutrition & Dietetics  X   Dietetics and Clinical Nutrition Services, Other 
45 9858 Psychology, Experimental X    Experimental Psychology 
46 9498 Biology X    Biology/Biological Sciences, General 
47 9337 Geriatrics & Gerontology    X Gerontology 
48 9138 
Health Care Sciences & 
Services 
 X   Health/Health Care Administration/Management 
49 8887 Chemistry, Analytical X    Analytical Chemistry 
50 8838 Chemistry, Physical X    Chemical Physics 
51 8782 Obstetrics & Gynecology  X   Obstetrics and Gynecology 
52 7722 Psychology, Multidisciplinary X    Psychology, Other 
53 7363 Statistics & Probability X    Mathematical Statistics and Probability 
54 7175 Health Policy & Services    X Public Policy Analysis 
55 6912 Gerontology    X Gerontology 




X    Computer Science, Other 
58 5984 Critical Care Medicine  X   Critical Care Medicine 




X    NA 
61 5645 Neuroimaging  X   Diagnostic Radiology 
62 5611 Sport Sciences  X   Sports Medicine 
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X    Materials Science 
66 5207 Parasitology X    Parasitology 
67 5043 Transplantation  X   Nephrology 
68 5027 
Audiology & Speech-Language 
Pathology 
 X   Audiology/Audiologist and Speech-Language Pathology/Pathologist 
69 4761 Social Sciences, Biomedical    X Social Sciences, Other 
70 4664 Nursing  X   Nursing—Registered Nurse Training (RN, ASN, BSN, MSN) 
71 4422 Zoology X    Zoology/Animal Biology 
72 4383 Orthopedics  X   Orthopedics/Orthopedic Surgery 
73 4302 Otorhinolaryngology  X   Otolaryngology 
74 4268 Rheumatology  X   Rheumatology 
75 4069 Reproductive Biology X    Reproductive Biology 
76 3981 Cell & Tissue Engineering X    Biomedical/Medical Engineering 
77 3972 Optics X    Optics/Optical Sciences 
78 3720 Medical Informatics    X Medical Informatics 
79 3671 
Dentistry, Oral Surgery & 
Medicine 
 X   Dentistry (DDS, DMD 
80 3261 Evolutionary Biology X    Evolutionary Biology 
81 3152 Spectroscopy X    Radiation Biology/Radiobiology 
82 3049 Family Studies    X Human Development and Family Studies, General 
83 3023 Acoustics X    Acoustics 
84 2992 Anesthesiology  X   Anesthesiology 
85 2977 Psychology, Biological X    Psychology, Other 
86 2909 
Physics, Atomic, Molecular & 
Chemical 
X    Atomic/Molecular Physics 
87 2884 Dermatology  X   Dermatology 
88 2866 Plant Sciences X    Plant Sciences, General 
89 2758 Physics, Applied X    Physics, Other 
90 2579 
Veterinary Sciences  X   
Veterinary Sciences/Veterinary Clinical Sciences, General (Cert, MS, 
PhD) 
91 2523 Linguistics    X Linguistics 
92 2391 Tropical Medicine  X   Community Health and Preventive Medicine 
93 2304 Psychology, Social X    Social Psychology 
94 2211 
Engineering, Electrical & 
Electronic 
X    Electrical, Electronics, and Communications Engineering 
95 2118 Allergy  X   Allergies and Immunology 
96 2059 Anatomy & Morphology X    Anatomy 
97 1940 Ecology X    Ecology 
98 1937 
Chemistry, Inorganic & 
Nuclear 
X    Inorganic Chemistry 




   X Social Sciences, Other 
101 1633 Polymer Science X    Polymer Chemistry 
102 1607 Sociology    X Sociology 
103 1576 Social Work    X Social Work 
104 1561 Food Science & Technology X    Food Science 




X    Computer and Information Sciences, General 
107 1368 
Education & Educational 
Research 
   X Education, General 




   X Science Teacher Education/General Science Teacher Education 
110 1220 Entomology X    Entomology 
111 1212 
Computer Science, Artificial 
Intelligence 




 X   Laboratory Medicine 
113 1180 Demography    X Demography and Population Studies 
114 1153 
Information Science & Library 
Science 
   X Library Science/Librarianship 
115 1151 Women's Studies    X Women’s Studies 
116 1128 Mycology X    Mycology 
117 1116 Crystallography X    Atomic/Molecular Physics 
118 1116 Engineering, Environmental X    Environmental/Environmental Health Engineering 
119 1030 Chemistry, Applied X    Chemistry, Other 
120 1024 Economics    X Economics, General 
121 886 
Imaging Science & 
Photographic Technology 
 X   Diagnostic Radiology 




X    Applied Mathematics, Other 
124 827 Education, Special    X Special Education and Teaching, General 
125 766 
Integrative & Complementary 
Medicine 
 X   
Alternative and Complementary Medicine and Medical Systems, 
Other 
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X    Instrumentation Technology/Technician 
128 667 Criminology & Penology    X Criminology 
129 657 Physics, Multidisciplinary X    Physics, Other 
130 648 Anthropology    X Anthropology 
131 638 Physics, Fluids & Plasmas X    Plasma and High-Temperature Physics 
132 614 Psychology, Mathematical X    Psychology, Other 
133 546 Communication    X Communication Studies/Speech Communication and Rhetoric 
134 533 Nuclear Science & Technology X    Nuclear Engineering 
135 512 Primary Health Care  X   Health/Health Care Administration/Management 
136 505 Ethics    X Ethics 
137 477 Microscopy X    Instrumentation Technology/Technician 
138 470 Electrochemistry X    Chemistry, Other 
139 430 Marine & Freshwater Biology X    Marine Biology and Biological Oceanography 
140 418 Medical Ethics    X Bioethics/Medical Ethics 
141 379 Ergonomics  X    NA 
142 376 Mathematics, Applied X    Applied Mathematics 
143 375 
Social Sciences, Mathematical 
Methods 
   X Social Sciences, Other 
144 337 Agriculture, Multidisciplinary X    Agriculture, Agriculture Operations, and Related Sciences, Other 
145 336 
Computer Science, Theory & 
Methods 
X    Computer Science 
146 309 Law    X Law (LLB, JD) 
147 307 Social Issues    X Social Sciences, Other 
148 281 
Computer Science, Software 
Engineering 
X    Computer Software Engineering 
149 281 Ethnic Studies    X Ethnic, Cultural Minority, and Gender Studies, Other 
150 270 Engineering, Chemical X    Chemical Engineering 
151 254 Andrology  X   Urology 
152 244 Medicine, Legal  X   Medical Scientist (MS, Ph.D.) 
153 244 
Meteorology & Atmospheric 
Sciences 
X    Atmospheric Sciences and Meteorology, General 
154 240 Water Resources X    Hydrology and Water Resources Science 
155 225 Engineering, Industrial X    Industrial Engineering 
156 224 Language & Linguistics    X Linguistics 
157 211 
Agriculture, Dairy & Animal 
Science 
X    Dairy Science 
158 206 Transportation    X Transportation/Transportation Management 
159 205 Fisheries X    Fishing and Fisheries Sciences and Management 
160 205 Mechanics X    Engineering Mechanics 
161 165 Environmental Studies    X Environmental Studies 
162 154 Automation & Control Systems X    Electrical, Electronics, and Communications Engineering 
163 152 Religion    X Religion/Religious Studies 




X    Computer Science, Other 
166 145 Engineering, Multidisciplinary X    Engineering, General 
167 121 Engineering, Mechanical X    Mechanical Engineering 
168 121 Geography    X Geography 
169 103 Geosciences, Multidisciplinary X    Geological and Earth Sciences/Geosciences, Other 
170 97 Robotics X    Artificial Intelligence and Robotics 
171 95 Management    X Business Administration and Management, General 
172 94 
Hospitality, Leisure, Sport & 
Tourism 
   X Parks, Recreation, and Leisure Studies 
173 82 Biodiversity Conservation X    Ecology, Evolution, Systematics, and Population Biology, Other 
174 77 
History & Philosophy Of 
Science 
   X History and Philosophy of Science and Technology 
175 74 Planning & Development    X Land Use Planning and Management/Development 
176 73 Energy & Fuels X    Petroleum Engineering 
177 71 Urban Studies    X Urban Studies/Affairs 
178 68 Mathematics X    Mathematics, General 
179 67 
Operations Research & 
Management Science 
   X Operations Research 
180 65 Industrial Relations & Labor    X Labor and Industrial Relations 
181 62 Physics, Nuclear X    Nuclear Physics 
182 59 
Construction & Building 
Technology 
X    Construction Engineering 
183 57 
Computer Science, Hardware 
& Architecture 
X    Computer Hardware Engineering 
184 52 Telecommunications X    Computer Systems Networking and Telecommunications 
185 49 
Materials Science, Coatings & 
Films 
X    Materials Science 
186 48 Business    X Business/Managerial Economics 
187 48 Physics, Particles & Fields X    Elementary Particle Physics 
188 42 Agronomy X    Soil Science and Agronomy, General 
189 41 Engineering, Civil X    Civil Engineering, General 
190 41 Thermodynamics X    Mechanical Engineering 
191 40 Engineering, Manufacturing X    Manufacturing Engineering 
192 39 Business, Finance    X Finance, General 
193 38 Public Administration    X Public Administration 
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194 35 History    X History, General 
195 35 Philosophy    X Philosophy 
196 33 Remote Sensing X    Geological and Earth Sciences/Geosciences, Other 
197 32 Astronomy & Astrophysics X    Astronomy and Astrophysics, Other 
198 31 Geography, Physical    X Geography, Other 
199 30 
Metallurgy & Metallurgical 
Engineering 
X    Metallurgical Engineering 
200 28 Limnology X    Aquatic Biology/Limnology 
201 28 Psychology, Psychoanalysis X    Psychoanalysis and Psychotherapy 
202 27 Area Studies    X Area Studies, Other 
203 27 
GREEN & SUSTAINABLE 
SCIENCE & TECHNOLOGY 
  X    
204 27 International Relations    X International Relations and Affairs 
205 25 History Of Social Sciences    X History, Other 
206 24 Ornithology X    Animal Sciences, General 
207 23 Geochemistry & Geophysics X    Geochemistry 
208 23 Horticulture X    Agricultural and Horticultural Plant Breeding 
209 23 Humanities, Multidisciplinary    X Humanities/Humanistic Studies 
210 19 Music    X Music, General 
211 18 Agricultural Engineering X    Agricultural/Biological Engineering and Bioengineering 
212 18 Soil Science X    Soil Science and Agronomy, General 
213 16 
Transportation Science & 
Technology 
X    Transportation and Highway Engineering 
214 15 Materials Science, Ceramics X    Materials Science 
215 15 Oceanography X    Oceanography, Chemical and Physical 
216 14 Engineering, Aerospace X    Aerospace, Aeronautical, and Astronautical Engineering 
217 13 
Materials Science, 
Characterization & Testing 
X    Materials Science 
218 11 Mineralogy X    Geochemistry and Petrology 
219 9 Film, Radio, Television    X Radio and Television 
220 9 Materials Science, Composites X    Materials Science 
221 9 Materials Science, Textiles X    Materials Science 
222 7 Cultural Studies    X Ethnic, Cultural Minority, and Gender Studies, Other 
223 5 
Agricultural Economics & 
Policy 
   X Agricultural Economics 
224 5 Archaeology    X Paleontology 
225 5 Forestry X    Forestry, General 
226 5 Literature    X Foreign Languages and Literatures, General 
227 5 Mining & Mineral Processing X    Mining and Mineral Engineering 
228 2 Geology X    Geology/Earth Science, General 
229 2 
Materials Science, Paper & 
Wood 
X    Materials Science 


































2 107 Boston Coll 0.0012 0 2010 
100 107 Univ Texas Arlington 0.0076 0 2010 
9 107 Clemson Univ 0.0117 0 2010 
107 46 Univ Wisconsin Milwaukee 0.0183 1 2010 
46 107 Syracuse Univ 0.0190 0 2010 
27 107 Kansas State Univ 0.0217 0 2010 
49 107 Texas Tech Univ 0.0280 0 2010 
22 107 Georgia State Univ 0.0289 0 2010 
4 107 Brandeis Univ 0.0317 0 2010 
63 107 Univ Cent Florida 0.0324 0 2010 
62 107 Univ Cal Santa Cruz 0.0374 0 2010 
36 90 Oregon State Univ 0.0409 0 2008 
59 90 Univ Cal Riverside 0.0463 0 2008 
13 90 CUNY 0.0480 0 2008 
16 90 Florida Int Univ 0.0539 0 2008 
43 90 SUNY Albany 0.0556 0 2008 
72 90 Univ Houston 0.0560 0 2008 
90 72 Univ Notre Dame 0.0595 1 2008 
6 90 CALTECH 0.0677 0 2008 
18 90 George Mason Univ 0.0685 0 2008 
1 90 Arizona State Univ 0.0695 0 2008 
25 90 Iowa State Univ 0.0705 0 2008 
89 90 Univ N Texas 0.0798 0 2008 
110 90 Virginia Tech 0.0849 0 2008 
40 7 Rice Univ 0.0859 0 2006 
7 33 Carnegie Mellon Univ 0.1109 1 2006 
33 7 Northeastern Univ 0.1204 0 2006 
79 10 Univ Maryland College Park 0.1275 0 2008 
38 10 Princeton Univ 0.1299 0 2008 
111 10 Washington State Univ 0.1338 0 2008 
10 111 Colorado State Univ 0.1340 1 2008 
61 10 Univ Cal Santa Barbara 0.1356 0 2008 
66 10 Univ Colorado Boulder 0.1443 0 2008 
71 10 Univ Hawaii Manoa 0.1733 0 2008 
41 21 Rutgers State Univ 0.1769 0 2007 
32 21 N Carolina State Univ 0.1908 0 2007 
96 21 Univ S Carolina 0.1939 0 2007 
68 21 Univ Delaware 0.2074 0 2007 
21 17 Georgia Inst Technol 0.2185 1 2007 
17 21 Florida State Univ 0.2192 0 2007 
101 21 Univ Texas Austin 0.2403 0 2007 
92 21 Univ Oregon 0.2550 0 2007 
47 21 Temple Univ 0.2580 0 2007 
39 45 Purdue Univ 0.3224 1 2008 
29 45 MIT 0.3462 1 2008 
45 54 SUNY Stony Brook 0.3608 0 2009 
54 45 Univ Arkansas 0.3691 1 2009 
76 97 Univ Kansas 0.3798 1 2011 
97 76 Univ S Florida 0.3858 0 2011 
30 20 Michigan State Univ 0.4088 0 2010 
114 20 W Virginia Univ 0.4226 0 2010 
84 20 Univ Mississippi 0.4279 0 2010 
44 20 SUNY Buffalo 0.4290 0 2010 
78 20 Univ Louisville 0.4313 0 2010 
20 78 Georgetown Univ 0.4315 1 2010 
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74 20 Univ Illinois Urbana Champaign 0.4789 0 2010 
70 20 Univ Georgia 0.4826 0 2010 
48 80 Texas A&M Univ 0.5046 0 2010 
51 80 Tulane Univ 0.5343 0 2010 
91 80 Univ Oklahoma 0.5366 0 2010 
80 91 Univ Massachusetts Amherst 0.5369 1 2010 
87 91 Univ New Mexico 0.5485 1 2010 
86 81 Univ Nebraska 0.5950 0 2012 
55 81 Univ Cal Berkeley 0.5990 0 2012 
5 81 Brown Univ 0.6095 0 2012 
81 102 Univ Miami 0.6313 1 2012 
57 102 Univ Cal Irvine 0.6317 1 2010 
102 57 Univ Texas Dallas 0.6389 0 2010 
113 24 Wayne State Univ 0.6427 0 2008 
24 113 Indiana Univ 0.6523 1 2008 
28 98 Louisiana State Univ 0.6763 0 2010 
98 99 Univ So Cal 0.6878 1 2010 
73 99 Univ Illinois Chicago 0.6879 1 2009 
19 99 George Washington Univ 0.6913 1 2010 
99 95 Univ Tennessee 0.6965 0 2006 
95 99 Univ Rochester 0.6985 1 2006 
50 99 Tufts Univ 0.7130 1 2008 
85 104 Univ Missouri 0.7311 1 2007 
31 104 NYU 0.7349 1 2009 
104 115 Univ Virginia 0.7549 0 2006 
115 104 Yale Univ 0.7552 1 2006 
11 53 Columbia Univ 0.7697 1 2006 
8 53 Case Western Reserve Univ 0.7756 1 2007 
53 8 Univ Arizona 0.7802 0 2007 
67 103 Univ Connecticut 0.7915 0 2008 
103 67 Univ Utah 0.7960 1 2008 
64 67 Univ Chicago 0.8080 1 2007 
65 67 Univ Cincinnati 0.8080 1 2009 
3 67 Boston Univ 0.8114 1 2008 
75 67 Univ Iowa 0.8243 1 2007 
42 67 Stanford Univ 0.8260 1 2008 
109 67 Virginia Commonwealth Univ 0.8274 1 2010 
77 67 Univ Kentucky 0.8452 1 2011 
34 67 Northwestern Univ 0.8541 1 2008 
83 67 Univ Minnesota 0.8579 1 2011 
35 67 Ohio State Univ 0.8762 1 2008 
82 67 Univ Michigan 0.8771 1 2007 
52 67 Univ Alabama 0.8799 1 2008 
37 67 Penn State Univ 0.8838 1 2011 
14 67 Duke Univ 0.8844 1 2006 
15 67 Emory Univ 0.8900 1 2007 
12 67 Cornell Univ 0.8931 1 2007 
94 67 Univ Pittsburgh 0.8977 1 2006 
26 67 Johns Hopkins Univ 0.9047 1 2007 
60 67 Univ Cal San Diego 0.9050 1 2010 
56 67 Univ Cal Davis 0.9051 1 2006 
105 67 Univ Washington Seattle 0.9131 1 2007 
112 67 Washington Univ St Louis 0.9187 1 2007 
108 67 Vanderbilt Univ 0.9191 1 2007 
93 67 Univ Penn 0.9272 1 2006 
106 67 Univ Wisconsin Madison 0.9306 1 2006 
23 67 Harvard Univ 0.9344 1 2008 
69 67 Univ Florida 0.9366 1 2009 




APPENDIX G. Data summary and correlation between variables having all Carnegie R1 
universities in the sample 
 
Table G1. Summary of data 
Variable Obs Mean Std.dev Min Max 
Non-clinical science publications 1,725 215.61 220.83 1.00 1659.00 
Mean forward citations (per paper) 1,725 49.76 23.12 8.88 220.41 
Mean forward citations from clinical science (per paper) 1,725 6.30 3.88 0.00 30.15 
Mean TS score (institution-year unit) 1,725 0.12 0.05 0.00 0.27 
R&D (million $) 1,725 197.17 185.67 0.90 882.69 
Researcher 1,725 1246.71 961.17 60.00 8511.00 
Medical 1,725 0.58 0.49 0.00 1.00 
Public 1,725 0.30 0.46 0.00 1.00 
Degree centrality 1,725 141.28 54.58 4.00 228.00 
Multidisciplinarity  1,725 2.01 0.14 1.29 2.49 
Race diversity 1,725 1.60 0.26 0.50 2.38 
* Note: Unit is institution-year 
Table G2. Correlation between variables 
 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 
(1) Non-clinical science publications 1.00           
(2) Mean forward citations (per paper) 0.16*** 1.00          
(3) Mean forward citations from clinical science (per paper) 0.33*** 0.61*** 1.00         
(4) Mean TS score (institution-year unit) 0.26*** -0.10*** 0.59*** 1.00        
(5) R&D (million $) 0.82***   0.00 0.26*** 0.35*** 1.00       
(6) Researcher 0.76*** 0..12*** 0.34*** 0.31*** 0.71*** 1.00      
(7) Medical 0.46***  0.01 0.43*** 0.61*** 0.54*** 0.43*** 1.00     
(8) Private 0.27*** 0.20*** 0.23*** 0.08*** 0.17*** 0.04** 0.17*** 1.00    
(9) Degree centrality 0.70*** -0.11*** 0.20*** 0.38*** 0.73*** 0.58*** 0.57*** 0.16*** 1.00   
(10) Multidisciplinarity (institution-year unit) 0.15*** -0.48*** -0.17*** 0.30*** 0.20*** 0.10*** 0.16*** -0.08*** 0.43*** 1.00  
(11) Race diversity  0.03 -0.21***   0.03 0.27*** 0.06** 0.22*** 0.17*** 0.13*** 0.20*** 0.33*** 1.00 
 
Note: *** p < 0.01, ** p< 0.05, * < 0.10 
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APPENDIX H. More DID regression results for test on Hypothesis 1 
 
Table H1. Difference-in-difference OLS regression (not dropping unmatched institutions) 
 Without covariates With covariates 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA*POST 31.40*** 31.31*** 30.64*** 30.57*** 13.19*** 13.61*** 11.69*** 12.07*** 
CTSA 94.81***  95.76***  34.51***  37.19***  
POST 4.37** 4.37** -11.35*** -11.46***   -5.15**   -4.84**   -2.46   -2.63 
Researcher     23.71*** 20.64*** 21.99*** 18.59*** 
R&D     0.19*** 0.19*** 0.20***  0.19*** 
Med school        0.93  -5.89   -2.43   -9.05 
Private      25.32**       24.87**  
Multidisciplinarity     23.71*** 27.86***  22.89** 22.33** 
Centrality         0.00 -0.01   -0.00    -0.05 
Constant 26.42** 71.78*** 13.10 58.90*** -58.87*** -33.07* -55.63***  -16.18 
Observation 1380 1380 1380 1380 1380 1380 1380 1380 
σu 67.92 83.51 67.96 84.05 41.18 53.70 41.20 56.31 
σe 19.54 19.54 17.68 17.68 15.84 15.84 15.08 15.08 
ρ 0.92 0.95 0.94 0.96 0.87 0.92 0.88 0.93 
Year FE NO NO YES YES NO NO YES YES 
Institution FE NO YES NO YES NO YES NO YES 
 
 
Table H2. Difference-in-difference Poisson regression (not dropping unmatched institutions) 
 Without covariates With covariates 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA*POST 0.01*** 0.10*** 0.08*** 0.08*** 0.09***    0.09***    0.05*  0.05* 
CTSA 1.52***  1.55***  1.08***  1.10***  
POST 0.16*** 0.16*** -0.07*** -0.07*** -0.10*** -0.10***   -0.05* -0.05* 
Researcher     0.07*** 0.06*** 0.05***          
0.05*** 
R&D     0.00*** 0.00*** 0.00*** 0.00*** 
Med school        0.27***    0.13*    0.20** 0.06 
Private        0.01     0.02  
Multidisciplinarity     0.79*** 0.88*** 0.99*** 1.00*** 
Centrality     0.00*** 0.00*** 0.00*** 0.00*** 
Constant 3.27***  3.06***  1.02***     0.68**  
Observation 1380 1380 1380 1380 1380 1380 1380 1380 
Pseudo R2 0.013 0.125 0.047 0.238 0.104 0.214 0.104 0.253 
Year FE YES YES YES YES YES YES YES YES 






Table H3. Difference-in-difference Poisson regression results (dropping CTSA direct supported 
publications, not dropping unmatched institutions) 
 Without covariates With covariates 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA*POST   0.04* 0.04*   0.02 0.02  0.03  0.04 -0.01 -0.01 
CTSA 1.51***  1.53***   1.11***   1.10***  
POST 0.16***    0.16***   -0.03 -0.03 -0.08*** -0.08*** -0.01 -0.01 
Researcher      0.07***  0.07***  0.06***  0.05*** 
R&D      0.00*  0.00*  0.00***  0.00*** 
Med school     -0.27***  0.13  0.19**  0.05 
Private      0.00   0.02  
Multidisciplinarity      0.76***  0.85***  1.06***  1.07*** 
Centrality      0.00**  0.00***  0.00***  0.00*** 
Constant 3.27***  3.07***   1.14***   0.57*  
Observation 1380 1380 1380 1380 1380 1380 1380 1380 
Pseudo R2 0.013 0.079 0.042 0.182 0.107 0.156 0.103 0.198 
Year FE YES YES YES YES YES YES YES YES 




Table H4. Difference-in-difference OLS regression results (dropping unmatched institutions) 
 Without covariates With covariates 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA*POST 14.01*** 13.94*** 13.71*** 13.65***   8.99***  9.15***    8.63***   8.70*** 
CTSA 50.35***  50.66***   25.91***   25.64***  
POST 4.35*** 4.36***   -3.72*   -3.77**    -4.33*** -3.76***   -1.58    -1.69 
Researcher        8.11*** 6.71*** 7.29***     5.50** 
R&D        0.16***  0.14*** 0.17***    0.15*** 
Med school         4.05 -4.79    1.39    -6.67* 
Private        17.62***   17.73***  
Multidisciplinarity       12.53** 16.92***  15.69** 15.09** 
Centrality         0.05**   0.04*   0.08***      0.04 
Constant 26.72*** 44.07*** 19.14*** 36.59***  -27.53** -13.72 -34.54***     -9.09 
Observation 1080 1080 1080 1080 1080 1080 1080 1080 
σu 36.98 44.38 37.01 44.56 19.66 33.16 19.68 33.94 
σe 11.55 11.55 10.38 10.38 10.02 10.02 9.51 9.51 
ρ 0.91 0.94 0.93 0.95 0.79 0.92 0.81 0.93 
Year FE NO NO YES YES NO NO YES YES 







Table H5. Difference-in-difference Poisson regression results (dropping unmatched institutions)  
 Without covariates With covariates 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA*POST   0.06** 0.06** 0.04*   0.04*  0.07***  0.07***   0.05*   0.05* 
CTSA 1.06***     1.07***   0.82***    0.81***  
POST 0.16***   0.16***   -0.03 -0.03 -0.10*** -0.09***  -0.04  -0.04 
Researcher      0.09***  0.08***   0.05*   0.04 
R&D         0.00   0.00***   0.00* 
Med school      0.26***  0.15*   0.19**   0.07 
Private           0.00  
Multidisciplinarity      0.78***   0.87***   1.00***   1.01*** 
Centrality      0.00***   0.00***   0.00***   0.00*** 
Constant 3.28***  3.09***   1.05***    0.58*  
Observation 1080 1080 1080 1080 1080 1080 1080 1080 
Pseudo R2 0.007 0.057 0.019 0.137 0.106 0.121 0.074 0.153 
Year FE YES YES YES YES YES YES YES YES 




Table H6. Difference-in-difference Poisson regression results (dropping CTSA direct supported 
publications, dropping unmatched institutions) 
 Without covariates With covariates 
 (1) (2) (3) (4) (5) (6) (7) (8) 
CTSA*POST  -0.01  -0.01  -0.03 -0.03  0.02  0.02 -0.00   -0.00 
CTSA 1.05***  1.06***   0.84***   0.82***  
POST 0.16*** 0.16***   0.01 0.01 -0.09*** -0.08*** -0.02   -0.02 
Researcher      0.10***  0.09***  0.06**    0.05* 
R&D     -0.00 -0.00*  0.00    0.00 
Med school      0.27***  0.16*  0.19**    0.08 
Private      0.00   0.00  
Multidisciplinarity      0.79***  0.88***  1.06***   1.07*** 
Centrality      0.00***  0.00***  0.00***   0.00*** 
Constant 3.28***  3.10***   1.06***   0.48  
Observation 1080 1080 1080 1080 1080 1080 1080 1080 
Pseudo R2 0.007 0.033 0.016 0.109 0.112 0.091 0.077 0.127 
Year FE YES YES YES YES YES YES YES YES 








APPENDIX I. Counts and portion of CTSA supported papers by institution-year 
 
Table I1. Counts of all CTSA supported publications regardless of forward citation counts 
Institution 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Sum 
Boston Univ     1 4 12 27 29 33 42 49 197 
Case Western Reserve Univ 3 29 45 91 121 187 346 374 370 313 1879 
Columbia Univ 1 7 28 51 70 100 140 204 236 264 1101 
Cornell Univ     14 41 55 86 110 173 124 150 753 
Duke Univ   5 26 34 50 45 54 46 60 92 412 
Emory Univ   14 124 147 187 220 267 210 208 207 1584 
George Washington Univ           4 16 33 37 62 152 
Georgetown Univ     2 7 11 25 51 38 54 64 252 
Harvard Univ       27 98 203 230 271 280 314 1423 
Johns Hopkins Univ     18 56 133 155 178 204 413 387 1544 
NYU       1 11 36 55 78 94 75 350 
Northwestern Univ     45 84 128 182 199 182 81 141 1042 
Ohio State Univ   1 36 95 143 190 182 148 138 118 1051 
Penn State Univ     1 1 4 8 40 38 60 59 211 
Stanford Univ       1 13 29 64 92 102 135 436 
Tufts Univ     1 10 17 41 36 44 51 65 265 
Univ Alabama     2 9 24 42 64 83 85 80 389 
Univ Arkansas       1 8 34 74 73 114 93 397 
Univ Cal Davis   4 18 30 54 55 63 60 52 67 403 
Univ Cal Irvine     1     12 24 34 42 119 232 
Univ Cal Los Angeles 1   1   2 52 249 358 327 335 1325 
Univ Cal San Diego         1 12 38 54 59 75 239 
Univ Chicago     2 18 40 48 67 62 479 319 1035 
Univ Cincinnati   2 5 39 85 101 248 414 422 531 1847 
Univ Florida   4 12 15 19 45 423 105 95 150 868 
Univ Illinois Chicago         14 44 53 54 75 85 325 
Univ Iowa     20 35 55 52 59 74 57 62 414 
Univ Kansas       1   1 31 37 62 54 186 
Univ Kentucky   2 5 5 4 13 69 84 114 127 423 
Univ Massachusetts Amherst           34 14 69 57 57 231 
Univ Miami           2 1 23 23 20 69 
Univ Michigan 1   10 34 89 131 134 175 145 174 893 
Univ Minnesota       2 3 8 44 79 178 172 486 
Univ New Mexico     1 3 14 16 85 124 97 109 449 
Univ N Carolina Chapel Hill     7 39 81 108 131 177 200 225 968 
Univ Penn   2 38 52 70 115 113 143 153 180 866 
Univ Pittsburgh 3 190 202 173 301 405 411 504 434 460 3083 
Univ Rochester   1 33 35 57 69 134 85 128 142 684 
Univ So Cal         2 10 72 95 58 78 315 
Univ Utah     2 13 22 38 68 73 98 131 445 
Univ Washington Seattle     22 49 90 304 171 146 161 164 1107 
Univ Wisconsin Madison     16 44 146 169 197 204 292 275 1343 
Vanderbilt Univ   1 10 57 85 167 245 297 347 367 1576 
Virginia Commonwealth Univ           30 57 84 71 77 319 
Washington Univ St Louis     20 104 151 232 285 335 354 359 1840 




Table I2. Counts of CTSA supported non-clinical publications with five or more forward 
citations 
Institution 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Sum 
Boston Univ    1 1 4 3 5 8 10 41 
Case Western Reserve Univ 1 8 12 28 23 40 79 79 80 48 424 
Columbia Univ   1 6 12 13 33 42 41 36 229 
Cornell Univ   2 9 2 13 14 16 17 17 100 
Duke Univ   3 1 2 3 1 2 1 2 15 
Emory Univ  3 23 28 33 38 31 34 42 23 279 
George Washington Univ       4 5 5 16 36 
Georgetown Univ    1 4 4 7 5 6 5 50 
Harvard Univ    2 15 32 25 33 25 26 202 
Johns Hopkins Univ    7 26 32 28 40 64 43 291 
NYU     2 8 13 15 16 9 85 
Northwestern Univ   15 25 26 39 40 27 14 27 248 
Ohio State Univ   7 13 30 30 36 26 14 15 185 
Penn State Univ      3 6 9 8 9 48 
Stanford Univ     2 6 10 9 12 20 78 
Tufts Univ    4 4 3 4 4 4 11 39 
Univ Alabama   1 2 7 7 7 16 9 10 69 
Univ Arkansas     3 7 15 16 28 16 101 
Univ Cal Davis   6 5 5 6 12 10 14 9 74 
Univ Cal Irvine      2 5 5 4 18 50 
Univ Cal Los Angeles      9 45 58 54 49 295 
Univ Cal San Diego     1 3 5 8 8 12 50 
Univ Chicago    5 9 8 12 17 118 63 254 
Univ Cincinnati  1  4 7 10 30 40 56 58 251 
Univ Florida   1  1 4 99 14 12 25 194 
Univ Illinois Chicago     2 11 12 9 17 18 83 
Univ Iowa   6 8 16 13 17 12 13 10 102 
Univ Kansas       7 5 4 3 23 
Univ Kentucky   1    13 15 27 28 103 
Univ Massachusetts Amherst      6 1 16 18 10 68 
Univ Miami        5 3 3 13 
Univ Michigan   3 4 6 12 28 29 27 27 163 
Univ Minnesota    2 1 4 7 13 14 21 89 
Univ New Mexico    1 1 1 12 18 3 14 53 
Univ N Carolina Chapel Hill   1 5 6 7 15 28 24 19 140 
Univ Penn   6 11 8 18 15 20 24 22 145 
Univ Pittsburgh  20 28 28 46 67 62 63 67 71 463 
Univ Rochester   6 9 8 6 26 17 23 15 116 
Univ So Cal       6 12 5 7 33 
Univ Utah   1 2 6 7 12 8 7 16 68 
Univ Washington Seattle   2 5 12 34 24 15 12 18 136 
Univ Wisconsin Madison   1 5 23 23 20 23 32 32 191 
Vanderbilt Univ   2 9 11 40 44 58 54 63 323 
Virginia Commonwealth Univ      5 3 11 12 10 53 
Washington Univ St Louis   4 12 9 26 45 38 39 44 270 




Table I3. Portion of CTSA supported publications with five or more forward citations among all 
publications 
Institution 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Boston Univ       0 0 0.01 0.01 0.01 0.02 0.03 
Case Western Reserve Univ 0 0.02 0.03 0.05 0.04 0.09 0.17 0.18 0.19 0.13 
Columbia Univ     0 0.01 0.02 0.02 0.05 0.06 0.06 0.06 
Cornell Univ     0 0.02 0.01 0.02 0.02 0.03 0.03 0.03 
Duke Univ     0.01 0 0.01 0.01 0 0.01 0 0.01 
Emory Univ   0.01 0.06 0.06 0.07 0.07 0.06 0.07 0.08 0.05 
George Washington Univ           0.01 0.05 0.06 0.04 0.13 
Georgetown Univ       0.01 0.03 0.02 0.04 0.04 0.06 0.05 
Harvard Univ       0 0.01 0.02 0.01 0.02 0.02 0.02 
Johns Hopkins Univ       0.01 0.04 0.04 0.03 0.05 0.08 0.06 
NYU         0 0.02 0.03 0.04 0.04 0.02 
Northwestern Univ     0.04 0.05 0.05 0.07 0.08 0.05 0.02 0.05 
Ohio State Univ     0.02 0.03 0.07 0.08 0.09 0.06 0.04 0.05 
Penn State Univ           0.01 0.02 0.03 0.04 0.03 
Stanford Univ         0 0.01 0.01 0.01 0.01 0.03 
Tufts Univ       0.02 0.02 0.02 0.02 0.02 0.02 0.05 
Univ Alabama     0 0.01 0.02 0.02 0.02 0.04 0.02 0.04 
Univ Arkansas         0.03 0.06 0.14 0.16 0.32 0.17 
Univ Cal Davis     0.02 0.02 0.01 0.01 0.03 0.02 0.03 0.02 
Univ Cal Irvine           0 0.01 0.01 0.01 0.06 
Univ Cal Los Angeles           0.01 0.05 0.08 0.08 0.07 
Univ Cal San Diego         0 0 0.01 0.01 0.01 0.01 
Univ Chicago       0.01 0.02 0.02 0.03 0.03 0.24 0.20 
Univ Cincinnati   0 0 0.01 0.02 0.03 0.10 0.13 0.20 0.22 
Univ Florida     0 0  0.01 0.01 0.27 0.05 0.04 0.08 
Univ Illinois Chicago         0.01 0.04 0.04 0.03 0.07 0.07 
Univ Iowa     0.02 0.02 0.04 0.03 0.05 0.03 0.03 0.03 
Univ Kansas       0 0  0  0.03 0.02 0.02 0.02 
Univ Kentucky     0 0  0  0 0.05 0.07 0.14 0.16 
Univ Massachusetts Amherst           0.02 0 0.04 0.04 0.03 
Univ Miami               0.02 0.02 0.02 
Univ Michigan     0 0 0.01 0.01 0.03 0.03 0.03 0.03 
Univ Minnesota       0 0 0.01 0.01 0.02 0.03 0.03 
Univ New Mexico       0.01 0.01 0.01 0.09 0.19 0.03 0.12 
Univ N Carolina Chapel Hill     0 0.01 0.01 0.01 0.02 0.03 0.03 0.03 
Univ Penn     0.01 0.01 0.01 0.02 0.02 0.02 0.03 0.03 
Univ Pittsburgh   0.04 0.04 0.04 0.07 0.09 0.09 0.09 0.09 0.10 
Univ Rochester     0.02 0.03 0.03 0.02 0.09 0.05 0.07 0.07 
Univ So Cal         0   0.01 0.03 0.01 0.02 
Univ Utah     0 0.01 0.01 0.02 0.03 0.02 0.03 0.05 
Univ Washington Seattle     0 0.01 0.01 0.04 0.03 0.02 0.02 0.03 
Univ Wisconsin Madison     0 0.01 0.04 0.03 0.03 0.04 0.05 0.05 
Vanderbilt Univ     0 0.02 0.02 0.07 0.06 0.08 0.09 0.11 
Virginia Commonwealth Univ           0.03 0.02 0.07 0.07 0.06 
Washington Univ St Louis     0.01 0.02 0.01 0.04 0.06 0.05 0.06 0.07 







Table I4. Portion of CTSA supported non-clinical publications with five or more forward 
citations among all non-clinical science publications 
Institution 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
Boston Univ    0.00 0.00 0.01 0.01 0.01 0.02 0.03 
Case Western Reserve Univ 0.00 0.02 0.03 0.05 0.04 0.08 0.15 0.16 0.17 0.11 
Columbia Univ   0.00 0.01 0.02 0.02 0.05 0.06 0.06 0.05 
Cornell Univ   0.00 0.02 0.00 0.02 0.02 0.02 0.03 0.03 
Duke Univ   0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
Emory Univ  0.01 0.05 0.06 0.07 0.07 0.06 0.06 0.07 0.04 
George Washington Univ       0.04 0.05 0.04 0.13 
Georgetown Univ    0.01 0.03 0.02 0.04 0.03 0.04 0.04 
Harvard Univ    0.00 0.01 0.02 0.01 0.02 0.01 0.02 
Johns Hopkins Univ    0.01 0.03 0.04 0.03 0.05 0.07 0.05 
NYU     0.00 0.02 0.03 0.03 0.04 0.02 
Northwestern Univ   0.03 0.05 0.05 0.07 0.07 0.05 0.02 0.04 
Ohio State Univ   0.02 0.03 0.07 0.07 0.08 0.06 0.03 0.04 
Penn State Univ      0.01 0.02 0.02 0.02 0.02 
Stanford Univ     0.00 0.01 0.01 0.01 0.01 0.02 
Tufts Univ    0.02 0.02 0.01 0.02 0.02 0.02 0.05 
Univ Alabama   0.00 0.01 0.02 0.02 0.02 0.04 0.02 0.03 
Univ Arkansas     0.03 0.06 0.13 0.14 0.25 0.16 
Univ Cal Davis   0.02 0.01 0.01 0.01 0.03 0.02 0.03 0.02 
Univ Cal Irvine      0.00 0.01 0.01 0.01 0.05 
Univ Cal Los Angeles      0.01 0.05 0.07 0.07 0.06 
Univ Cal San Diego     0.00 0.00 0.00 0.01 0.01 0.01 
Univ Chicago    0.01 0.02 0.01 0.02 0.03 0.21 0.17 
Univ Cincinnati  0.00  0.01 0.02 0.03 0.09 0.11 0.16 0.16 
Univ Florida   0.00  0.00 0.01 0.25 0.04 0.03 0.06 
Univ Illinois Chicago     0.01 0.03 0.04 0.03 0.06 0.06 
Univ Iowa   0.02 0.02 0.04 0.03 0.04 0.02 0.03 0.02 
Univ Kansas       0.02 0.02 0.02 0.01 
Univ Kentucky   0.00    0.05 0.06 0.12 0.12 
Univ Massachusetts Amherst      0.02 0.00 0.04 0.04 0.02 
Univ Miami        0.02 0.02 0.01 
Univ Michigan   0.00 0.00 0.01 0.01 0.03 0.03 0.03 0.03 
Univ Minnesota    0.00 0.00 0.01 0.01 0.02 0.02 0.03 
Univ New Mexico    0.01 0.01 0.01 0.09 0.15 0.03 0.10 
Univ N Carolina Chapel Hill   0.00 0.01 0.01 0.01 0.02 0.03 0.03 0.02 
Univ Penn   0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 
Univ Pittsburgh  0.03 0.04 0.04 0.07 0.08 0.09 0.08 0.08 0.08 
Univ Rochester   0.02 0.03 0.02 0.02 0.07 0.05 0.07 0.05 
Univ So Cal       0.01 0.03 0.01 0.02 
Univ Utah   0.00 0.01 0.01 0.02 0.03 0.02 0.02 0.04 
Univ Washington Seattle   0.00 0.01 0.01 0.04 0.03 0.01 0.01 0.02 
Univ Wisconsin Madison   0.00 0.01 0.04 0.03 0.03 0.03 0.04 0.05 
Vanderbilt Univ   0.00 0.02 0.02 0.06 0.06 0.08 0.07 0.09 
Virginia Commonwealth Univ      0.03 0.02 0.06 0.07 0.04 
Washington Univ St Louis   0.01 0.02 0.01 0.04 0.06 0.05 0.05 0.06 




APPENDIX J. Model estimation results for testing mediation effects 
 
Table J1. Detailed result of mediation tests of inter-organizational collaboration  
Year 









2009 .0762*** YES -.01036 NO 0.1309 YES -.0002 NO .0764 NA 
2010 .1121*** YES -.0536** YES 0.0193 YES -.0011 NO .1132 NA 
2011 .3141*** YES .01660 NO 0.1669 YES .0003 NO .3138** NA 
2012 .1922*** YES .01583 NO NA NO .0003 NO .1919 NA 
2013 .3950*** YES .0521** YES 0.1742 YES .0010 NO .3940*** NA 
2014 .6004*** YES .0682*** YES 0.2084 YES .0010* YES .5993*** .0017 
2015 .6374*** YES .0933*** YES 0.2917 YES .0014** YES .6359*** .0022 
 
 
Table J2. Detailed result of mediation tests of Shannon diversity 
Year 









2009 .0762*** YES 0.0020 NO 0.0018 YES -0.0016 NO 0.0778 NA 
2010 .1121*** YES -0.0029 NO 0.0015 YES 0.0011 NO 0.1110 NA 
2011 .3141*** YES 0.0024 NO NA NO 0.0003 NO .3139** NA 
2012 .1922*** YES -0.0135 NO -0.0018 NO -0.002 NO 0.1939 NA 
2013 .3950*** YES 0.0001 NO NA NO 0.0003 NO 0.1919 NA 
2014 .6004*** YES 0.0007 NO -0.0004 NO -0.0003 NO .6006*** NA 
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